{
  "cells": [
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "7QgsNxpvYO3C",
        "outputId": "f9bce564-6a50-4dd4-b01e-45848c4b3eea"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: langchain in /usr/local/lib/python3.10/dist-packages (0.2.16)\n",
            "Requirement already satisfied: PyYAML>=5.3 in /usr/local/lib/python3.10/dist-packages (from langchain) (6.0.2)\n",
            "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.0.32)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /usr/local/lib/python3.10/dist-packages (from langchain) (3.10.5)\n",
            "Requirement already satisfied: async-timeout<5.0.0,>=4.0.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (4.0.3)\n",
            "Requirement already satisfied: langchain-core<0.3.0,>=0.2.38 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.2.38)\n",
            "Requirement already satisfied: langchain-text-splitters<0.3.0,>=0.2.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.2.4)\n",
            "Requirement already satisfied: langsmith<0.2.0,>=0.1.17 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.1.116)\n",
            "Requirement already satisfied: numpy<2,>=1 in /usr/local/lib/python3.10/dist-packages (from langchain) (1.26.4)\n",
            "Requirement already satisfied: pydantic<3,>=1 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.8.2)\n",
            "Requirement already satisfied: requests<3,>=2 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.32.3)\n",
            "Requirement already satisfied: tenacity!=8.4.0,<9.0.0,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (8.5.0)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (2.4.0)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.3.1)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (24.2.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.4.1)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (6.0.5)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.9.4)\n",
            "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3.0,>=0.2.38->langchain) (1.33)\n",
            "Requirement already satisfied: packaging<25,>=23.2 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3.0,>=0.2.38->langchain) (24.1)\n",
            "Requirement already satisfied: typing-extensions>=4.7 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3.0,>=0.2.38->langchain) (4.12.2)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.17->langchain) (0.27.2)\n",
            "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.17->langchain) (3.10.7)\n",
            "Requirement already satisfied: annotated-types>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1->langchain) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.20.1 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1->langchain) (2.20.1)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (3.8)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (2024.8.30)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy<3,>=1.4->langchain) (3.0.3)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (3.7.1)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.0.5)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.3.1)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (0.14.0)\n",
            "Requirement already satisfied: jsonpointer>=1.9 in /usr/local/lib/python3.10/dist-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.3.0,>=0.2.38->langchain) (3.0.0)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.2.2)\n"
          ]
        }
      ],
      "source": [
        "!pip install langchain"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "A0dHXJiYYJJB"
      },
      "outputs": [],
      "source": [
        "import langchain"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "FkzE5anpaGwu",
        "outputId": "87910afc-cc9a-41b1-8f03-21889237f31f"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: langchain in /usr/local/lib/python3.10/dist-packages (0.2.16)\n",
            "Requirement already satisfied: PyYAML>=5.3 in /usr/local/lib/python3.10/dist-packages (from langchain) (6.0.2)\n",
            "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.0.32)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /usr/local/lib/python3.10/dist-packages (from langchain) (3.10.5)\n",
            "Requirement already satisfied: async-timeout<5.0.0,>=4.0.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (4.0.3)\n",
            "Requirement already satisfied: langchain-core<0.3.0,>=0.2.38 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.2.38)\n",
            "Requirement already satisfied: langchain-text-splitters<0.3.0,>=0.2.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.2.4)\n",
            "Requirement already satisfied: langsmith<0.2.0,>=0.1.17 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.1.116)\n",
            "Requirement already satisfied: numpy<2,>=1 in /usr/local/lib/python3.10/dist-packages (from langchain) (1.26.4)\n",
            "Requirement already satisfied: pydantic<3,>=1 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.8.2)\n",
            "Requirement already satisfied: requests<3,>=2 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.32.3)\n",
            "Requirement already satisfied: tenacity!=8.4.0,<9.0.0,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (8.5.0)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (2.4.0)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.3.1)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (24.2.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.4.1)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (6.0.5)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.9.4)\n",
            "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3.0,>=0.2.38->langchain) (1.33)\n",
            "Requirement already satisfied: packaging<25,>=23.2 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3.0,>=0.2.38->langchain) (24.1)\n",
            "Requirement already satisfied: typing-extensions>=4.7 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3.0,>=0.2.38->langchain) (4.12.2)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.17->langchain) (0.27.2)\n",
            "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.17->langchain) (3.10.7)\n",
            "Requirement already satisfied: annotated-types>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1->langchain) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.20.1 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1->langchain) (2.20.1)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (3.8)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (2024.8.30)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy<3,>=1.4->langchain) (3.0.3)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (3.7.1)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.0.5)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.3.1)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (0.14.0)\n",
            "Requirement already satisfied: jsonpointer>=1.9 in /usr/local/lib/python3.10/dist-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.3.0,>=0.2.38->langchain) (3.0.0)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.2.2)\n",
            "Requirement already satisfied: langchain_community in /usr/local/lib/python3.10/dist-packages (0.2.16)\n",
            "Requirement already satisfied: PyYAML>=5.3 in /usr/local/lib/python3.10/dist-packages (from langchain_community) (6.0.2)\n",
            "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /usr/local/lib/python3.10/dist-packages (from langchain_community) (2.0.32)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /usr/local/lib/python3.10/dist-packages (from langchain_community) (3.10.5)\n",
            "Requirement already satisfied: dataclasses-json<0.7,>=0.5.7 in /usr/local/lib/python3.10/dist-packages (from langchain_community) (0.6.7)\n",
            "Requirement already satisfied: langchain<0.3.0,>=0.2.16 in /usr/local/lib/python3.10/dist-packages (from langchain_community) (0.2.16)\n",
            "Requirement already satisfied: langchain-core<0.3.0,>=0.2.38 in /usr/local/lib/python3.10/dist-packages (from langchain_community) (0.2.38)\n",
            "Requirement already satisfied: langsmith<0.2.0,>=0.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain_community) (0.1.116)\n",
            "Requirement already satisfied: numpy<2,>=1 in /usr/local/lib/python3.10/dist-packages (from langchain_community) (1.26.4)\n",
            "Requirement already satisfied: requests<3,>=2 in /usr/local/lib/python3.10/dist-packages (from langchain_community) (2.32.3)\n",
            "Requirement already satisfied: tenacity!=8.4.0,<9.0.0,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain_community) (8.5.0)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (2.4.0)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (1.3.1)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (24.2.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (1.4.1)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (6.0.5)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (1.9.4)\n",
            "Requirement already satisfied: async-timeout<5.0,>=4.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (4.0.3)\n",
            "Requirement already satisfied: marshmallow<4.0.0,>=3.18.0 in /usr/local/lib/python3.10/dist-packages (from dataclasses-json<0.7,>=0.5.7->langchain_community) (3.22.0)\n",
            "Requirement already satisfied: typing-inspect<1,>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from dataclasses-json<0.7,>=0.5.7->langchain_community) (0.9.0)\n",
            "Requirement already satisfied: langchain-text-splitters<0.3.0,>=0.2.0 in /usr/local/lib/python3.10/dist-packages (from langchain<0.3.0,>=0.2.16->langchain_community) (0.2.4)\n",
            "Requirement already satisfied: pydantic<3,>=1 in /usr/local/lib/python3.10/dist-packages (from langchain<0.3.0,>=0.2.16->langchain_community) (2.8.2)\n",
            "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3.0,>=0.2.38->langchain_community) (1.33)\n",
            "Requirement already satisfied: packaging<25,>=23.2 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3.0,>=0.2.38->langchain_community) (24.1)\n",
            "Requirement already satisfied: typing-extensions>=4.7 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3.0,>=0.2.38->langchain_community) (4.12.2)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.0->langchain_community) (0.27.2)\n",
            "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.0->langchain_community) (3.10.7)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain_community) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain_community) (3.8)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain_community) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain_community) (2024.8.30)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy<3,>=1.4->langchain_community) (3.0.3)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.0->langchain_community) (3.7.1)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.0->langchain_community) (1.0.5)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.0->langchain_community) (1.3.1)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.0->langchain_community) (0.14.0)\n",
            "Requirement already satisfied: jsonpointer>=1.9 in /usr/local/lib/python3.10/dist-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.3.0,>=0.2.38->langchain_community) (3.0.0)\n",
            "Requirement already satisfied: annotated-types>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1->langchain<0.3.0,>=0.2.16->langchain_community) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.20.1 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1->langchain<0.3.0,>=0.2.16->langchain_community) (2.20.1)\n",
            "Requirement already satisfied: mypy-extensions>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from typing-inspect<1,>=0.4.0->dataclasses-json<0.7,>=0.5.7->langchain_community) (1.0.0)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.0->langchain_community) (1.2.2)\n"
          ]
        }
      ],
      "source": [
        "!pip install langchain --upgrade\n",
        "!pip install langchain_community\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "tybf0IPuYcSb"
      },
      "outputs": [],
      "source": [
        "from langchain_community.document_loaders import DirectoryLoader\n",
        "from langchain.document_loaders import TextLoader\n",
        "from langchain_community.document_loaders import PyPDFLoader\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "r1x5LQMtaWYQ"
      },
      "outputs": [],
      "source": [
        "from langchain.text_splitter import RecursiveCharacterTextSplitter"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "HmBKiXbiamjj"
      },
      "outputs": [],
      "source": [
        "text_splitter = RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=200)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "m_NTsbeda7QF"
      },
      "outputs": [],
      "source": [
        "from langchain.embeddings import HuggingFaceEmbeddings"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "3muoVokgbIHW",
        "outputId": "311078d5-06c0-4677-b8a9-2c7a28d9447e"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: sentence_transformers in /usr/local/lib/python3.10/dist-packages (3.0.1)\n",
            "Requirement already satisfied: transformers<5.0.0,>=4.34.0 in /usr/local/lib/python3.10/dist-packages (from sentence_transformers) (4.44.2)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from sentence_transformers) (4.66.5)\n",
            "Requirement already satisfied: torch>=1.11.0 in /usr/local/lib/python3.10/dist-packages (from sentence_transformers) (2.4.0+cu121)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.10/dist-packages (from sentence_transformers) (1.26.4)\n",
            "Requirement already satisfied: scikit-learn in /usr/local/lib/python3.10/dist-packages (from sentence_transformers) (1.3.2)\n",
            "Requirement already satisfied: scipy in /usr/local/lib/python3.10/dist-packages (from sentence_transformers) (1.13.1)\n",
            "Requirement already satisfied: huggingface-hub>=0.15.1 in /usr/local/lib/python3.10/dist-packages (from sentence_transformers) (0.24.6)\n",
            "Requirement already satisfied: Pillow in /usr/local/lib/python3.10/dist-packages (from sentence_transformers) (9.4.0)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.15.1->sentence_transformers) (3.15.4)\n",
            "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.15.1->sentence_transformers) (2024.6.1)\n",
            "Requirement already satisfied: packaging>=20.9 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.15.1->sentence_transformers) (24.1)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.15.1->sentence_transformers) (6.0.2)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.15.1->sentence_transformers) (2.32.3)\n",
            "Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.15.1->sentence_transformers) (4.12.2)\n",
            "Requirement already satisfied: sympy in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence_transformers) (1.13.2)\n",
            "Requirement already satisfied: networkx in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence_transformers) (3.3)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence_transformers) (3.1.4)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.10/dist-packages (from transformers<5.0.0,>=4.34.0->sentence_transformers) (2024.5.15)\n",
            "Requirement already satisfied: safetensors>=0.4.1 in /usr/local/lib/python3.10/dist-packages (from transformers<5.0.0,>=4.34.0->sentence_transformers) (0.4.4)\n",
            "Requirement already satisfied: tokenizers<0.20,>=0.19 in /usr/local/lib/python3.10/dist-packages (from transformers<5.0.0,>=4.34.0->sentence_transformers) (0.19.1)\n",
            "Requirement already satisfied: joblib>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from scikit-learn->sentence_transformers) (1.4.2)\n",
            "Requirement already satisfied: threadpoolctl>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from scikit-learn->sentence_transformers) (3.5.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->torch>=1.11.0->sentence_transformers) (2.1.5)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.15.1->sentence_transformers) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.15.1->sentence_transformers) (3.8)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.15.1->sentence_transformers) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.15.1->sentence_transformers) (2024.8.30)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.10/dist-packages (from sympy->torch>=1.11.0->sentence_transformers) (1.3.0)\n"
          ]
        }
      ],
      "source": [
        "!pip install sentence_transformers"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "U07MAJ_ha7Lj"
      },
      "outputs": [],
      "source": [
        "huggingface_embeddings=HuggingFaceEmbeddings(\n",
        "    model_name=\"BAAI/bge-small-en-v1.5\",      #sentence-transformers/all-MiniLM-l6-v2\n",
        "    model_kwargs={'device':'cpu'},\n",
        "    encode_kwargs={'normalize_embeddings':True}\n",
        "\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "xWNWy0zJa7Jc",
        "outputId": "1fbb4499-f41c-488b-dcf4-53d9c20ab821"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: pypdf in /usr/local/lib/python3.10/dist-packages (4.3.1)\n",
            "Requirement already satisfied: typing_extensions>=4.0 in /usr/local/lib/python3.10/dist-packages (from pypdf) (4.12.2)\n"
          ]
        }
      ],
      "source": [
        "!pip install pypdf\n",
        "# The pypdf package is required by the PyPDFLoader\n",
        "\n",
        "loader = DirectoryLoader('./Data/', glob=\"**/*.pdf\",loader_cls=PyPDFLoader)\n",
        "docs = loader.load()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "isxPWDKva7HT"
      },
      "outputs": [],
      "source": [
        "texts = text_splitter.split_documents(docs)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "CBUh0XMma7E1",
        "outputId": "f82a719e-5a1b-4f41-e874-7c8f1a0b4f58"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 1}, page_content='2PRIMARY PREVENTION OF DIABETESAcknowledgement\\nWe acknowledge the contributions of the following staff\\nDr.Shabana Tharkar - Dept. of EpidemiologyMs.Nandhini - Dept. of Nutrition  andDr.K.Satyavani –Asst. Director of Research.\\nPublished by\\nM. V. Hospital for Diabetes &\\nDiabetes Research Centre(WHO Collaborating Centre for Research, Education & Trainingin Diabetes)4, Main Road, RoyapuramChennai 600 013, India\\nDesign & Production\\nTrendset Communications\\nChennai 600 033. (trendsetco@gmail.com)'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 2}, page_content='primary prevention of diabetes\\n3 PRIMARY PREVENTION OF DIABETESForeword\\nIt is now well known that there is a pandemic of Type 2\\nDiabetes in the world particularly in developing countries.This fact has several implications for the health care systemin the developing countries because this condition isassociated with metabolic and vascular complications whichin turn increases the mortality and health care costs andcompromises the quality and life expectancy of the society.\\nIt is therefore important to aim for primary prevention of\\ndiabetes particularly in countries where there is a highprevalence.\\nThis manual aims to provide an overview of this subject to\\nhealth care professionals, paramedics and other voluntaryservices involved in health care promotion.\\nThe WHO Collaborating Centre for Diabetes in India is'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 2}, page_content='health care professionals, paramedics and other voluntaryservices involved in health care promotion.\\nThe WHO Collaborating Centre for Diabetes in India is\\nactively involved in prevention of diabetes, childhood obesityand other related disorders and is regularly bringing out sucheducation materials to improve the awareness among all thepeople involved in health care.\\nWe sincerely hope this manual will go a long way in\\npreventing this pandemic of diabetes in the world particularlyin the developing countries.\\nDr. Vijay Viswanathan MD,PhD\\nHead of the WHO Collaborating Centre in India andMV Hospital for Diabetes and Diabetes Research CentreChennai, India.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 3}, page_content='4PRIMARY PREVENTION OF DIABETESThere are umpteen number of evidences\\nto establish the fact that diabetes hasreached EPIDEMIC proportions in India.\\nThere is a huge unparalleled burden of\\nillness caused by diabetes. As the\\ndeveloping world is expected to bear the\\nbrunt of the escalating diabetes epidemicin the future, diabetes prevention is\\nproving especially urgent and difficult in\\ndeveloping countries.\\nIn India, health policies and services need\\nto put more emphasis on non-\\ncommunicable diseases such as diabetes.This manual is expected to benefit the\\ngeneral population and the health\\npersonnel in generating awareness onprevention of diabetes, and the policy\\nmakers in implementing prevention\\nprogrammes on a nationwide basis.Towards a healthier\\nNation…...Steps for transformingdisease to health'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 4}, page_content='primary prevention of diabetes\\n5 PRIMARY PREVENTION OF DIABETESAround the globe news on diabetes (courtesy IDF)\\n•Diabetes is the fourth leading cause of global death by\\ndisease.\\n•Each year 3.8 million deaths are attributableto diabetes. An even greater number die from\\ncardiovascular disease made worse by diabetes-relatedlipid disorders and hypertension.\\n•Diabetes is a common cause of kidney failure indeveloped countries and is responsible for the huge\\ncost of dialysis.\\n•Diabetic retinopathy is the leading cause of vision loss\\nin adults of working age (20 to 65 years) in\\nindustrialized countries.\\n•Atleast 50% of all people with diabetes are unawareof their condition. In some countries this figure may\\nreach 80%.\\n•Upto 80% of type 2 diabetes is preventable by adopting\\na healthy diet and increasing physical activity\\nThe Indian Scenario…\\n•In India, around 40.9 million  people are affected by\\ndiabetes'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 5}, page_content='6PRIMARY PREVENTION OF DIABETES•Indians develop diabetes at an earlier age and with\\nlower levels of obesity.\\n•Prev alence is escalating at very abnormal proportions\\nin India.\\nThese hard facts necessitate immediate action.\\nEvolution of Diabetes\\nDue to the natural history of the disease and stages in\\nevolution, the good news  is that Diabetes is\\nPREVENTABLE at an early stage.\\nPre - diabetes stage\\nEGI Early Glucose IntoleranceIFG Impaired Fasting GlucoseIGT Impaired Glucose Tolerance\\nFor details see page 12'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 6}, page_content='primary prevention of diabetes\\n7 PRIMARY PREVENTION OF DIABETESDifferent stages in the development of diabetes mellitus:\\nPrevention Strategies\\nThe contents of this manual are evidence based.  This\\nmanual speaks on the most important level of prevention;\\n(1) Health promotion,\\n(2)  Primary prevention\\nThe goal of health promotion is to help people establish\\nan active lifestyle and healthy eating habits early in life\\nand to maintain this behavior throughout their lives.\\nThe goal of primary prevention is to help those who are\\nat risk of developing the disease and hence prevent or\\npostpone the onset of disease by establishing more active\\nlifestyles and healthier eating habits.\\nPrimary prevention can be accomplished by promotion\\nof health and reduction of risk factors through theindividual and on a community basis.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 7}, page_content='8PRIMARY PREVENTION OF DIABETESFor the programme on prevention of diabetes two\\napproaches can be used.\\nHigh risk approach\\n• Focuses on the high risk group, involving individual\\ncounseling. This approach can also be used by the general\\npractitioners while attending to patients and counsel thefamilies for prevention of diabetes among the high risk\\ngroups.\\nPopulation approach\\n• The focus is on the entire\\npopulation or community as awhole. This approach can be used\\nwhere the prevalence is high and\\nthe entire community is targeted.\\nFor example – Urban areas,\\nmetropolitan cities.\\nFor good results in achieving a reduction in the prevalence\\nand incidence of diabetes both the approaches are needed.\\nThe function of protecting and developing health must rank\\neven above that of restoring it when it is impaired.\\n– Hippocrates'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 8}, page_content='primary prevention of diabetes\\n9 PRIMARY PREVENTION OF DIABETESThose with Pre-diabetes\\nconditions[IFG & IGT]\\nThose with positive family history of\\ndiabetes\\nThose aged above 40 yearsStressful and sedentary jobsPeople with high blood pressure and\\ncholesterol\\nIncreased Body Mass Index –\\nBMI(General Obesity)\\nIncreased waist circumference (central\\nobesity)\\nSedentary lifestylesWomen with history of high blood\\nsugar during pregnancyThe focus of primary prevention\\ncan be on the following high risk\\ncategories:'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 9}, page_content='10 PRIMARY PREVENTION OF DIABETESPrimary prevention of diabetes\\nPopulation strategy: Since Indians are genetically\\npredisposed to the development of diabetes and have a\\nlower threshold for the disorder, the best strategy that canbe adopted is the population strategy. This may be\\ncombined with high risk approach to achieve greater\\nsuccess.\\nWith an easy access to tertiary care centres and availability\\nof complex comprehensive care the approach differs inan urban setting. Community intervention strategies\\naimed at the primary prevention of diabetes must include\\ncommunity-based exercise and healthy nutritionprograms targeting people at a high risk for diabetes.\\nEfforts could include advocacy for increasing the\\navailability of diabetes education programs.\\nFive simple tools to identify high risk category;\\n• Age above 40 years\\n• Positive family history of diabetes\\n• Increased abdominal fatness\\n(Waist circumference Male >=90cms,\\nFemale >=85cms)'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 10}, page_content='primary prevention of diabetes\\n11 PRIMARY PREVENTION OF DIABETES• Pre-diabetes\\n(Impaired fasting glucose >=110mg/dl\\nImpaired Glucose Tolerance 140-199mg/dl)\\n• Sedentary lifestyle\\nThe table below shows the assessment of risk based on\\nthe number of risk factors present.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 11}, page_content='12 PRIMARY PREVENTION OF DIABETESSimple diagnostic tests\\n• Fasting blood glucose\\n• Oral Glucose Tolerance Test(GTT)\\n• Measurement of body mass index and waist\\ncircumference\\n• Lipid profile\\n• Blood pressure• Assessment of dietary habits\\n• Assessment of physical activity level\\n• Evaluation of stress\\nDiagnosis of diabetes and pre- diabetes conditions:\\nFasting 1 hr PP 2 hr PP\\nNormal < 110 - =<140EGI – Early Glucose Intolerance < 110 >=160 =<140\\nIFG-Impaired fasting Glucose 110 – 125 - -\\nIGT - Impaired Glucose Tolerance - - 140 – 199Diabetes >= 126 - >= 200Conditions GTT values in mg/dl'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 12}, page_content='primary prevention of diabetes\\n13 PRIMARY PREVENTION OF DIABETESCalculation of Body Mass Index (BMI)\\nBody Mass Index (BMI) is an anthropometric index of\\ngeneral obesity which is calculated by using height and\\nweight measurement.\\n                               BMI = Weight in kgs\\n                                           (Height in meters) 2\\nFor example: Weight = 50Kgs.\\nHeight = 150 cmsBMI = 50/1.5*1.5 = 22.2 Kg/m\\n2.\\nFor Indian Adults,\\nBMI Upto 25 kg/m2 is Normal,\\nBMI>=25 Kg/m2 is Overweight and\\nBMI>=30 Kg/m2 is Obese.\\nWaist Circumference\\nMeasurement of waist circumference is a simple procedure\\nwhich can be done at home using a simple measurementtape.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 13}, page_content='14 PRIMARY PREVENTION OF DIABETES\\n• Take off your shirt and\\nloosen your belt\\n• Position the tape on the\\nnavel\\n• When taking measurement,\\nthe abdomen should be\\nrelaxed and you should be\\nbreathing out\\n• Record the measurement\\n“Those of you who fall in any of the above risk category\\nmust go for check up atleast once in 6 months”.For Indian adults,\\nNormal male - waist circumference\\nupto  90 cms\\nNormal female - waist circumference\\nupto 85 cms'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 14}, page_content='primary prevention of diabetes\\n15 PRIMARY PREVENTION OF DIABETESBlood sugar\\nBody mass\\nIndex(Weight inKgs/Height inmetre\\n2)Always maintain\\nyour fasting bloodsugar level below110mg/dl.\\nPost prandial\\nblood sugar levelafter one and halfhours should beless than140mg/dl.\\nAlways maintain a\\nBMI of less than 25kg/m\\n2. Any\\nincrease indicatesoverweight andbecomes a riskfactorIf fasting and post\\nprandial sugar isabove the specifiedlimit, advocatelifestylemodification.\\nAdopt a  healthy\\ndiet\\nIncrease the\\nphysical activity bywalking, jogging,swimming,involvement insports, games and inhealth clubs.\\nStress reduction\\nmethods like yoga,meditation must beperformed.\\nTarget towards\\nreduction of weight.\\nBMI>25kg/m\\n2\\nshould target\\ntowards weightreductionParameters Optimum\\nmeasurementRecommendationsRecommendations'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 15}, page_content='16 PRIMARY PREVENTION OF DIABETESMaintain ideal\\nbodyweight(Height incms – 100).\\nFor healthy\\npeople – Goal isto maintain 120/80 mm/Hg.Forpeople above 40years with ahistory of bloodpressure maintainless than 140/90mm/HgCombined effort\\nfrom lifestylemodification bydoing strict dietcontrol and regularphysical activity.If obese,medications forweight reductiontherapy must beconsidered alongwith LSM.\\nPromote healthy\\nlifestylemodification.\\nAdvocate reducing\\nweight\\nReduce sodium\\n(salt) intake.\\nTake a variety of\\nfruits, vegetablesand low-fat dairyproducts\\nAvoid fried foods\\nand reduce oilconsumption in anyform\\nDo atleast 30\\nminutes of physicalactivity everyday.\\nStop smoking and\\nalcohol habits.Body weight\\nBlood pressure'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 16}, page_content='primary prevention of diabetes\\n17 PRIMARY PREVENTION OF DIABETESMaintain cholesterol\\nlevel <200mg/dl.\\nHDL cholesterol\\nshould be more than40mg/dl in men andmore than 50mg/dlin women.\\nTriglycerides should\\nbe less than 150 mg/dl.\\nLDL cholesterol\\nshould be less than100 mg/dl.Drug therapy is\\nrecommended forthose with BP of140/90 mm/Hg orhigher.\\nIf lipid profile is\\nhigher than thenormal 1. Regularand daily physicalactivity for  atleast30 mins .2. Targettowards weightreduction 3. Strictdiet control.4.Consider drugtherapy – lipidlowering agents ifthe profile ispersistentlyabnormal in spite ofRegular exercise anddiet control.Lipid profile'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 17}, page_content='18 PRIMARY PREVENTION OF DIABETESMethods for creating awareness\\nAwareness education on\\nprimary prevention of\\ndiabetes can be done by the\\nfollowing ways:\\nMethods\\n• Camps – Screening\\nand education camps.\\n• Awareness Campaigns/ programs\\n• Exhibitions/Fairs• Seminars/Conferences• Rallies/Walks\\n• Folk Arts\\nChannels\\n• Distribution of pamphlets, manuals, cards\\n• Advertisements in magazines, newspapers and other\\ncommonly read books.\\n• T.V, Radio, Media\\n• Health education curriculum in schools, workplaces.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 18}, page_content='primary prevention of diabetes\\n19 PRIMARY PREVENTION OF DIABETES• Lectures in various places like, Public meetings,\\nreligious gatherings.\\n• Awareness programs by lecture and counseling in\\nschools, colleges, offices, women’s organizations\\nPersonnel who can be involved in spreading awareness\\non primary prevention at the National level are\\n• Private health organizations\\n• Government bodies\\n• NGOs and local bodies\\n• Self help groups• NSS and NCC scouts.• Social and service clubs\\n• Health workers / Health educators\\n• Community welfare associations• General Practitioners\\nThis should never be a “ONE TIME” Program\\nbut   a\\nREGULAR ONGOING PROCESS.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 19}, page_content='20 PRIMARY PREVENTION OF DIABETESPrimary Prevention of diabetes in a\\nrural setting\\nThe methods for primary prevention of diabetes in villages\\nmay be slightly different from the urban areas due to non\\navailability of easy access to tertiary care centres. Theprimary prevention programmes in the rural part of India\\nmust be done with the available infrastructure. The\\nprevalence of diabetes in rural India varies widely\\nanywhere between 2 to 6 % and even higher as obtained\\nfrom studies from other parts of India.\\nPoints for consideration\\n• The general conditions and risk factors of the disease\\nvary considerably among the rural population.\\n• The rural population have a lower BMI.\\n• Physical activity is comparatively higher than their\\nurban counterpart, however in recent times people\\nhave started using motorised vehicles and machinesfor agriculture, thereby reducing their physical activity\\nlevel.\\n• Due to poverty and inaccessibility, the food consumed'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 19}, page_content='have started using motorised vehicles and machinesfor agriculture, thereby reducing their physical activity\\nlevel.\\n• Due to poverty and inaccessibility, the food consumed\\nby the rural population is unbalanced diet – large\\nproportion of rice with little or no vegetables andfruits.\\n• Access to tertiary care centres is minimal.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 20}, page_content='primary prevention of diabetes\\n21 PRIMARY PREVENTION OF DIABETES• The prevalence is comparatively lesser than the urban\\npopulation.\\nHence the approach for education on prevention of\\ndiabetes differs from the urban.\\nHigh Risk approach\\nThose at high risk must be identified and focus of\\nprevention mu st be on the individuals and their family.\\nPlease refer pages 9 to 11 to identify high risk category.\\nThe contents under urban setting may be followed as\\nappropriate and if applicable to rural areas.\\nSalient points for rural setting\\n1. The target high risk groups can be counseled for\\nprevention of diabetes.\\n2. Focus should be made on changes in diet pattern after\\ninitial assessment of dietary habits.\\n3. The role and importance of increasing physical activity\\nshould be stressed.\\n4. The primary health centres, village health nurse and\\nthe workers at grass root level, panchayat heads may\\nco- ordinate in awareness programmes and othereducational activities related to diabetes prevention.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 21}, page_content='22 PRIMARY PREVENTION OF DIABETES\\nGuidelines for Lifestyle Modification\\nin a nutshell\\nLifestyle modification involves modifying and regulating\\nthe changes in all the day to day activities of life like diet,physical activity, beliefs and behaviour. All these together\\ninfluence the body health status.\\nPhysical Activity\\n1.   Increase activities like walking,\\njogging, skipping, swimming.\\n2. Walking should be increased\\ngradually. About a Km in 20 mins\\nwhich can be increased to 2 kms in20 min over a week’s time. Ideal is a\\ncontinuous walk for 30 mins daily.\\n3. Use the stairs instead of the lift. Just\\n10 minutes of stair climbing is equal\\nto 30 minutes of walking.\\n4. Use bicycles for short distances\\ninstead of a motorized vehicle.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 22}, page_content='primary prevention of diabetes\\n23 PRIMARY PREVENTION OF DIABETES\\n5. Get involved in outdoor sports rather than indoor\\ngames.\\n6. Spend leisure time in activities like gardening or\\nexercise\\n7. Minimize TV watching8. Reduce the time spent in playing computer games or\\naimless internet browsing.\\n9. Those with sedentary jobs can include atleast 30-45\\nminutes of exercise\\ndaily.\\nStress reduction\\n1. Do yoga and\\nmeditation to relievestress.\\n2. Deep breathing exercises\\ncan also be done to reducestress.\\n3. Regular practice of relaxation techniques like listening\\nto therapeutic music.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 23}, page_content='24 PRIMARY PREVENTION OF DIABETES\\nDietary modification\\n1. Aim for negative energy balance (i.e.)\\nfood intake should be less than the\\nenergy expenditure.\\n2. Include vegetables and greens in the\\nmain meals.\\n3. Plenty of fruit consumption is recommended but avoid\\nfruits in  juice form.\\n4. Increase foods rich in fibre content and decrease\\ncarbohydrate contents\\n5. Moderate intake of food rich in proteins and cereals6. Minimize taking food rich in fats and fried food.\\n7. Avoid sweets and milk products in all forms.\\n8. Avoid snacking in-between major meals and while\\nwatching TV.\\nLack of commitment in LSM does not serve the\\npurpose. There should be a committed and\\ncombined effort to achieve the goal of goodhealth.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 24}, page_content='primary prevention of diabetes\\n25 PRIMARY PREVENTION OF DIABETESRole of healthy and balanced diet\\nA diet high in nutrients is the key to good health. In order\\nto maintain your body weight one should take a balanceddiet.\\nA diet which has all the nutrients such as carbohydrate,\\nprotein, fat, vitamins, minerals in appropriate proportion\\nis called a balanced diet.\\nFood Guide Pyramid\\nFood Guide Pyramid is a visual representation of the\\nvariety & proportion of foods that could be included in aday’s diet. The different food groups are arranged in the\\nform of a pyramid.\\n• The base of the pyramid contains cereals & starches\\nwhich provide the major part of the day’s energy. All\\ncereals could be included, in their respective quantitiesprescribed to you. This group contributes\\ncarbohydrates to our body.\\n• The next level is shared by fruits & vegetables.\\nAdequate intake of these provides antioxidants,\\nvitamins, minerals & fibre. 1 fruit per day is\\nrecommended. About 500gm of vegetables (in any'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 25}, page_content='26 PRIMARY PREVENTION OF DIABETES'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 26}, page_content='primary prevention of diabetes\\n27 PRIMARY PREVENTION OF DIABETESform like soup, salad etc) per day needs to be taken to\\nmeet the requirement of vitamins and minerals.\\n•Protein foods  ( vegetarian food like legumes-dhal &\\nwholegrams, & Non-vegetarian food, like fish /chicken /egg white) and low fat milk / milk products\\nform the next level. The quantity of these foods would\\nvary for each individual.\\n•Nuts and oils  form the fourth level in the pyramid. A\\nhandful of boiled/roasted nuts can be taken daily. Forthose who are overweight/ obese, nuts could be\\nincluded occasionally by doing adjustments in the fat\\nconsumption.\\n• The tip of the pyramid contains sugar, saturated fat\\nand refined foods  which should be taken sparingly.\\nOil intake should be limited to 25-35 ml/day. Oilconsumption should be reduced for people with\\nobesity.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 27}, page_content='28 PRIMARY PREVENTION OF DIABETESCereals\\nPulses\\nVegetables\\nFruits\\nDairy\\nProducts\\nMeat\\nproductsAll whole grains\\ncereals suchasWhole wheat,oats,ragi, milletsbrown rice etc\\nDhals or grams\\nwith outercapsules(Skin)and  Sprouts\\nVegetables rich in\\nfiber like greens,brinjal,cauliflower,gourds, salads\\nAll fresh, frozen\\nfruits and dryfruits\\nSkimmed milk,\\nUnsweetenedyoghurt, curd,buttermilk\\nFish, chicken, egg\\nwhite – Boiled,steamed, grilled,roasted, barbecueor stewMaida, polished rice,\\nrefined foodproducts, instantpreparations.\\nFried food such as\\nvada, bonda,frieddhals\\nFrying, deep frying,\\npickle, dehydratingthe vegetables\\nCanned, Bottled,\\nJuice, Squash\\nCheese, ghee, ice\\ncream, milk cream,Whole milk\\nRed meat, organ\\nmeat, egg yolk,frying and deepfryingTypes of\\nfoodPreferred Avoid'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 28}, page_content='primary prevention of diabetes\\n29 PRIMARY PREVENTION OF DIABETESSugar and\\nsweets\\nOils\\nBeveragesSugar, honey, jaggery\\n- 3-4 tsp a day\\nOlive, groundnut,\\nsunflower , safflower,\\nGingely oil –25- 30 ml/day\\nWater, Buttermilk,\\nClear soups, Tender\\ncoconut waterSweets prepared\\nwith oil andvanaspathi\\nPalm oil, coconut oil,\\nlard, vanaspathi ,refined andprocessed oil\\nTea, coffee, aerated\\ndrinks, soda,alcohol.\\nWate r: Drinking more water keeps your stomach full and\\nsuppresses the appetite which will reduce your food\\nintake.\\nFiber:  Foods rich in fibers are low in calories and gives\\nfullness to your stomach easily.  Foods like apple,pineapple, papaya, strawberries, broccoli, cauliflower,\\nlady’s finger, brinjal, stem of plantain plant and whole\\ngrains are rich in fibers.\\nGood fats:  We need some essential fatty acids (good fat)\\nfor our body for the normal metabolism. This fat will\\nnaturally reduce the bad fat in the body. Fish, Walnuts,pistachio, flax seeds, pumpkin seeds, soyabean, canola oil,'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 28}, page_content='for our body for the normal metabolism. This fat will\\nnaturally reduce the bad fat in the body. Fish, Walnuts,pistachio, flax seeds, pumpkin seeds, soyabean, canola oil,\\nand cotton seed oil are the richest source of essential fatty\\nacids.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 29}, page_content='30 PRIMARY PREVENTION OF DIABETESGuidelines to doctors\\n1. Display charts and posters in your clinic on prevention\\nof diabetes\\n2. Spread awareness on healthy lifestyle during clinical\\npractice\\n3. Do one to one counseling of high risk group during\\ngeneral practice\\n4. Advice and motivate the families of your patients to\\nadopt a healthy lifestyle in a short and crisp manner\\n5. Your nurses and assistants can also give advice and\\nspread awareness on diabetes prevention  among your\\ngeneral patients during the routine practice\\n6. Blood glucose tests in high risk categories are\\nrecommended\\nGuidelines to healthworkers / NGOs\\n1. Identify those at high risk\\n2. Give adequate  advice on healthy lifestyle habits\\n3. More counseling should be done particularly to those\\nwith family history of diabetes'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 30}, page_content='primary prevention of diabetes\\n31 PRIMARY PREVENTION OF DIABETES4. Propagate the message of prevention of diabetes even\\nwhile addressing  on any other subject  or disease\\n5. Utilize a lot of display items and pictorial\\nrepresentation for easy understanding of  the message\\namong the people\\n6. Multi lingual lectures, creating public friendly\\natmosphere and individual counseling can be done\\nto create awareness.\\nGuidelines for the general public\\n1. Though knowledge plays an important role in\\nmaintaining good health, attitude is solely responsiblefor preventing diseases\\n2. Implement healthy lifestyle techniques as advised by\\nthe doctors and the media to prevent diabetes\\n3. Be more cautious if you are overweight or have a\\nfamily history of diabetes\\n4. Try  and adopt lifestyle modification if you have a\\nsedentary or low physical activity\\n5. Inculcate healthy eating pattern among your children\\nduring early childhood and discourage fast food and\\njunk food habits.'),\n",
              " Document(metadata={'source': 'Data/MVH_Primary-prevention-of-diabetes.pdf', 'page': 31}, page_content='32 PRIMARY PREVENTION OF DIABETESTen  Commandments for prevention of\\ndiabetes:\\n1. Adopt “Eat less and walk more” principle\\n2. Aim for ideal body weight\\n3. Minimize sugars and sweets\\n4. Avoid food rich in fats and oils\\n5. Eat plenty of vegetables greens, grains and fruits\\n6. Those with sedentary jobs can include atleast 30-45\\nminutes of exercise daily.\\n7. Minimize T.V .watching and spend leisure time in\\nactivities like gardening or exercise\\n8. Check your blood sugar and blood cholesterol levels\\nif you are in the high risk group.\\n9. Practice yoga, meditation and other relaxation\\ntechniques for stress control\\n10. Those at risk must be more cautious and aim for\\nhealthy habits to prevent diabetes'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 0}, page_content='See discussions, st ats, and author pr ofiles f or this public ation at : https://www .researchgate.ne t/public ation/353152586\\nPrevention and Control of Cardiovascular Diseases in India Needs a\\nStrengthened and Well-Fu nctioning Primary Health Care System: A Narrative\\nReview\\nArticle \\xa0\\xa0 in\\xa0\\xa0Journal of Medic al Evidenc e · May 2021\\nDOI: 10.4103/ JME.JME_166_20\\nCITATIONS\\n4READS\\n452\\n6 author s, including:\\nRoy Daniel\\nAll India Instit ute of Medic al Scienc es\\n33 PUBLICA TIONS \\xa0\\xa0\\xa0131 CITATIONS \\xa0\\xa0\\xa0\\nSEE PROFILE\\nAjee t Singh Bhadoria\\nAll India Instit ute of Medic al Scienc es Rishik esh\\n229 PUBLICA TIONS \\xa0\\xa0\\xa03,798  CITATIONS \\xa0\\xa0\\xa0\\nSEE PROFILE\\nAll c ontent f ollo wing this p age was uplo aded b y Roy Daniel  on 01 April 2022.\\nThe user has r equest ed enhanc ement of the do wnlo aded file.'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 1}, page_content='AbstractReview Article\\nIntroductIon\\nThe non‑communicable diseases (NCDs) contribute to nearly \\ntwo‑thirds of the total burden of diseases in India.[1‑3] The \\ncardiovascular diseases (CVDs) account for nearly half of total \\nNCD deaths and around 28% of all deaths in the country.[3,4] \\nThis review article analyses how the ongoing and proposed \\ninitiatives to strengthen the primary health‑care (PHC) system \\ncan contribute to prevention and control of CVDs.\\nMaterIals  and Methods\\nThe desk review of published literature was conducted. The \\nwebsites of the ministries and departments of health and family welfare of the  union and the  state governments in India as well \\nas the online databases including Medline/PubMed, Scopus, \\nEmbase and Google Scholar were searched. The desk review \\nwas supplemented by the hand search of the additional literature \\nin libraries. The desk review was done independently by two \\nauthors (CL and SM). The keywords of CVDs, NCDs, Primary'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 1}, page_content='was supplemented by the hand search of the additional literature \\nin libraries. The desk review was done independently by two \\nauthors (CL and SM). The keywords of CVDs, NCDs, Primary \\nHealth care and India were used for search in identified databases \\nin various combination. The initial literature review was done \\nfrom January to August 2019, which was updated in July 2020.This article reviews the ongoing initiatives to prevent and control cardiovascular diseases (CVDs) and non‑communicable diseases (NCDs) \\nin India and analyses the role of primary health care (PHC) system. The authors note that in last 2 decades, there has been increasing policy \\nrecognition of the challenges posed by CVDs and NCDs in India. The review of ongoing government health program in India indicate \\nthat while the interventions to tackle CVDs and NCD have also been launched and scaled up, a majority of these initiatives continue to be'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 1}, page_content='that while the interventions to tackle CVDs and NCD have also been launched and scaled up, a majority of these initiatives continue to be \\ndelivered through district or sub‑district levels. Though, there has been plans, the scale up through PHC system is at early stage only. There \\nis sufficient scientific evidence that the effective prevention and control of CVDs need accessible health services and a series of public health \\ninterventions through strengthened PHC system. There are learnings from COVID‑19 pandemic response in India (in areas such as private \\nsector engagement, effective enforcement of health regulation, community engagement and the use of tele‑consultations), which can be useful. \\nThe authors conclude that a strengthened and well‑functioning PHC system can ensure increased access to CVD and NCD services. As India \\nplans to scale up ongoing health programs and launch a few new initiatives, the learnings from the past, documented in this paper, could be'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 1}, page_content='plans to scale up ongoing health programs and launch a few new initiatives, the learnings from the past, documented in this paper, could be \\nuseful. These steps would help India to accelerate progress towards universal health coverage.\\nKeywords:  Ayushman Bharat Program, COVID‑19, cardiovascular diseases, health and wellness centres, India, primary health care, \\nPradhan Mantri Atma Nirbhar Swasth Bharat Yojana, universal health coverage\\nAddress for correspondence:  Dr. Chandrakant Lahariya,  \\nB‑7/24/2, First Floor, Safdarjung Enclave Main, New Delhi ‑ 110 029, India.  \\nE‑mail: c.lahariya@gmail.com\\nThis is an open access journal, and articles are distributed under the terms of the Creative \\nCommons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to \\nremix, tweak, and build upon the work non‑commercially, as long as appropriate credit \\nis given and the new creations are licensed under the identical terms.'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 1}, page_content='remix, tweak, and build upon the work non‑commercially, as long as appropriate credit \\nis given and the new creations are licensed under the identical terms.\\nFor reprints contact:  WKHLRPMedknow_reprints@wolterskluwer.com\\nHow to cite this article:  Lahariya C, Mishra S, Daniel RA, Bhadoria AS, \\nMishra DK, Smith RD. Prevention and control of cardiovascular diseases in \\nindia needs a strengthened and well ‑functioning primary health care system: \\nA narrative review. J Med Evid 0;0:0.Prevention and Control of Cardiovascular Diseases in India \\nNeeds a Strengthened and Well-functioning Primary Health \\nCare System: A Narrative Review\\nChandrakant Lahariya1*, Surabhi Mishra2, Roy Arokiam Daniel3, Ajeet Singh Bhadoria4, Deepak Kumar Mishra5, Robert Dean Smith6\\n1Department of Health Systems, World Health Organization India Country Office, New Delhi, India, 2Department of Community Medicine, Himalayan Institute of Medical'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 1}, page_content='1Department of Health Systems, World Health Organization India Country Office, New Delhi, India, 2Department of Community Medicine, Himalayan Institute of Medical \\nSciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India, 3Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India, \\n4Department of Community and Family Medicine, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India, 5The Heart Clinic, Vasai‑Virar, Maharashtra, \\nIndia, 6Department of Anthropology and Sociology, Graduate Institute of International and Development Studies, Geneva, Switzerland\\nAccess this article online\\nQuick Response Code:\\nWebsite:   \\nwww.journaljme.org\\nDOI:   \\n10.4103/JME.JME_166_20\\n© 2021 Journal of Medical Evidence | Published by Wolters Kluwer - Medknow\\n1\\nReceived: 20‑09‑2020 Revised:  03‑12‑2020 Accepted:  09‑02‑2021 Available Online:  08‑07‑2021\\n[Downloaded free from http://www.journaljme.org on Tuesday, July 13, 2021, IP: 10.232.74.22]'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 2}, page_content='Lahariya, et al.: Primary health care and cardiovascular diseases in IndiaEpidemiology of cardiovascular diseases in India\\nIndia has witnessed a rapid transition in CVD risk factors \\nin the past two decades. As an example, the prevalence of \\nhypertension in urban settings has remained nearly stagnant \\nyet relatively high at 28% to 32%, whereas it has increased \\nin rural population[4] from around 10%–12% in the 1990s to \\n22%–25% in 2016.[4,5] A similar upward trend in the prevalence \\nof obesity has been documented.[6] The upward trends in \\ntobacco usage, sedentary lifestyle, abdominal obesity and \\nother metabolic risk factors have contributed to the increased \\nburden of CVDs in India. The CVDs and NCDs, are at times \\nincorrectly  considered as urban only phenomenon. The recent, \\nepidemiological studies have found that the prevalence of \\nrisk factors and disease burden of NCDs and CVDs in rural \\nareas is only marginally lower (than the urban settings) and is'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 2}, page_content='epidemiological studies have found that the prevalence of \\nrisk factors and disease burden of NCDs and CVDs in rural \\nareas is only marginally lower (than the urban settings) and is \\nincreasing at a rapid pace. This situation has evolved alongside \\nthe better scientific understanding of the risk factors for NCDs \\nand CVDs, providing opportunities to develop, design and \\nimplement a range of health interventions. The modifiable risk \\nfactors underscore the scope to reduce the burden of CVDs \\nin India [Table 1].\\nEvolution of key programmes to tackle non -communicable \\ndiseases in India\\nIn the last few years, there has been a series of programmatic \\ninterventions to tackle the CVDs in India  [Box 1]. One of \\nthe key initiatives, the National Programme for Prevention \\nand Control of Cancer, Diabetes, Cardiovascular Diseases \\nand Stroke (NPCDCS), was launched in January 2010.[7] The'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 2}, page_content='the key initiatives, the National Programme for Prevention \\nand Control of Cancer, Diabetes, Cardiovascular Diseases \\nand Stroke (NPCDCS), was launched in January 2010.[7] The \\nprogramme proposed and adopted opportunistic screening approach and has been implemented on a hub‑and‑spoke \\nmodel.[7] Tertiary level hospitals and medical colleges serve as \\n‘hubs,’ whereas peripheral facilities are expected to function \\nas spokes [Figure 1]. The NPCDCS aimed to deliver these \\nservices initially through district hospitals and then scaling up \\nto sub‑district level facilities. The programme focused upon \\nincreasing awareness in the community regarding NCDs and \\nCVDs risk factors, adoption of healthy lifestyles and individual \\nand family counselling for those initiated on treatment, for \\nthe improved compliance.[7] Nearly a decade after launch, by \\nMarch 2020, NPCDCS was being implemented through 665 \\ndistrict NCD cells, 637 district NCD clinics and 4472 NCD'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 2}, page_content='the improved compliance.[7] Nearly a decade after launch, by \\nMarch 2020, NPCDCS was being implemented through 665 \\ndistrict NCD cells, 637 district NCD clinics and 4472 NCD \\nclinics at community health centres (CHCs), across India.[7] \\nThe CVDs specific modifiable risk factors reduction strategies \\nunder NPCDCS and other related programmes are summarized \\nin Table 2.\\nIn 2014, India became the first country in the world to adopt \\nthe World Health Organization’s action plan on NCDs. The \\nplan, termed as ‘25 by 25 plan for NCDs’, proposes a 25% \\nrelative reduction in the overall mortality from CVDs, cancer, \\ndiabetes or chronic respiratory diseases by 2025.[8] In India, \\nthe national action plan (NAP) for prevention and control of \\nNCDs (2017–2022) has been released. The NAP focuses on \\n4 priority areas of (a) integrated and multisectoral coordination \\nmechanisms, (b) prevention and health promotion, (c) health \\nsystems strengthening and (d) surveillance, monitoring,'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 2}, page_content='4 priority areas of (a) integrated and multisectoral coordination \\nmechanisms, (b) prevention and health promotion, (c) health \\nsystems strengthening and (d) surveillance, monitoring, \\nevaluation and research.\\nStarting 2018 and 2019, ‘Eat Right India’ and ‘Fit India’ \\ncampaigns have been launched, which are expected to \\nTable  1: Risk factors of cardiovascular diseases\\nModifiable risk factors Nonmodifiable risk factors\\nBehavioural risk factors\\nMajor\\nTobacco (smoked or smokeless or e‑cigarettes) use\\nUnhealthy diet\\nHigh intake of salt (>5 g/d)\\nHigh intake of sugar and trans fats, and\\nLow consumption of fruits and vege table s\\nPhysical inactivity/sedentary life style\\nHarmful consumption of alcohol (>75 g/day)\\nMinor\\nPerceived stress\\nHousehold air pollution and other environmental hazards (occupational hazards, water and air pollution, etc.)\\nHormonal pillsAge\\nSex\\nGenetic factors/heredity\\nFamily history of diabetes mellitus, \\nhypertension, and dyslipidaemia\\nEthnicity\\nType A personality'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 2}, page_content='Hormonal pillsAge\\nSex\\nGenetic factors/heredity\\nFamily history of diabetes mellitus, \\nhypertension, and dyslipidaemia\\nEthnicity\\nType A personality\\nHormones (hyper‑oestrogenaemia)\\nBiological risk factors*\\nOver weight (Body mass index (BMI) ≥23 kg/m2)/obesity (BMI ≥25 kg/m2) for Asian Indians\\nHigh blood pressure (hypertension)\\nRaised blood sugar (diabetes mellitus)\\nRaised total cholesterol/lipids (dyslipidaemia)\\nUnderlying drivers\\nSocial determinants of health\\nPopulation ageing\\nUrbanisation\\nGlobalisation\\n*Development of biological risk factors takes place only if behavioural risk factors are not managed/modified\\nJournal of Medical Evidence ¦ V olume XX ¦ Issue XX ¦  Month 2021\\n2\\n[Downloaded free from http://www.journaljme.org on Tuesday, July 13, 2021, IP: 10.232.74.22]'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 3}, page_content='Lahariya, et al.: Primary health care and cardiovascular diseases in Indiacontribute to reduce the burden of NCDs and CVDs in the \\ncountry.[9,10] The SWOT analysis of ongoing key CVDs \\ninterventions is provided in Box 2.\\nTwo decades of evidence synthesis\\nIndia, for the last two decades, has been facing a dual burden \\nof diseases where the communicable diseases are still a challenge, but NCDs are rapidly increasing. Considering the \\nchallenge of communicable diseases was fully well known \\nsince independence, the government health services across the \\ncountry were designed mainly to tackle infectious diseases. The \\nchallenge of NCDs was not fully acknowledged till as recent as \\nyear 2002. The second national health policy (NHP) of India, \\nreleased in that year, had very limited attention on NCDs.[11] \\nArguably, it was only after 2005, when epidemiologists and \\npublic health community generated and released additional \\nepidemiological analyses, evidence and data, that NCDs and'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 3}, page_content='Arguably, it was only after 2005, when epidemiologists and \\npublic health community generated and released additional \\nepidemiological analyses, evidence and data, that NCDs and \\nCVDs started getting some policy attention.[12‑14]\\nIndia’s third and the latest NHP was released in 2017 and  \\nacknowledged the challenge of importance of NCDs and \\nCVDs in the country and has provided a fresh opportunity \\nto strengthen efforts for NCD prevention and control in \\nIndia.[15] India specific burden of disease report, released in \\nlate 2017,  highlighted the state‑specific burden of diseases and \\nhow the NCDs and CVDs are the emerging challenges.[4] These \\ndevelopments were followed by launch of Ayushman Bharat \\nProgramme (ABP) in February 2018.[16] The ABP had one of \\nthe two arms, named as health and wellness centres (HWCs), \\nwhich aims to strengthen PHC system through augmentation \\nof human resources and broadening of package of services, \\nwhich include NCDs and CVDs services.[16‑18]'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 3}, page_content='which aims to strengthen PHC system through augmentation \\nof human resources and broadening of package of services, \\nwhich include NCDs and CVDs services.[16‑18]\\nThe policy formulation essential but not sufficient\\nThe vertical disease specific programmes, fragmented service \\ndelivery and the missing links in health service delivery are a \\nfew recognised challenges in health services in most low‑ and \\nmiddle‑income countries as well as in India. A weak or very Box 1: Various policies and programmes to tackle \\nnoncommunicable diseases India\\nYears Programmes\\n2003 India becomes a signatory to Framework convention on \\ntobacco control (FCTC); the tobacco control Act of India, \\n2003 enacted\\n2007 National tobacco control programme (NTCP) launched\\n2010 National programme for prevention and control of cancer, \\ndiabetes, CVDs and stroke  (NPCDCS) launched\\n2011 New Delhi ‘call for action’ to combat NCDs\\n2013 National NCD monitoring framework developed'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 3}, page_content='diabetes, CVDs and stroke  (NPCDCS) launched\\n2011 New Delhi ‘call for action’ to combat NCDs\\n2013 National NCD monitoring framework developed\\n2014 A consultation for National multisectoral action plan  \\n(NMAP) organised\\n2014 Joint mission of United Nations (UN) interagency task force\\n2015 Country framework for action to engage the sectors beyond \\nhealth for NCDs\\n2016 Inter‑ministerial consultation agree on NMAP\\n2017 National health policy 2017 released, which emphasised the \\nimportance to prevent and control NCDs in India\\n2018 Ayushman Bharat Programme with two components launched\\n2018 Eat right India campaign\\n2019 Fit India campaign\\n2021 Pradhan Mantri Atma Nirbhar Swasth Bharat Yojana announced\\nJournal of Medical Evidence ¦ V olume XX ¦ Issue XX ¦  Month 2021\\n3\\nFigure  1: Hub‑and‑spoke model of NPCDCS\\n[Downloaded free from http://www.journaljme.org on Tuesday, July 13, 2021, IP: 10.232.74.22]'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 4}, page_content='Lahariya, et al.: Primary health care and cardiovascular diseases in IndiaTable  2: Cardiovascular diseases risk factors reduction strategies at individual, family and community level\\nModifiable risk factors Risk factor reduction strategies\\nTobacco (smoke \\nor smokeless or \\ne‑cigarettes) useQuit tobacco use\\nUsing 3 steps to counsel: (i) Ask: Using Fagerstrom nicotine dependence questionnaire to identify extent of dependency; (ii) \\nAssist: In quitting by using a balance Sheet in local language to discuss pros and cons of using/quitting tobacco, and (iii) \\nArrange: For referrals and follow up. Involve family, if required\\nHealth promotion activities such as organising community campaigns, disseminating health information, working with local \\ngroups as a part of anti‑tobacco movement\\nCOTPA, under NTCP bans smoking in public places, its advertising, and sale to minors. It mandates compulsory display'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 4}, page_content='groups as a part of anti‑tobacco movement\\nCOTPA, under NTCP bans smoking in public places, its advertising, and sale to minors. It mandates compulsory display \\nof health warnings on tobacco products. NTCP provides tuberculosis cessation centres at DH to provide regular out‑patient \\ntobacco cessation services\\nNational Tobacco Quitline and mCessation are initiatives, where people can get telephonic counselling and tips to quit \\ntobacco\\nUnhealthy diet (high \\nintake of salt (>5 g/d), \\nsugar, trans fats, and low \\nfruits and vege table s \\nconsumption)Promote healthy dietary practices\\nUsing 3 steps to counsel: (i) Ask: routine diet (using 24 h recall method and unhealthy diet checklist). Compute and score \\nBMI and WHR based on anthropometric measurements, (ii) Assist: In behaviour change by using traffic signal approach, \\nand balance sheet in local language to discuss pros and cons of eating healthy/unhealthy diet. Prepare meal plan preferably'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 4}, page_content='and balance sheet in local language to discuss pros and cons of eating healthy/unhealthy diet. Prepare meal plan preferably \\nafter consulting with MO, considering subject’s age and medical condition. Planned meal must be a blend of four major \\nfood groups‑energy giving, body building, protective and fibre‑rich, ensuring limited energy intake from fat to 30% of total \\ncalorie intake, sugar to 10% and daily intake of salt to <5 g/day. (iii) Arrange for referrals and follow up for those with \\nestablished NCDs for specific dietary recommendation or any medical assistance\\nThe community needs to be educated about healthy dietary practices\\nHarmful alcohol \\nconsumption (>75 g/d)Manage alcohol use disorders\\nUsing 3 steps to counsel: (i) Ask: for hazardous drinkers (using AUDIT‑C assessment tool); (ii) Assist in behaviour change by \\nusing traffic signal approach, and balance sheet in local language to discuss pros and cons of using/quitting alcohol. Special'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 4}, page_content='using traffic signal approach, and balance sheet in local language to discuss pros and cons of using/quitting alcohol. Special \\ncounselling on relapse prevention to high dependents (iii) Arrange for referrals and follow up. involve family, if required\\nAlcohol‑related special health promotion activities in community\\nPhysical inactivity/\\nsedentary life stylePromoting Physical Activity (PA)\\nUsing 3 steps to counsel: (i) Ask: for PA levels. Compute and score BMI and WHR based on anthropometric \\nmeasurements; (ii) Assist in behaviour change by using traffic signal approach, and balance sheet in local language to \\ndiscuss pros and cons of enough PA. Advice about exact PA level preferably after consulting with MO, considering subject’s \\nage and medical condition. WHO recommends minimum 60 min daily moderate‑to‑vigorous intensity PA for ages 5‑17; \\nand 150 min of moderate intensity PA per week with at least 75 min of vigorous intensity aerobic activity for ages ≥18; (iii)'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 4}, page_content='and 150 min of moderate intensity PA per week with at least 75 min of vigorous intensity aerobic activity for ages ≥18; (iii) \\nArrange for referrals and follow‑up\\nPA‑related special health promotion activities in community\\nPerceived stress Reducing perceived stress\\nUse 3 steps to counsel: (i) Ask: Using checklist for depression, (ii) Assist: By encouraging healthy coping skills, (iii) Arrange \\nfor referral and follow‑up for those with significant depression and anxiety or suicidal risk. Involve family , if required\\nCommunity awareness regarding silent stress, healthy coping skills, and help seeking care for depression, anxiety or suicidal \\nthoughts\\nIndoor air pollution Reducing indoor air pollution: Maintain indoors cleanliness by using (i) Cleaner fuels (electricity, LPG or piped gas, solar \\ncookers, biogas), (ii) Proper chimneys in cooking area, (iii) Improving ventilation inside house, (iv) Avoiding passive smoking'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 4}, page_content='cookers, biogas), (ii) Proper chimneys in cooking area, (iii) Improving ventilation inside house, (iv) Avoiding passive smoking \\nor secondhand smoke, (v) No livestock inside the house or maintaining cleanliness when there are pets inside or around the \\nhouse, (vi) Keep walls and floors dry to reduce exposure to dust mites and moulds. Wear mask or cover nose and mouth during \\nhouse cleaning\\nCOTPA: Cigarettes and Other Tobacco Products Act, NTCP: National tuberculosis control programme, DH: District hospitals, BMI: Body mass index, \\nWHR: Waist‑hip ratio, MO: Medical officer, AUDIT‑C: Alcohol use disorders identification test ‑ Concise, PA: Physical activity\\nJournal of Medical Evidence ¦ V olume XX ¦ Issue XX ¦  Month 2021\\n4\\nlimited continuum of care across the levels often results in low  \\nawareness, persistent low disease detection rates, poor use of \\nevidence‑based interventions and low rates of adherence to care.\\nAlthough various government initiatives to tackle NCDs and'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 4}, page_content='awareness, persistent low disease detection rates, poor use of \\nevidence‑based interventions and low rates of adherence to care.\\nAlthough various government initiatives to tackle NCDs and \\nCVDs in India had been designed for scale up till primary \\nhealth care systems, most continue to be delivered through \\ndistrict and sub‑district level health facilities. The experience \\nfrom national programmes aimed at tobacco control; AIDS \\ncontrol and mental health have provided learnings that if \\nprogrammes are delivered through district and sub‑district \\nlevel facilities only, the utilisation remains sub‑optimal and \\nimpact marginal. It is not surprising that NPCDCS in India \\nhad made limited impact. The preventive and promotive health interventions (also termed as public health interventions) for \\nNCDs and CVDs can be best delivered when services are \\nclose to the people and through primary health‑care facilities.\\nThe sub‑optimal functioning of government PHC system'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 4}, page_content='NCDs and CVDs can be best delivered when services are \\nclose to the people and through primary health‑care facilities.\\nThe sub‑optimal functioning of government PHC system \\nbecomes a deterrent for policy makers and programme \\nmanagers to rapidly expand the programme through PHC \\nservices. A  study conducted in Madhya Pradesh state of India, \\nwhich had assessed the readiness of health facilities, found \\nthat only 11% of PHCs were equipped and ready to treat \\nand prevent CVDs.[19] Yet, a major responsibility to deliver \\npreventive and promotive services is on government health \\nsub‑system as there is limited incentive to private health sector \\nto deliver such services.[20]\\n[Downloaded free from http://www.journaljme.org on Tuesday, July 13, 2021, IP: 10.232.74.22]'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 5}, page_content='Lahariya, et al.: Primary health care and cardiovascular diseases in IndiaBox 2: Strengths weaknesses opportunities threats analysis of cardiovascular diseases prevention and control \\nprogrammes in India\\nStrengths Weaknesses\\nNational programme for tackling NCDs has evolved and there is wide \\nunderstanding and awareness about interventions\\nIntegration of key non‑communicable diseases is being given attention\\nNPCDCS has been scaled up to cover most of the districts in India\\nThere seems to be a political will to tackle NCDs\\nMany new and complementary health initiatives are being startedLow and insufficient government funding\\nShortage of human resources\\nCapacity of front‑line health workers in tackling \\nNCDs is limited\\nPHCs are not well equipped, though provisions are \\nmade through NPCDCS\\nPoor monitoring and evaluation\\nLow levels of community awareness and participation\\nOpportunities Threats\\nAdopt ‘best buys’\\nExpand the NCD surveillance by the states'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 5}, page_content='made through NPCDCS\\nPoor monitoring and evaluation\\nLow levels of community awareness and participation\\nOpportunities Threats\\nAdopt ‘best buys’\\nExpand the NCD surveillance by the states\\nRecognition of the need for increased funding for health\\nRecruitment of Community Health Officers (CHOs) under HWCs\\nRenewed emphasis on health promotion with vulnerability assessment\\nTraffic signal system proposed to be implemented by FSSAI for all \\npackaged food items\\nHWC initiative under ABPRising burden of NCDs and CVDs\\nDiversity in sub‑populations require local level \\nstrategies\\nGlobalisation, urbanisation in food habits and lifestyle\\nCommercial determinants of health\\nGrowing private sectors with focus largely on curative \\nservices\\nInequities in the health care system\\nCVDs: Cardiovascular diseases, NCDs: Noncommunicable diseases, FSSAI: Food Safety and Standards Authority of India, HWCs: Health and wellness'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 5}, page_content='services\\nInequities in the health care system\\nCVDs: Cardiovascular diseases, NCDs: Noncommunicable diseases, FSSAI: Food Safety and Standards Authority of India, HWCs: Health and wellness \\ncentres, ABP: Ayushman Bharat Programme, NPCDCS: National programme for prevention and control of cancer, diabetes, CVDs and stroke, PHC: Primary \\nhealth care\\nJournal of Medical Evidence ¦ V olume XX ¦ Issue XX ¦  Month 2021\\n5India has nearly a decade of experience in the implementation \\nof various initiatives to tackle CVDs and NCDs. Now, the \\nHWCs initiatives under ABP is another opportunity for CVD \\nand NCD prevention, which should be optimally utilised. As \\npart of the expanded package of services under HWCs, the \\nservices for NCDs including CVDs have been included and \\nthere is focus upon the assured provision of preventive and \\npromotive health services. The population‑based screening  \\n(PBS) is proposed to be done and community‑based assessment'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 5}, page_content='there is focus upon the assured provision of preventive and \\npromotive health services. The population‑based screening  \\n(PBS) is proposed to be done and community‑based assessment \\nchecklist (CBAC) is to be filled.[21] These are the opportunity \\nto expand the CVD prevention and treatment services through \\nPHC system, ensuring the continuity of care.\\nStrengthening PHC services is not the need for rural population \\nonly. The urban population in India is nearly half of the rural \\npopulation; yet, a number of primary health centres in urban \\nIndia are one‑fifth of the PHCs in rural India.[22] While the \\nPHC facilities in rural India need to be made functional, in \\nurban settings, the newer PHC facilities need to be set up and \\nthe already existing facilities should be upgraded to deliver \\ncomprehensive PHC services and made functional.[23] The \\ninterest of a number of Indian states in setting up community \\nor Mohalla  clinics is another opportunity.[24] There is'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 5}, page_content='comprehensive PHC services and made functional.[23] The \\ninterest of a number of Indian states in setting up community \\nor Mohalla  clinics is another opportunity.[24] There is \\nemerging evidence that community clinics in Indian states are \\nmaking health services available and accessible to poor and \\nmarginalised, addressing health inequities.[24,25] These clinics \\ncan also help tackle NCDs and ensure continuity of care as well. \\nHowever, this will succeed only if the scale up is not ‘notional’ \\nbut actually make the facilities functional and the proposed \\nservices ‘available’ in an assured manner. It will require focused \\nattention and oversight by the union and state governments.\\nIn tackling the burden of CVDs and NCDs, there is  need \\nto optimise and harmonise the ongoing discourses. There is renewed focus in India on increased engagement of urban local \\nbodies in delivery of health services. The 74th amendment in the'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 5}, page_content='to optimise and harmonise the ongoing discourses. There is renewed focus in India on increased engagement of urban local \\nbodies in delivery of health services. The 74th amendment in the \\nconstitution of India has assigned the responsibility of primary \\ncare and public health to the urban local bodies (ULBs). \\nHowever, very few ULBs in India prioritise spending on health \\nand delivery of the health services.[26] Of the total government \\nspending on health, only 4% is contributed by the ULBs.[27,28] \\nIt is time that ULBs take more responsibility in provision of \\nhealth services through a stronger PHC system.\\nThe prevention and control of CVDs and NCDs[29] can and \\nshould benefit from the  learnings from COVID‑19 pandemic \\nresponse.[30] The need for strengthening public health services, \\nthe role of community participation and the role of effective \\nenforcement of  health regulation  has been widely understood \\nin COVID‑19 pandemic response. It was the community and'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 5}, page_content='the role of community participation and the role of effective \\nenforcement of  health regulation  has been widely understood \\nin COVID‑19 pandemic response. It was the community and \\npeople who adhered to public health advices such as face \\nmasks, hand washing and physical distancing which helped in \\nthe fight against the pandemic.[28,30] Sustaining such behavior \\nover a longer period of time require effective public health \\ncommunication. The learnings from pandemic can be used to \\nmotivate and engage people for another set of public health \\ninterventions such as healthy diet, regular physical activity, \\nno smoking and to avoid harmful use of alcohol. If people \\ncan adhere to and follow one set of public health advice; they \\ncan also be ‘nudged’ to follow another set of advices. The \\napplication of learnings from COVID‑19 pandemic can help \\nin reducing the burden of NCDs and CVDs.\\nIt can be argued that people followed public health advice'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 5}, page_content='application of learnings from COVID‑19 pandemic can help \\nin reducing the burden of NCDs and CVDs.\\nIt can be argued that people followed public health advice \\nwhen there were functioning health services such as testing \\nand treatment for conditions for which they were expected \\nto adhere to public health advice. It can work if the health \\nfacilities are strengthened to provide assure, timely and \\n[Downloaded free from http://www.journaljme.org on Tuesday, July 13, 2021, IP: 10.232.74.22]'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 6}, page_content='Lahariya, et al.: Primary health care and cardiovascular diseases in India\\nJournal of Medical Evidence ¦ V olume XX ¦ Issue XX ¦  Month 20216\\naffordable testing and treatment services for CVDs and NCDs \\nthrough government sector. That might be the right motivation \\nfor people to adhere to the preventive advice. This need to \\nbe studied further; however, there is evidence to argue that \\npreventive and promotive advice is more likely to be adhered \\nto, when curative and diagnostic services are functional (for \\nsame disease conditions). \\nAnother learning from COVID‑19 pandemic is that it is \\nhealth‑care systems and not just medical care system which is \\nneeded to tackle the ongoing ‘silent pandemics’ such as CVDs \\nand NCDs as well as the pandemics due to novel pathogens. \\nThe medical care system supplemented by a stronger and \\nwell‑functioning public health services make the health‑care \\nsystem.\\nIn a mix health‑care system such as India, the effective'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 6}, page_content='The medical care system supplemented by a stronger and \\nwell‑functioning public health services make the health‑care \\nsystem.\\nIn a mix health‑care system such as India, the effective \\ncontrol of CVDs and NCDs required that both public and \\nprivate sector worked together. It needs to be explored \\nhow private sector can be better engaged in preventive and \\npromotive interventions. Considering private sector focuses \\nupon  delivery of  curative and medical care services, getting \\nthem engaged in preventive and promotive services requires \\nadditional strategies and resources. The effective referral \\nlinkage – two ways and not just one direction – will help to \\nensure that speciality services at secondary and tertiary care \\nare used by those who need them, and the specialist doctor’s \\ntime is not consumed for caring for the conditions, which can \\nbe tackled at primary care level.\\nThe innovations and new tools such as legalisation of \\ntele‑consultation during COVID‑19 pandemic could be'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 6}, page_content='be tackled at primary care level.\\nThe innovations and new tools such as legalisation of \\ntele‑consultation during COVID‑19 pandemic could be \\nimmensely useful platform or NCDs and CVD‑related \\nservices in India. The tele‑consultation approaches has been \\nwidely adopted by the private health sector in India. It holds \\nthe potential to make specialist services available through \\ntele‑consultation at rural and remote PHCs and health \\nsub‑centres. This will save resources from the government and \\ntime for the people in accessing health services. This can also \\npartly contribute to address widespread inequities in provision \\nof health services as well as in health outcomes.  \\nIn February 2021, a new initiative to strengthen health systems, \\nPradhan Mantri Atma Nirbhar Swasth Bharat Yojana, was \\nannounced in the union budget (2021–2022) of India. This \\nprogramme, in addition to other components, has focus \\non setting up urban PHCs and strengthening rural HWC'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 6}, page_content='announced in the union budget (2021–2022) of India. This \\nprogramme, in addition to other components, has focus \\non setting up urban PHCs and strengthening rural HWC \\ninfrastructure. As part of this initiative, a total of 28,812 \\nHWCs would be upgraded and made functional.[31] This \\ninitiative should also be explored and used to to scale up CVD \\nand NCD services. Alongside, a provision of unconditional \\ngrant for health has been made through the fifteenth finance \\ncommission to the elected local bodies (urban local bodies and \\nPanchayati Raj  Institutions).[32,33] A total of Rs 70,000 crore \\nwill be allocated over a period of 5 years, and in the financial \\nyear 2021–2022, Rs. 13,192 crore has been allocated. This \\ngrant is another opportunity where health programme managers \\nof state governments need to work closely  and in coordination with officials of the local bodies to use the funds for preventive, \\npromotive and other public health interventions.[32]\\nconclusIon'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 6}, page_content='of state governments need to work closely  and in coordination with officials of the local bodies to use the funds for preventive, \\npromotive and other public health interventions.[32]\\nconclusIon\\nThere is a dual burden of communicable and noncommunicable \\ndiseases in India. A  proportion of CVDs and NCDs are \\npreven table . The strengthening of PHC system and the \\nprovision of public health services has potential to tackle the \\nburden of CVDs and NCDs in India. The initiatives such as \\nHWCs under ABP and recently announced ‘Pradhan Mantri \\nAtma Nirbhar Swasth Bharat Yojana’ should be used for \\nintegration and accelerated scaled up of CVDs and NCDs \\nservices and to ensure continuity of care. The learnings from \\nCOVID‑19 pandemic such as public health communication, \\nmeaningful private sector engagement, community engagement \\nand participation, legalisation of tele‑consultations as well \\nas  the renewed interest of state governments in setting up'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 6}, page_content='meaningful private sector engagement, community engagement \\nand participation, legalisation of tele‑consultations as well \\nas  the renewed interest of state governments in setting up \\ncommunity clinics should be effectively used. The increased \\navailability, accessibility and affordability of CVDs and NCDs \\nservices through PHC system is the right approach and it will \\nalso help India to accelerate progress toward universal health \\ncoverage.\\nDisclaimer\\nCL is the staff member of the World Health Organization \\n(WHO). The views in this article are personal, and do not \\nnecessarily represent the decisions, policy, or views of \\ninstitutions/organizations, CL and other authors, which they \\nhave been affiliated at present or in the past. \\nFinancial support and sponsorship\\nNil.\\nConflicts of interest\\nThere are no conflicts of interest.\\nreferences\\n1. World Health Organization. Global Status Report on Noncommunicable \\nDiseases 2010. Geneva: World Health Organization; 2011. p. 1‑89.'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 6}, page_content='There are no conflicts of interest.\\nreferences\\n1. World Health Organization. Global Status Report on Noncommunicable \\nDiseases 2010. Geneva: World Health Organization; 2011. p. 1‑89.\\n2. World Health Organization. Cardiovascular Diseases: Fact sheet. Geneva: \\nWorld Health Organization; 2017. Available from: https://www.who.int/\\nen/news‑room/fact‑sheets/detail/cardiovascular‑diseases‑(cvds). [Last \\naccessed on 2019 May 27].\\n3. Institute of Health Metrics and Evaluation. Global Burden of Disease. \\nCompare; 2010. Available from: http://vizhub.healthdata.org/\\ngbd‑compare/. [Last accessed on 2019 May 27].\\n4. India State‑Level Disease Burden Initiative CVD Collaborators. The \\nchanging patterns of cardiovascular diseases and their risk factors in the \\nstates of India: The Global Burden of Disease Study 1990‑2016. Lancet \\nGlob Health 2018;6:e1339‑51.\\n5. Gupta R. Convergence in urban‑rural prevalence of hypertension in \\nIndia. J Hum Hypertens 2016;30:79‑82.'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 6}, page_content='Glob Health 2018;6:e1339‑51.\\n5. Gupta R. Convergence in urban‑rural prevalence of hypertension in \\nIndia. J Hum Hypertens 2016;30:79‑82.\\n6. Wang Y , Chen HJ, Shaikh S, Mathur P. Is obesity becoming a public \\nhealth problem in India? Examine the shift from under – To overnutrition \\nproblems over time. Obes Rev 2009;10:456‑74.\\n7. Govt of India. National Programme for Prevention and Control of \\nCancer, Diabetes, Cardiovascular Diseases and Stroke. MoHFW, \\nNirman Bhawan, Govt of India. Available from: https://dghs.gov.in/\\ncontent/1363_3_NationalProgrammePreventionControl.aspx. [Last \\naccessed on 2019 May 27, at 19:30 IST].\\n8. Ministry of Health and Family Welfare. National Action Plan 2025. \\n[Downloaded free from http://www.journaljme.org on Tuesday, July 13, 2021, IP: 10.232.74.22]'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 7}, page_content='Lahariya, et al.: Primary health care and cardiovascular diseases in India\\nJournal of Medical Evidence ¦ V olume XX ¦ Issue XX ¦  Month 20217WHO’s Action Plan for Prevention and Control of NCDs. PIB Release; \\n02 Dec, 2014. Available from: https://pib.gov.in/newsite/PrintRelease.\\naspx?relid=112334. [Last accessed on 2019 May 27, at 19:30 IST].\\n9. Eat Right India. Accessed from: https://eatrightindia.gov.in/index. [Last \\naccessed on 2021 Jan 24, at 14:30 hrs IST].\\n10. Fit India. Available from: http://fitindia.gov.in/. [Last accessed on 2021 \\nJan 24, at 14:30 hrs IST].\\n11. Govt of India. National Health Policy 2002. New Delhi: MoHFW, Govt \\nof India; 2002.\\n12. Gupta R, Joshi P, Mohan V , Reddy KS, Yusuf S. Epidemiology \\nand causation of coronary heart disease and stroke in India. Heart \\n2008;94:16‑26.\\n13. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al . \\nEffect of potentially modifiable risk factors associated with myocardial'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 7}, page_content='2008;94:16‑26.\\n13. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al . \\nEffect of potentially modifiable risk factors associated with myocardial \\ninfarction in 52 countries (the INTERHEART study): Case‑control \\nstudy. Lancet 2004;364:937‑52.\\n14. Gupta R, Guptha S, Sharma KK, Gupta A, Deedwania P. Regional \\nvariations in cardiovascular risk factors in India: India heart watch. \\nWorld J Cardiol 2012;4:112‑20.\\n15. Government of India. National Health Policy 2017. New Delhi: Ministry \\nof Health and Family Welfare, Government of India; 2017.\\n16. Lahariya C. ‘Ayushman Bharat’ Program and Universal Health Coverage \\nin India. Indian Pediatr 2018;55:495‑506.\\n17. Lahariya C. Health & wellness centers to strengthen primary health \\ncare in India: Concept, progress and ways forward. Indian J Pediatr \\n2020;87:916‑29.\\n18. Lahariya C, Sundararaman T, Ved RR, Adithyan GS, De Graeve H, \\nJhalani M, et al. What makes primary healthcare facilities functional,'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 7}, page_content='2020;87:916‑29.\\n18. Lahariya C, Sundararaman T, Ved RR, Adithyan GS, De Graeve H, \\nJhalani M, et al. What makes primary healthcare facilities functional, \\nand increases the utilization? Learnings from 12 case studies. J Family \\nMed Prim Care 2020;9:539‑46.\\n19. Pakhare A, Kumar S, Goyal S, Joshi R. Assessment of primary care \\nfacilities for cardiovascular disease preparedness in Madhya Pradesh, \\nIndia. BMC Health Serv Res 2015;15:408.\\n20. Lahariya C. Stronger government health sub‑system is the way to \\nadvance universal health coverage in India. J Med Evid 2020;1:133‑7.\\n21. Government of India. Ayushman Bharat: Comprehensive Primary \\nHealth Care through Health and Wellness Centres: Operational \\nGuidelines. New Delhi: Ministry of Health and Family Welfare, Govt \\nof India; 2018. Accessed from: https://ab‑hwc.nhp.gov.in/download/\\ndocument/45a4ab64b74ab124cfd853ec9a0127e4.pdf. [Last accessed \\non 2021 Feb 07, at 21:30 Hrs IST].'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 7}, page_content='of India; 2018. Accessed from: https://ab‑hwc.nhp.gov.in/download/\\ndocument/45a4ab64b74ab124cfd853ec9a0127e4.pdf. [Last accessed \\non 2021 Feb 07, at 21:30 Hrs IST].\\n22. Lahariya C. Mohalla Clinics of Delhi, India: Could these become \\nplatform to strengthen primary healthcare? J Family Med Prim Care 2017;6:1‑10.\\n23. Lahariya C, Bhagwat S, Saksena P, Samuel R. Strengthening Urban \\nhealth for advancing universal health coverage in India. J Health \\nManage 2016;18:361‑6.\\n24. Lahariya C. Access, utilization, perceived quality, and satisfaction \\nwith health services at Mohalla (Community) Clinics of Delhi, India. \\nJ Family Med Prim Care 2020;9:5872‑80.\\n25. Agrawal T, Bhattacharya S, Lahariya C. Pattern of use and determinants \\nof return visits at community or Mohalla clinics of Delhi, India. Indian \\nJ Community Med 2020;45:77‑82.\\n26. Lahariya C. Basthi Dawakhana of Telangana, India: The first Urban \\nlocal body led community clinic initiatives of India. J Family Med Prim \\nCare 2019;8:1401‑7.'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 7}, page_content='J Community Med 2020;45:77‑82.\\n26. Lahariya C. Basthi Dawakhana of Telangana, India: The first Urban \\nlocal body led community clinic initiatives of India. J Family Med Prim \\nCare 2019;8:1401‑7.\\n27. Lahariya C. Union Budget 2021‑22 and Health: Time to Redeem the \\nPledge. New Delhi: The Times of India; 25 January 2021. Available from: \\nhttps://timesofindia.indiatimes.com/business/india‑business/opinion‑\\nunion‑budget‑2021‑may‑look‑to‑provide‑funding‑boost‑to‑healthcare‑se\\nctor/articleshow/80454597.cms. [Last accessed on 2021 Feb 06, at 19:30 \\nIST].\\n28. Lahariya C, Kang G, Guleria R. For India, Pandemic is an \\nOpportunity to Move Towards Universal Health Coverage. \\nNew Delhi: Indian Express; 9 December, 2020. Accessed from: \\nhttps://indianexpress.com/article/opinion/columns/needed‑more‑ \\nwealth‑in‑health‑sector‑coronavirus/. [Last accessed on 2021 Jan 24, at \\n14:30 hrs IST].\\n29. Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 7}, page_content='wealth‑in‑health‑sector‑coronavirus/. [Last accessed on 2021 Jan 24, at \\n14:30 hrs IST].\\n29. Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in \\nIndia: Current epidemiology and future directions. Circulation \\n2016;133:1605‑20.\\n30. Lahariya C, Kang G, Guleria R. Till We Win: India’s Fight Against the \\nCOVID‑19 Pandemic. New Delhi: Penguin Random House India; 2020.\\n31. Ministry of Finance. Union Budget 2021‑22. New Delhi: Ministry of \\nFinance; 2021. Accessed from: https://www.indiabudget.gov.in/. [Last \\naccessed on 2021 Feb 06, at 19:30 IST].\\n32. Pandharipande N. Govt Should Educate Public on Linkages Between \\nHealth, Economic Growth, Says Chandrakant Lahariya. New Delhi: The \\nFirstpost; 9 February, 2021. Accessed from: https://www.firstpost.com/\\nindia/govt‑should‑educate‑public‑on‑linkages‑between‑health‑econom\\nic‑growth‑says‑chandrakant‑lahariya‑9283791.html. [Last accessed on \\n2021 Feb 09, at 10:00 am IST].\\n33. Press Information Bureau. The Report of the Fifteenth Finance'),\n",
              " Document(metadata={'source': 'Data/JMedEvid000-1254579_032905.pdf', 'page': 7}, page_content='ic‑growth‑says‑chandrakant‑lahariya‑9283791.html. [Last accessed on \\n2021 Feb 09, at 10:00 am IST].\\n33. Press Information Bureau. The Report of the Fifteenth Finance \\nCommission. Fifteenth Finance Commission. Press Release; 01 \\nFebruary, 2021. Accessed from: https://pib.gov.in/PressReleasePage.\\naspx?PRID=1693868. [Last accessed on 2021 Feb 07, at 21:30 hrs IST].\\n[Downloaded free from http://www.journaljme.org on Tuesday, July 13, 2021, IP: 10.232.74.22]\\nView publication stats'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 0}, page_content='Prevention of \\nCardiovascular Disease\\nPocket Guidelines for Assessment and  \\nManagement of Cardiovascular Risk \\nGeneva,  \\nReprint 2012Predicting\\nHeart \\nAttackand\\nStroke risk'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 2}, page_content='Prevention of  \\nCardiovascular Disease\\nPocket Guidelines for Assessment and  \\nManagement of Cardiovascular Risk \\nReprint 2012'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 3}, page_content='WHO library Cataloguing-in-Publication Data \\nPrevention of cardiovascular disease : pocket guidelines for assessment and management of \\ncardiovascular risk : (WHO/ISH cardiovascular risk prediction charts for the European Region).\\n1.Cardiovascular diseases – prevention and control. 2.Cardiovascular diseases – diagnosis.  \\n3.Risk factors. 4.Risk assessment. 5.Guidelines. 6.Charts. 7.European Region (WHO).  \\nI.World Health Organization. II.Title: Pocket guidelines for assessment and management of \\ncardiovascular risk : (WHO/ISH cardiovascular risk prediction charts for the European Region).\\nISBN 978 92 4 154727 7    (NLM classification: WG 120)\\nWHO/ISH charts for all WHO Member States are in the compact disc.\\nOther risk prediction charts are already available for Australia, Canada, New Zealand , United \\nStates of America and many countries  in Europe. \\n© World Health Organization 2012\\nAll rights reserved. Publications of the World Health Organization can be obtained from WHO Press,'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 3}, page_content='States of America and many countries  in Europe. \\n© World Health Organization 2012\\nAll rights reserved. Publications of the World Health Organization can be obtained from WHO Press, \\nWorld Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate \\nWHO publications – whether for sale or for noncommercial distribution – should be addressed to \\nWHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int). \\nThe designations employed and the presentation of the material in this publication do not imply the \\nexpression of any opinion whatsoever on the part of the World Health Organization concerning the \\nlegal status of any country, territory, city or area or of its authorities, or concerning the delimitation of'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 3}, page_content='legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of \\nits frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.\\nThe mention of specific companies or of certain manufacturers’ products does not imply that they \\nare endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are \\ndistinguished by initial capital letters.\\nAll reasonable precautions have been taken by the World Health Organization to verify the \\ninformation contained in this publication. However, the published material is being distributed \\nwithout warranty of any kind, either expressed or implied. The responsibility for the interpretation'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 3}, page_content='information contained in this publication. However, the published material is being distributed \\nwithout warranty of any kind, either expressed or implied. The responsibility for the interpretation \\nand use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. \\nPrinted in'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 4}, page_content='Contents \\nIntroduction 1\\nTarget audience 2\\nSettings 2\\nResource needs 2\\nWhat are the goals of implementing these guidelines ? 2\\nWho needs referral to a specialist facility? 3\\nPart \\n1Assessing and managing cardiovascular risk in people with \\nrisk factors who have not yet developed clinically manifest cardiovascular disease (primary prevention)5\\nWhen is grading cardiovascular risk using charts unnecessary for making treatment decisions? 7\\nInstructions for using WHO/ISH risk prediction charts 7\\nPractice points 9\\nTable 1  WHO/ISH risk prediction charts by epidemiological sub-\\nregion and WHO Member States 10\\nFigure 1  An example of a WHO/ISH risk prediction chart 12\\nRecommendations for prevention of cardiovascular disease 18\\nPart \\n2Management of people with established coronary heart disease \\n(CHD), Cerebrovascular disease (CeVD) or peripheral vascular \\ndisease (secondary prevention)25\\nRecommendations for prevention of recurrent CHD (heart attack) \\nand CeVD (stroke) events 26'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 4}, page_content='(CHD), Cerebrovascular disease (CeVD) or peripheral vascular \\ndisease (secondary prevention)25\\nRecommendations for prevention of recurrent CHD (heart attack) \\nand CeVD (stroke) events 26\\nTable 2  Causes and clinical features of secondary hypertension 31\\nTable 3  Clinical features of malignant hypertension 31\\nTable 4  Drugs and daily dosages 32'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 6}, page_content='1Introduction\\nCardiovascular disease (CVD) is a major cause of disability and premature \\ndeath throughout the world. The underlying pathology is atherosclerosis, which develops over many years and is usually advanced by the time symptoms occur, generally in middle age. Acute coronary events (heart attacks) and cerebrovascular events (strokes) frequently occur suddenly, and are often fatal before medical care can be given. Risk factor modification can reduce clinical events and premature death in people with established cardiovascular disease as well as in those who are at high cardiovascular risk due to one or more risk factors. \\nThese pocket guidelines provide evidence-based guidance on how to reduce \\nthe incidence of first and recurrent clinical events due to coronary heart disease (CHD), cerebrovascular disease (CeVD) and peripheral vascular disease in two categories of people. They include;'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 6}, page_content='the incidence of first and recurrent clinical events due to coronary heart disease (CHD), cerebrovascular disease (CeVD) and peripheral vascular disease in two categories of people. They include;\\n1. People with risk factors who have not yet developed clinically manifest cardiovascular disease (primary prevention).\\n1 \\n2. People with established CHD, CeVD or peripheral vascular disease (secondary prevention).\\n2 \\nThe accompanying World Health Organization/International Society of Hypertension (WHO/ISH) risk prediction charts (see CD and table 1) enable the estimation of total cardiovascular risk of people in the first category. The evidence-based recommendations given in Part 1 of these guidelines, provide guidance on which specific preventive actions to initiate, and with what degree of intensity. \\nPeople in the second category have high cardiovascular risk and need'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 6}, page_content='People in the second category have high cardiovascular risk and need \\nintensive lifestyle interventions and appropriate drug therapy as elaborated in Part II of these guidelines. Risk stratification using risk charts is not required for making treatment decisions in them. \\n1 World Health Organization. Prevention of Cardiovascular Disease. Guidelines for assessment and \\nmanagement of cardiovascular risk. Geneva, 2007.\\n2 World Health Organization. Prevention of recurrent heart attacks and strokes in low and middle income populations. Evidence-based recommendations for policy makers and health professionals. Geneva, 2003.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 7}, page_content='2Target audience \\nThese pocket guidelines can be used by physicians and non-physician health \\nworkers, at all levels of health care including primary care. Hypertension, diabetes or established cardiovascular disease may be used as entry points for implementing these guidelines. \\nSettings\\nPrimary care and other levels of care including low resource settings\\nResource needs \\n ■Human resources : Medical doctor or trained nurse/non-physician health \\nworker \\n ■Equipment : Stethoscope, accurate blood pressure measurement device1, \\nmeasuring tape and weighing scale, equipment for testing urine glucose and urine albumin, and assay of blood glucose and blood cholesterol \\n ■Drugs : Thiazide diuretics, beta blockers, angiotensin converting enzyme \\ninhibitors, calcium channel blockers, aspirin, metformin, insulin, statins \\n ■Other facilities : System for maintaining medical records, referral facilities \\nWhat are the goals of implementing these guidelines?'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 7}, page_content='■Other facilities : System for maintaining medical records, referral facilities \\nWhat are the goals of implementing these guidelines?\\nThe goals are to prevent CHD and CeVD events by lowering cardiovascular risk. The recommendations assist people to:\\n ■quit tobacco use, or reduce the amount smoked, or not start the habit \\n ■make healthy food choices\\n ■be physically active \\n ■reduce body mass index, waist–hip ratio/waist circumference \\n ■lower blood pressure \\n ■lower blood cholesterol and low density lipoprotein cholesterol  \\n(LDL-cholesterol)\\n ■control glycaemia\\n ■take antiplatelet therapy as recommended. \\n1 Parati G, Mendis S, Abegunde D, Asmar R, Mieke S, Murray A, Shengelia B, Steenvoorden G, Van \\nMontfrans G, O’Brien E; World Health Organization. Recommendations for blood pressure measuring \\ndevices for office/clinic use in low resource settings. Blood Press Monit.  2005 Feb;10(1):3-10.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 8}, page_content='3Who needs referral to a specialist facility ?\\nReferral is required if there are clinical features suggestive of: \\n ■acute cardiovascular events such as: heart attack, angina, heart failure, \\narrhythmias, stroke, transient ischemic attack\\n ■secondary hypertension (table 2 ), malignant hypertension, (table 3 )\\n ■diabetes mellitus (newly diagnosed or uncontrolled) \\n ■established cardiovascular disease (newly diagnosed or if not assessed in a specialist facility). \\nOnce the condition of the above categories of people is assessed and stabilized, they can be followed up in a primary care facility based on the recommendations provided in these pocket guidelines. They will need periodic reassessments in speciality care.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 10}, page_content='5Part 1\\nAssessing and managing cardiovascular \\nrisk in people with risk factors who have not yet developed clinically manifest cardiovascular disease (primary prevention)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 12}, page_content='7When can the decision be made to give drugs  even before \\ngrading the cardiovascular risk?\\nSome individuals are at high cardiovascular risk because they have established \\ncardiovascular disease or very high levels of individual risk factors. All of them need intensive lifestyle interventions and appropriate drug therapy\\n1,2. They \\ninclude people: \\n ■with established cardiovascular disease\\n ■without established CVD who have a total cholesterol ≥ 8 mmol/l (320 mg/dl) or low-density lipoprotein (LDL) cholesterol ≥ 6 mmol/l (240 mg/dl) or TC/HDL-C (total cholesterol/high density lipoprotein cholesterol) ratio >8\\n ■without established CVD who have persistent raised blood pressure (>160–170/100–105 mmHg)\\n ■with type 1 or 2 diabetes, with overt nephropathy or other significant renal disease\\n ■with renal failure or renal impairment.\\nInstructions for using WHO/ISH risk prediction charts'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 12}, page_content='■with type 1 or 2 diabetes, with overt nephropathy or other significant renal disease\\n ■with renal failure or renal impairment.\\nInstructions for using WHO/ISH risk prediction charts \\nThe WHO/ISH risk prediction charts indicate 10-year risk of a fatal or non-fatal major cardiovascular event (myocardial infarction or stroke), according to age, sex, blood pressure, smoking status, total blood cholesterol and presence or absence of diabetes mellitus for 14 WHO epidemiological sub-regions. \\nThere are two sets of charts. One set (14 charts) can be used in settings where \\nblood cholesterol can be measured. The other set (14 charts) is for settings in which blood cholesterol cannot be measured. These are less accurate. Both sets are available in colour and shades of black on a compact disc. \\nEach chart can only be used in countries of the specific WHO epidemiological \\nsub-region as shown in table 1. \\nThe charts provide approximate estimates of CVD risk in people who do'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 12}, page_content='Each chart can only be used in countries of the specific WHO epidemiological \\nsub-region as shown in table 1. \\nThe charts provide approximate estimates of CVD risk in people who do \\nnot have established coronary heart disease, stroke or other atherosclerotic disease. They are useful as tools to help identify those at high cardiovascular risk, and to motivate patients, particularly to change behaviour and, when appropriate, to take antihypertensive, lipid-lowering drugs and aspirin. \\n1 World Health Organization. Prevention of recurrent heart attacks and strokes in low and middle income \\npopulations. Evidence-based recommendations for policy makers and health professionals. Geneva, 2003 .\\n2 World Health Organization. Avoiding heart attacks and strokes. Don`t be a victim protect yourself. Geneva 2005.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 13}, page_content='8How do you use the charts to assess cardiovascular risk?  \\n(see figures 1, 2, 3, 4) \\n ■First make sure that you select the appropriate charts using information \\nin table 1.\\n ■If blood cholesterol cannot be measured due to resource limitations, the mean cholesterol value for the population can be used. \\n ■Before applying the chart to estimate the 10 year cardiovascular risk of an individual, the following information is necessary:\\n ● Presence or absence of diabetes1 \\n ● Gender \\n ● Smoker or non-smoker2\\n ● Age \\n ● Systolic blood pressure (SBP)3\\n ● Total blood cholesterol4 (if in mg/dl divide by 38 to convert to mmol/l).\\nOnce the above information is available proceed to estimate the 10-year cardiovascular risk as follows:\\nStep 1   Select the appropriate chart depending on the presence or absence of \\ndiabetes\\nStep 2  Select male or female tables \\nStep 3  Select smoker or non smoker boxes\\nStep 4   Select age group box (if age is 50-59 years select 50, if 60-69 years select 60 etc)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 13}, page_content='diabetes\\nStep 2  Select male or female tables \\nStep 3  Select smoker or non smoker boxes\\nStep 4   Select age group box (if age is 50-59 years select 50, if 60-69 years select 60 etc) \\nStep 5   Within this box find the nearest cell where the individuals systolic blood pressure (mm Hg) and total blood cholesterol level (mmol/l) cross. The colour of this cell determines the 10 year cardiovascular risk. \\n1 A person who has diabetes is defined as someone taking insulin or oral hypoglycaemic drugs, \\nor with a fasting plasma glucose concentration above 7.0 mmol/l (126 mg/dl) or a postprandial \\n(approximately 2 hours after a main meal) plasma glucose concentration above 11.0 mmol/l (200 \\nmg/l)on two separate occasions). For very low resource settings urine sugar test may be used to screen for diabetes if blood glucose assay is not feasible. If urine sugar test is positive a confirmatory \\nblood glucose test need to be arranged to diagnose diabetes mellitus.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 13}, page_content='blood glucose test need to be arranged to diagnose diabetes mellitus. \\n2 All current smokers and those who quit smoking less than 1 year before the assessment are \\nconsidered smokers for assessing cardiovascular risk.\\n3 Systolic blood pressure, taken as the mean of two readings on each of two occasions, is sufficient for assessing risk but not for establishing a pretreatment baseline.\\n4 The mean of two non-fasting measurements of serum cholesterol by dry chemistry, or one non-fasting laboratory measurement, is sufficient for assessing risk.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 14}, page_content='9Practice points\\nPlease note that CVD risk may be higher than indicated by the charts in the \\npresence of the following:\\n ■already on antihypertensive therapy\\n ■premature menopause\\n ■approaching the next age category or systolic blood pressure category\\n ■obesity (including central obesity)\\n ■sedentary lifestyle\\n ■family history of premature CHD or stroke in first degree relative (male < 55 years, female < 65 years) \\n ■raised triglyceride level (>2.0 mmol/l or 180 mg/dl)\\n ■low HDL cholesterol level (< 1 mmol/l or 40mg/dl in males, < 1.3 mmol/l or 50 mg/dl in females)\\n ■raised levels of C-reactive protein, fibrinogen, homocysteine, apolipoprotein B or Lp(a), or fasting glycaemia, or impaired glucose tolerance\\n ■microalbuminuria (increases the 5-year risk of diabetics by about 5%)\\n ■raised pulse rate \\n ■socioeconomic deprivation.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 15}, page_content='10Table 1. List of WHO/ISH risk prediction charts by \\nepidemiological sub-regions1 and WHO Member States\\nWHO/ISH risk prediction \\ncharts by epidemiological \\nsub regions WHO Member States\\nAfrica AFR D Algeria, Angola, Benin, Burkina Faso, Cameroon, Cape \\nVerde, Chad, Comoros, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, \\nSao Tome And Principe, Senegal, Seychelles, Sierra Leone, \\nTogo\\nAFR E Botswana, Burundi, Central African Republic, Congo, Côte d’Ivoire, Democratic Republic of The Congo, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe\\nThe Americas AMR A Canada\\n*, Cuba, United States of America*,'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 15}, page_content='The Americas AMR A Canada\\n*, Cuba, United States of America*, \\nAMR B Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Brazil, Chile, Colombia, Costa Rica, Dominica, Dominican Republic, El Salvador, Grenada, Guyana, Honduras, Jamaica, Mexico, Panama, Paraguay, Saint Kitts And Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela\\nAMR D Bolivia, Ecuador, Guatemala, Haiti, Nicaragua, Peru\\nEastern Mediterranean EMR B Bahrain, Iran (Islamic Republic of), Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Oman, Qatar, Saudi \\nArabia, Syrian Arab Republic, Tunisia, United Arab \\nEmirates\\nEMR D Afghanistan, Djibouti, Egypt, Iraq, Morocco, Pakistan, Somalia, Sudan, Yemen\\n1 Mortality strata: A: very low child mortality and very low adult mortality; B: low child mortality and \\nlow adult mortality; C: low child mortality and high adult mortality; D: high child mortality and'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 15}, page_content='low adult mortality; C: low child mortality and high adult mortality; D: high child mortality and \\nhigh adult mortality; E: high child mortality and very high adult mortality.\\n* Other risk prediction charts are already available for Australia, Canada, New Zealand , the United \\nStates of America and many countries in Europe.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 16}, page_content='11WHO/ISH risk prediction \\ncharts by epidemiological \\nsub regions WHO Member States\\nEurope* EUR A Andorra, Austria, Belgium, Croatia, Cyprus, Czech \\nRepublic, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Slovenia, \\nSpain, Sweden, Switzerland, United Kingdom\\nEUR B Albania, Armenia, Azerbaijan, Bosnia And Herzegovina, \\nBulgaria, Georgia, Kyrgyzstan, Poland, Romania, Serbia and Montenegro, Slovakia, Tajikistan, The Former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Uzbekistan\\nEUR C Belarus, Estonia, Hungary, Kazakhstan, Latvia, Lithuania, Republic of Moldova, Russian Federation, Ukraine\\nSouth-East Asia SEAR B Indonesia, Sri Lanka, Thailand\\nSEAR D Bangladesh, Bhutan, Democratic People’s Republic of Korea, India, Maldives, Myanmar, Nepal\\nWestern Pacific WPR A Australia\\n*, Brunei Darussalam, Japan, New Zealand*, \\nSingapore'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 16}, page_content='SEAR D Bangladesh, Bhutan, Democratic People’s Republic of Korea, India, Maldives, Myanmar, Nepal\\nWestern Pacific WPR A Australia\\n*, Brunei Darussalam, Japan, New Zealand*, \\nSingapore\\nWPR B Cambodia, China, Cook Islands, Democratic People’s Republic of Korea, Fiji, Kiribati, Lao People’s Democratic Republic, Malaysia, Marshall Islands, Micronesia \\n(Federated States of), Mongolia, Nauru, Niue, Palau, Papua \\nNew Guinea, Philippines, Samoa, Solomon Islands, Tonga, Tuvalu, Vanuatu, Viet Nam'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 17}, page_content='12Figure 1.  An example of a WHO/ISH risk prediction chart. 10-year risk of a fatal \\nor non-fatal cardiovascular event by gender, age, systolic blood pressure, total blood \\ncholesterol, smoking status and presence or absence of diabetes mellitus. \\nRisk Level <10% 10% to <20% 20% to <30% 30% to <40% ≥40%\\nPeople with Diabetes Mellitus\\nAge \\n(years)Male FemaleSBP\\n(mm Hg) Non-smoker Smoker Non-smoker Smoker\\n70180\\n160\\n140\\n120\\n60180\\n160\\n140\\n120\\n50180\\n160\\n140\\n120\\n40180\\n160\\n140\\n120\\n45678 45678 45678 45678\\nCholesterol  (mmol/l)\\nPeople without Diabetes Mellitus\\nAge \\n(years)Male FemaleSBP\\n(mm Hg) Non-smoker Smoker Non-smoker Smoker\\n70180\\n160\\n140\\n120\\n60180\\n160\\n140\\n120\\n50180\\n160\\n140\\n120\\n40180\\n160\\n140\\n120\\n45678 45678 45678 45678\\nCholesterol  (mmol/l)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 18}, page_content='13Recommendations* for prevention of cardiovascular \\ndisease in people with cardiovascular risk factors (according to individual total risk)a \\n10 year risk of cardiovascular event  \\n<10%, 10 to <20%, 20 to <30%, ≥30%\\nWhen resources are limited, individual counselling and provision of \\ncare may have to be prioritized according to cardiovascular risk.\\nRisk <10% Individuals in this category are at low risk. Low \\nrisk does not mean “no” risk.\\nConservative management focusing on lifestyle \\ninterventions is suggestedb.\\nRisk\\n 10% to <20%Individuals in this category are at moderate risk of fatal or non-fatal vascular events.\\nMonitor risk profile every 6–12 months.\\nRisk \\n20% to <30%Individuals in this category are at high risk of \\nfatal or non-fatal vascular events. \\nMonitor risk profile every 3–6 months.\\nRisk ≥30% Individuals in this category are at very high risk \\nof fatal or non-fatal vascular events. \\nMonitor risk profile every 3–6 months'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 18}, page_content='Monitor risk profile every 3–6 months.\\nRisk ≥30% Individuals in this category are at very high risk \\nof fatal or non-fatal vascular events. \\nMonitor risk profile every 3–6 months\\n* For levels of evidence and grades of recommendations see reference 1. \\na Excluding people with established CHD, CeVD and peripheral vascular disease\\nb Policy measures that create conducive environments for quitting tobacco, engaging in \\nphysical activity and consuming healthy diets are necessary to promote behavioural \\nchange. They will benefit the whole population. For individuals in low risk categories, \\nthey can have a health impact at lower cost, compared to individual counselling and therapeutic approaches.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 19}, page_content='14 SMOKING CESSATION\\nAll nonsmokers should be encouraged not to start smoking.\\nAll smokers should be strongly encouraged to quit smoking by a \\nhealth professional and supported in their efforts to do so. (1++, A) \\nIt is suggested that those who use other forms of tobacco be advised \\nto stop. (2+, C)\\nRisk \\n20% to <30%Nicotine replacement therapy and/or nortriptyline or amfebutamone (bupropion) should be offered to motivated smokers who fail to quit with counselling. (1++, B) \\nRisk ≥30% Nicotine replacement therapy and/or nortriptyline or amfebutamone (bupropion) should be offered to motivated smokers who fail to quit with counselling. (1++, B)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 20}, page_content='15DIETARY CHANGES\\nAll individuals should be strongly encouraged to reduce total fat and \\nsaturated fat intake. (1+, A)\\nTotal fat intake should be reduced to about 30% of calories, \\nsaturated fat to less than 10% of calories, transfatty acids intake should be reduced as much as possible or eliminated and most dietary fat should be polyunsaturated (up to 10% of calories) or monounsaturated (10–15% of calories). (1+, A)\\nAll individuals should be strongly encouraged to reduce daily salt \\nintake by at least one third and, if possible, to <5 g or <90 mmol per day. (1+, A)\\nAll individuals should be encouraged to eat at least 400 g a day of \\na range of fruits and vegetables as well as whole grains and pulses. (2+, A)\\nPHYSICAL ACTIVITY\\nAll individuals should be strongly encouraged to take at least 30 \\nminutes of moderate physical activity (e.g. brisk walking) a day, \\nthrough leisure time, daily tasks and work-related physical activity. (1+, A)\\nWEIGHT CONTROL'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 20}, page_content='minutes of moderate physical activity (e.g. brisk walking) a day, \\nthrough leisure time, daily tasks and work-related physical activity. (1+, A)\\nWEIGHT CONTROL\\nAll individuals who are overweight or obese should be encouraged \\nto lose weight through a combination of a reduced-energy diet \\n(dietary advice) and increased physical activity. (1+, A)\\nALCOHOL INTAKE\\nIndividuals who take more than 3 units of alcohol\\nc per day should \\nbe advised to reduce alcohol consumption. (2++, B)\\nc One unit (drink) = half pint of beer/lager (5 % alcohol), 100 ml of wine (10 % alcohol), spirits 25 ml \\n(40% alcohol)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 21}, page_content='16ANTIHYPERTENSIVE DRUGS√\\nAll individuals with blood pressure at or above 160/100 mmHg, or \\nlesser degree of raised blood pressure with target organ damage, should have drug treatment and specific lifestyle advice to lower their blood pressure and risk of cardiovascular disease. (2++, B) \\nAll individuals with blood pressure below 160/100 mmHg, or \\nwith no target organ damage need to be managed according to the cardiovascular risk (10 year risk of cardiovascular event <10%, 10 to <20%, 20 to <30%, ≥30%)\\nRisk <10% Individuals with persistent blood pressure ≥140/90 mmHg\\ne should continue lifestyle \\nstrategies to lower blood pressure and have their blood pressure and total cardiovascular risk reassessed every 2–5 years depending on clinical circumstances and resource availability.\\nRisk\\n 10% to <20%Individuals with persistent blood pressure ≥140/90 mmHg\\ne should continue lifestyle'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 21}, page_content='Risk\\n 10% to <20%Individuals with persistent blood pressure ≥140/90 mmHg\\ne should continue lifestyle \\nstrategies to lower blood pressure and have their blood pressure and total cardiovascular risk reassessed annually depending on clinical circumstances and resource availability.\\nRisk \\n20% to <30%Individuals with persistent blood pressure ≥140/90 mmHg\\ne who are unable to lower \\nblood pressure through lifestyle strategies with professional assistance within 4–6 months should be considered for one of the following drugs\\n√ to \\nreduce blood pressure and risk of cardiovascular disease: thiazide-like diuretic, ACE inhibitor, calcium channel blocker, beta-blocker\\nd.\\nA low-dose thiazide-like diuretic, ACE inhibitor or calcium channel blocker is recommended as first-line therapy. (1++, A)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 22}, page_content='17ANTIHYPERTENSIVE DRUGS√\\nRisk ≥30% Individuals with persistent blood pressure \\n≥130/80 mmHg should be given one of the following drugs to reduce blood pressure and risk of cardiovascular disease: thiazide-like diuretic, ACE inhibitor, calcium channel blocker, beta-\\nblocker\\nd.\\nA low-dose thiazide-like diuretic, ACE inhibitor or \\ncalcium channel blocker is recommended as first-\\nline therapy. (1++, A)\\nd Evidence from two recent meta-analyses indicates that for treatment of hypertension, \\nbeta-blockers are inferior to calcium-channel blockers and ACE inhibitors in reducing \\nthe frequency of hard endpoints. In addition, beta-blockers are less well tolerated than \\ndiuretics. Most of this evidence comes from trials where atenolol was the beta-blocker used.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 22}, page_content='the frequency of hard endpoints. In addition, beta-blockers are less well tolerated than \\ndiuretics. Most of this evidence comes from trials where atenolol was the beta-blocker used. \\ne Reducing blood pressure by 10–15/5–8 mmHg with drug treatment reduces combined CVD mortality and morbidity by about one-third, whatever the pretreatment absolute risk. However, applying this recommendation will lead to a large proportion of the \\nadult population receiving antihypertensive drugs. Even in some high-resource \\nsettings, current practice is to recommend drugs for this group only if the blood pressure is at or above 160/100 mmHg.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 23}, page_content='18LIPID-LOWERING DRUGS (STATINS)√\\nAll individuals with total cholesterol at or above 8 mmol/l (320 mg/\\ndl) should be advised to follow a lipid-lowering diet and given a statin to lower the risk of cardiovascular disease. (2++, B)\\nAll other individuals need to be managed according to the \\ncardiovascular risk as follows \\n(10 year risk of cardiovascular event <10%, 10 to <20%, 20 to 30%, \\n≥30%)\\nRisk <10% Should be advised to follow a lipid-lowering diet\\ng.\\nRisk 10 to <20% Should be advised to follow a lipid-lowering dietg.\\nRisk 20 to <30% Adults >40 years with persistently high serum cholesterol\\n (>5.0 mmol/l) and/or LDL cholesterol \\n>3.0 mmol/l, despite a lipid-lowering diet, should be given a statin. (1+, A) \\nRisk ≥30% Individuals in this risk category should be advised to follow a lipid-lowering diet and given a statin. (1++, A) \\nSerum cholesterol should be reduced to less than \\n5.0 mmol/l (LDL cholesterol to below 3.0 mmol/l) or by 25% (30% for LDL cholesterol), whichever is greater'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 23}, page_content='Serum cholesterol should be reduced to less than \\n5.0 mmol/l (LDL cholesterol to below 3.0 mmol/l) or by 25% (30% for LDL cholesterol), whichever is greater\\nf.\\nHYPOGLYCAEMIC DRUGS√\\nIndividuals with persistent fasting blood glucose >6 mmol/l despite diet control should be given metformin. (1+, A)\\nf Reducing cholesterol level by 20% (approximately 1 mmol/l) with statin treatment \\nwould be expected to yield a coronary heart disease mortality benefit of 30%, whatever \\nthe pretreatment absolute risk. However, applying this to the general population may \\nnot be cost effective. It will lead to a large proportion of the adult population receiving statins. Even in some high-resource settings, current practice is to recommend drugs for this group only if serum cholesterol is above 8mmol/l (320 mg/dl).\\ng There are no clinical trials that have evaluated the absolute and relative benefits of cholesterol lowering to different cholesterol targets in relation to clinical events.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 24}, page_content='19DRUGS THAT ARE NOT RECOMMENDED\\nHormone replacement, vitamins B, C, E and \\nfolic acid supplements are not recommended for \\nreduction of cardiovascular risk.\\n√ Best Practice points: Unless there are compelling indications to use specific drugs, \\nthe least expensive preparation of the above classes of drugs should be used. Good \\nquality generic preparations of medicines listed in WHO essential medicines list are \\nrecommended.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 25}, page_content='20'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 26}, page_content='21Part 2\\nManagement of people with established \\nCHD, CeVD or peripheral vascular disease (secondary prevention)\\nPeople with established cardiovascular disease (angina pectoris, coronary \\nheart disease, myocardial infarction, transient ischaemic attacks, cerebrovascular disease (CeVD) or peripheral vascular disease (PVD) or after coronary revascularization or carotid endarterectomy) are at very high risk of developing recurrent cardiovascular events. Risk charts are not necessary to make treatment decisions in them. \\nThe goal of applying the recommendations below, is to prevent recurrent \\ncardiovascular events by reducing their cardiovascular risk.'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 27}, page_content='22Recommendations* for prevention of recurrent  \\nCHD (heart attacks) and CeVD (strokes) events\\nLIFESTYLE ADVICE\\nIntensive life style advice should be given simultaneously with drug \\ntreatment \\nSMOKING CESSATION \\nAll individuals with established CHD and/or CeVD should be strongly encouraged to stop smoking by a health professional and supported in their efforts to do so. (IIa B)\\nCessation of other forms of tobacco use in individuals with \\nestablished CHD and /or CeVD is recommended. (IIa C)\\nNicotine replacement therapy should be offered to individuals who \\ncontinue to smoke at least 10 cigarettes a day or more, who are likely to be markedly nicotine dependent. The use of antidepressants for smoking cessation is not generally recommended for patients with CHD and /or CeVD (Ia B)\\nNon-smoking people with CHD and/or CeVD should be advised to \\navoid exposure to second-hand tobacco smoke as much as possible. \\n(IIa C)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 27}, page_content='Non-smoking people with CHD and/or CeVD should be advised to \\navoid exposure to second-hand tobacco smoke as much as possible. \\n(IIa C) \\nc One unit (drink) = half pint of beer/lager (5 % alcohol), 100 ml of wine (10 % alcohol), spirits 25 ml \\n(40% alcohol)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 28}, page_content='23DIETARY CHANGES \\nAll individuals with CHD and/or CeVD should be given advice to \\nadopt a pattern of diet which is likely to reduce the risk of recurrent \\nvascular disease. \\nTotal fat intake should be reduced to < 30% of calories, saturated \\nfat to < 10% of calories and transfatty acids should be reduced as much as possible or eliminated; most dietary fat should be polyunsaturated (up to 10% of calories) or monounsaturated (10–15% of calories). (IIa B)\\nAll individuals should be strongly encouraged to reduce daily salt \\nintake by at least one-third and, if possible, to <5 g or <90 mmol per day. (IIa B)\\nAll individuals should be encouraged to eat, at least 400 g a day, of a \\nrange fruits and vegetables, as well as whole grains and pulses. (1a, A) \\nPHYSICAL ACTIVITY\\nRegular light to moderate intensity physical exercise is \\nrecommended for all subjects recovering from major CHD events \\n(including coronary revascularization). (Ia A)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 28}, page_content='PHYSICAL ACTIVITY\\nRegular light to moderate intensity physical exercise is \\nrecommended for all subjects recovering from major CHD events \\n(including coronary revascularization). (Ia A)\\nSupervised programmes of exercise should where feasible be offered \\nto all subjects recovering from major CHD events and CeVD events. (Ia A)\\nWEIGHT CONTROL\\nIn patients with cardiovascular disease who are overweight or obese, weight loss should be advised through the combination of a reduced energy diet and increased physical activity. (IIa B) \\nALCOHOL INTAKE\\nIndividuals who take more than 3 units of alcohol\\nc per day should \\nbe advised to reduce alcohol consumption. (2++, B)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 29}, page_content='24ANTIHYPERTENSIVE DRUGS√\\nBlood pressure reduction should be considered in all patients with \\nestablished CHD, particularly with a blood pressure level above 140/90 mmHg. Lifestyle factors (particularly high alcohol intake) should be addressed first and if blood pressure is still above 140/90 mmHg, drug treatment is indicated. When beta-blockers and ACEI \\n(angiotensin converting enzyme inhibitors) cannot be given, or in \\ncases where blood pressure remains high, treatment with a thiazide diuretic is likely to reduce risk of recurrent vascular events. A target blood pressure of 130/80-85 mmHg is appropriate. \\nBlood pressure reduction should be considered in all patients with \\nprevious TIA or stroke to a target of <130/<80-85 mmHg (Ia A).\\nLIPID LOWERING DRUGS\\n√\\nTreatment with statins is recommended for all patients with established CHD. Treatment should be continued in the long term, probably lifelong. Patients at high baseline risk are particularly likely to benefit. (Ia A)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 29}, page_content='Treatment with a statin should be considered for all patients \\nwith established CeVD, especially if they also have evidence of \\nestablished CHD. (Ia A)\\nMonitoring of blood cholesterol levels is not mandatory. A total \\ncholesterol of less than 4.0 mmol/l (152 mg/dl) and LDL-cholesterol of less than 2.0 mmol/l (77 mg/dl), or a reduction of 25% in total cholesterol and 30% in LDL-cholesterol, whichever achieves the lower absolute risk level, may be desirable goals. \\nOther lipid lowering agents are not recommended, either as an \\nalternative to statins or in addition to them. (Ia A) \\nHYPOGLYCEMIC DRUGS\\n√\\nSecondary prevention of CHD, CeVD and PVD is important in patients with diabetes, whether type 1 or type 2. Individuals with persistent fasting blood glucose >6 mmol/l despite diet control should be given metformin and/or insulin as appropriate. (1+, A).'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 30}, page_content='ANTIPLATELET DRUGS√\\nAll patients with established CHD should be treated with regular \\naspirin in the absence of clear contraindications. Treatment should be initiated early and continued lifelong. (Ia A) \\nAll patients with a history of transient ischaemic attack or stroke \\npresumed due to cerebral ischaemia or infarction should be treated with long-term (probably lifelong) aspirin in the absence of clear contraindications. (Ia A)\\n FOLLOWING MYOCARDIAL INFARCTION AN ACEI\\n√\\nACE inhibitors are recommended in all patients following myocardial infarction, which should be initiated as early as possible and continued long-term, probably lifelong. The benefits of treatment are particularly great among patients with impaired left ventricular function. (Ia A)\\nFOLLOWING MYOCARDIAL INFARCTION A BETA \\nBLOCKER\\n√'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 30}, page_content='FOLLOWING MYOCARDIAL INFARCTION A BETA \\nBLOCKER\\n√\\nTreatment with beta-blockers is recommended in all patients with a history of myocardial infarction and those with CHD who have developed major left ventricular dysfunction leading to heart failure. (Ia A) Treatment should be continued for a minimum of 1–2 years after MI and probably lifelong, unless serious side effects occur. \\nBeta-blockers are probably beneficial in patients with angina, \\nalthough robust data are lacking. \\nANTICOAGULANT TREATMENT\\n√\\nLong term anticoagulation is not recommended in patients with a history of stroke or TIA who are in sinus rhythm. (Ia A) \\nLong term anticoagulation is recommended for patients with a \\nhistory of stroke or TIA who are in atrial fibrillation, at low risk of bleeding and in whom treatment with anticoagulants can be safely \\nmonitored. In circumstances in which anticoagulant monitoring is'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 30}, page_content='monitored. In circumstances in which anticoagulant monitoring is \\nnot possible, or if a patient cannot take anticoagulants, treatment with aspirin should be offered. (Ia A)'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 31}, page_content='26CORONARY REVASCULARIZATION \\nCABG (coronary artery bypass graft) surgery should be considered \\nas an adjunct to optimal medical treatment including aspirin, lipid \\nlowering treatment, ACE inhibitors and beta-blockers) in those \\npatients at moderate and high risk who are considered likely to have left main stem or triple vessel disease. (Ia A)\\nPTCA (percutaneous coronary angioplasty) should be considered for \\nrelief of anginal symptoms in patients with refractory angina who are already receiving optimal medical treatment. (Ia A)\\nCAROTID ENDARTERECTOMY \\nCarotid endarterectomy reduces the risk of recurrent stroke and death among patients with a previous TIA or non-disabling stroke in patients with severe ipsilateral carotid stenosis (70–99%) and possibly in patients with moderate degrees of stenosis (50–69%) though not in milder degrees of stenosis. (Ia A)\\nDRUGS THAT ARE NOT RECOMMENDED'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 31}, page_content='DRUGS THAT ARE NOT RECOMMENDED\\nOn the basis of current evidence, treatment with type 1 anti-arrhythmics, calcium channel blockers, antioxidant vitamins, folate and hormone replacement therapy are not recommended for CHD or CeVD patients. \\n* For levels of evidence and grades of recommendations see reference 2. \\n√ Best Practice point: Unless there are compelling indications to use specific drugs, the least expensive \\npreparation of the above classes of drugs should be used. Good quality generic preparations of \\nmedicines listed in WHO essential medicines list are recommended'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 32}, page_content='Table 2 Causes and clinical features of secondary hypertension\\nCause Clinical features \\nKidney diseases: \\nNephropathy \\nRenal artery stenosis History of episodes of blood or proteins in the urine, urinary \\ninfections, swelling of body \\nKidney disease in the family (polycystic kidney disease) \\nPhysical examination: abdomen or loin bruit, palpable \\nkidneys\\nPhaeochromocytoma \\nCushing syndrome \\nConn syndrome \\nAcromegaly Episodic symptoms: headache, flushing, sweatingHigh blood pressure fluctuant and sudden onset \\nTypical general appearance: truncal obesity, stretch marks, \\nWeakness, cramps, polyuria Tall stature, typical facies with prominent lower jaw, broad \\nspade shaped hands \\nCoarctation of the aortaHigh blood pressure in upper limbs but not in lower limbs. Delayed or weak femoral pulses\\nDrugs Contraceptive pill, anti-inflammatory drugs, steroids, sympathomimetics, nasal decongestants, appetite suppressants, cyclosporine, erythropoietin, liquorice, antidepressants'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 32}, page_content='Drugs Contraceptive pill, anti-inflammatory drugs, steroids, sympathomimetics, nasal decongestants, appetite suppressants, cyclosporine, erythropoietin, liquorice, antidepressants\\nTable 3 Clinical features of malignant hypertension \\nSymptoms Headache, blurred vision, nausea, vomiting, lethargy, chest-pain, dyspnoea, seizure, mental status changes, oliguria\\nPhysical signs\\n Abrupt rise in blood pressure (diastolic blood pressure often \\n> 120mmHg) \\nRetinal examination: papilloedema, flame-shaped retinal \\nhaemorrhages, soft exudates, \\nSigns of congestive heart failure and pulmonary oedemaNeurological deficits'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 33}, page_content='Table 4 Drugs and daily dosages \\nClass of drug Drug Daily dosage\\nACEI\\n(Angiotensin converting \\nenzyme inhibitors)Captopril \\nEnalaprilinitial dose 6.25 to 12.5 mg \\nthree times daily, increasing to 25–50 mg three times daily\\ninitial dose 2.5–5.0 mg twice \\ndaily, increasing to 10–20 mg \\ntwice daily  \\nCCBs (Calcium Channel Blockers)Nifedipine \\n(sustained release \\nformulations)Starting at 30 mg increasing to 120 mg once daily\\nThiazide diuretics Hypdrocholorothiazide \\nBendrofluazideStarting at 12.5 mg increasing \\nto 25 mg once daily\\n2.5 mg as a single daily dose . \\nBeta-blockers PropranololAtenololMetoprolol80 mg twice daily Starting at 50 mg to  \\n100mg once daily 50–100 mg twice daily \\nLipid lowering therapy Simvastatin, Initial dose 10 mg once at \\nnight, increasing to 40 mg \\nonce at night\\nAntiplatelet therapy  Aspirin Starting at 75-100 mg daily\\nHypoglycemic drugs Glibenclamide\\nMetforminStarting at 2.5 mg increasing \\nto 5\\xa0mg twice daily before meals\\nStarting at 0.5 g increasing to'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 33}, page_content='Antiplatelet therapy  Aspirin Starting at 75-100 mg daily\\nHypoglycemic drugs Glibenclamide\\nMetforminStarting at 2.5 mg increasing \\nto 5\\xa0mg twice daily before meals\\nStarting at 0.5 g increasing to \\n1.0 g three times daily'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 35}, page_content='CARDIO VASCULAR DISEASES\\nISBN 978 92 4 154727 7WHO/ISH risk prediction charts for all other epidemiological sub-regions are \\navailable on compact disc and at the WHO website:\\nhttp://www.who.int/cardiovascular_diseases\\nThe material in these pocket guidelines was adapted from WHO guidelines \\non primary and secondary prevention available on WHO website:\\nWorld Health Organization. Prevention of Cardiovascular Disease. Guidelines for \\nassessment and management of cardiovascular risk. Geneva, 2007.\\nWorld Health Organization. Prevention of recurrent heart attacks and strokes \\nin low- and middle-income populations. Evidence-based recommendations for policy-makers and health professionals. Geneva, 2003. \\nWorld Health Organization. Diagnosis and management of type 2 diabetes in \\nprimary care in low-resource settings, Geneva, 2011.\\nWorld Health organization. Scaling up action against noncommunicable \\ndiseases. How much will it cost? Geneva 2011.\\nContact information for training modules'),\n",
              " Document(metadata={'source': 'Data/simplifiedtools-m1.pdf', 'page': 35}, page_content='World Health organization. Scaling up action against noncommunicable \\ndiseases. How much will it cost? Geneva 2011.\\nContact information for training modules\\nTel: +41 22 791 3441E mail: mendiss@who.int'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 0}, page_content='REVIEW SERIES\\nLung cancer c1: Prevention of lung cancer\\nG E Goodman\\n.............................................................................................................................\\nThorax 2002; 57:994–999\\nCancer of the lung causes more deaths from cancer\\nworldwide than at any other site. The environmental,genetic, and dietary risk factors are discussed and\\nprogress in chemoprevention is reviewed. A better\\nunderstanding of the molecular events that occur duringcarcinogenesis has opened up new areas of research incancer prevention and a number of biochemical\\nmarkers of high risk individuals have been identified. It\\nis predicted that greater success in chemoprevention willbe achieved in the next decade than in the last.\\n..........................................................................\\nTHE PROBLEM\\nIn 1990 cancer caused an estimated six million\\ndeaths worldwide and, of these, lung cancer wasthe most frequent site with an estimated 945 000\\ndeaths.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 0}, page_content='THE PROBLEM\\nIn 1990 cancer caused an estimated six million\\ndeaths worldwide and, of these, lung cancer wasthe most frequent site with an estimated 945 000\\ndeaths.\\n1In 2002 the death rate from lung cancer\\nin the USA in both men and women is estimated\\nat 134 900, exceeding the combined total for\\nbreast, prostate, and colon cancer.2Lung cancer is\\nalso the leading cause of cancer death in all Euro-\\npean countries and is rapidly increasing in the\\ndeveloping world. Of 40 countries worldwide, the\\ncountries with the highest rates are Hungary(81.6/100 000 person years), the Czech Republic,the Russian Federation, Poland, and Denmark.\\n3\\nAmong women the highest rates were in the US\\n(25.6/100 000 person years), Denmark, Canada,the UK, and New Zealand.\\nENVIRONMENTAL RISK FACTORS\\nIn addition to being the biggest cancer killer, lungcancer is one of the few cancers with a welldeﬁned aetiology—namely, the inhalation of\\ntobacco smoke. In the USA the death rate from'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 0}, page_content='In addition to being the biggest cancer killer, lungcancer is one of the few cancers with a welldeﬁned aetiology—namely, the inhalation of\\ntobacco smoke. In the USA the death rate from\\nlung cancer parallels the 1965 peak and subse-quent decline in cigarette smoking rates. Theincidence of lung cancer peaked in 1990 with 41.4\\ndeaths per 1000 person years and has since fallen,\\nreaching a rate of 39.8 in 1995.\\n4Shopland et al5\\ndetermined the prevalence of smoking in each of\\nthe 50 states from surveys conducted in 1992 andcompared these rates with 1985. Kentucky and\\nWest Virginia were the highest rates with 32.29%\\nand 30.59% of the adult population 20 years orolder being current smokers. Utah had the lowestrate at 17.1%. Forty nine of the 51 areas had a\\ndecrease in smoking between 1985 and 1992–93.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 0}, page_content='and 30.59% of the adult population 20 years orolder being current smokers. Utah had the lowestrate at 17.1%. Forty nine of the 51 areas had a\\ndecrease in smoking between 1985 and 1992–93.\\nRhode Island experienced the greatest decline at–30.7%. Only Utah (+16.3%) and Wisconsin(+1.9%) showed increases. Nationally, the preva-lence of smoking declined 17% overall from 1985to 1992–93. Among subgroups, African Americanmen experienced the highest rates (31.3%)\\nfollowed by White men (26.4%) and Hispanicmens (25.0%). Among women, Whites andAfrican Americans were similar (22.9% and22.5%, respectively) whereas smoking amongHispanic women was signiﬁcantly less (12.7%).\\nWhile there have been similar declines in the\\nincidence of smoking in Canada and westernEurope, there is concern about the rising rates ofsmoking in developing countries.\\n6–8China, the\\nworld’s most populous country, has tripled\\ncigarette consumption between 1978 and 1987.9It'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 0}, page_content='6–8China, the\\nworld’s most populous country, has tripled\\ncigarette consumption between 1978 and 1987.9It\\nis estimated that 70% of Chinese men and 2% ofwomen smoke.\\n10Given the 20–30 year lag\\nbetween exposure and peak incidence of cancer,the potential coming epidemic stresses the urgent\\nneed to develop effective prevention strategies.\\nIn addition to the hazard of ﬁrst hand smoke,\\nthe 1986 US Surgeon General’s report concluded\\nthat cigarette smoke was a health risk to\\nnon-smokers. This has subsequently been sup-\\nported by over 24 studies showing that exposednon-smokers have an increased relative risk ofdeveloping cancer ranging from 1.41 to 2.01.\\n11–14\\nClearly, cigarette smoking remains the most\\nprevalent and uncontrolled environmental car-\\ncinogen in our society. The continued burden of\\ncurrent and ex-smokers in the US and western\\nEurope (the majority of Americans developinglung cancer are ex-smokers\\n15–17), the increasing\\nincidence of smokers in Asia, and the recruitment'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 0}, page_content='current and ex-smokers in the US and western\\nEurope (the majority of Americans developinglung cancer are ex-smokers\\n15–17), the increasing\\nincidence of smokers in Asia, and the recruitment\\nof new smokers worldwide guarantee that lung\\ncancer will remain the major cause of cancer\\ndeath worldwide for the next 25–50 years.\\nOver the past 10 years there have been\\nadvances in our understanding of the epidemiol-\\nogy and genetics of nicotine addiction.18These\\nﬁndings have opened new areas of smoking\\nprevention and cessation research using pharma-\\ncological interventions with both pharmacologi-\\ncal agents and nicotine replacement.19As health\\nprofessionals concerned about lung cancer, we\\nmust vigorously support smoking prevention and\\ncessation programmes.20We must champion\\nefforts to make tobacco abuse a socially and\\nculturally unacceptable habit and support all\\ngovernmental actions21to eliminate tobacco as an\\nenvironmental carcinogen.\\nGENETIC RISK FACTORS'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 0}, page_content='efforts to make tobacco abuse a socially and\\nculturally unacceptable habit and support all\\ngovernmental actions21to eliminate tobacco as an\\nenvironmental carcinogen.\\nGENETIC RISK FACTORS\\nNot all cigarette smokers go on to develop lung\\ncancer. Investigators are working to identifyfactors which can predict individual\\nsusceptibility.\\n22One area of study is the family of\\nenzymes responsible for carcinogen activation,\\ndegradation, and subsequent DNA repair.23These\\nenzymes display gene deletions and polymor-phisms which can affect enzyme activity. It has\\nbeen hypothesised that an individual’s enzyme\\nproﬁle is associated with lung cancer risk. Thisproﬁle could be used to counsel individuals and.......................\\nCorrespondence to:\\nG E Goodman, FredHutchinson CancerResearch Center, SwedishMedical Center CancerInstitute, Seattle,Washington, USA;gary.goodman@swedish.org\\n.......................994\\nwww.thoraxjnl.com'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 1}, page_content='could be used to select high risk individuals for speciﬁc\\nchemoprevention agents. These enzymes and the metabolicpathways they regulate also have the potential to become tar-\\ngets for preventive agents.\\nTo illustrate this point, benzo[a]pyrene, one of the many\\ncarcinogens found in cigarette smoke, is metabolically\\nactivated by the P450 family of hepatic enzymes (mainlyCYP1A1).\\n24–27The intermediate metabolites are chemically\\nactive and can bind to DNA and cause gene dysfunction.\\nGlutathione-S-transferase (GST), epoxide hydrolase (EH) and\\nN-acetytransferase (NAT) detoxify these products. Polymor-\\nphisms and/or gene deletions result in modiﬁed metabolicactivity.\\n18 28–32Enzymes responsible for DNA repair also display\\npolymorphisms.33–35Studies suggest that genetic alterations in\\neach of these enzyme families can have small effects on an\\nindividual’s risk of developing lung cancer.\\nGene-diet interaction will also require careful investigation.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 1}, page_content='each of these enzyme families can have small effects on an\\nindividual’s risk of developing lung cancer.\\nGene-diet interaction will also require careful investigation.\\nStudies suggest that low levels of vitamin E can increase the\\nGSTM1 associated risk.36Interactions with dietary enzyme\\nfactors such as folate and subsequent folate metabolism have\\nalso been suggested.37Although it is possible that a single\\npolymorphism or dietary interactions may signiﬁcantly alterthe relative risk, it is likely that many interactions, each hav-\\ning a subtle effect, can result in synergistic interactions that\\ngreatly affect the overall risk. Determining the risk proﬁle ofan individual based on their inherited polymorphisms andtheir potential dietary interaction will be a complex undertak-ing. Testing these hypotheses will require studies with a very\\nlarge sample size to achieve the statistical power.\\nDIETARY RISK FACTORS\\nNumerous studies have shown that the incidence of cancer'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 1}, page_content='large sample size to achieve the statistical power.\\nDIETARY RISK FACTORS\\nNumerous studies have shown that the incidence of cancer\\ncan be inversely related to the intake of many food groups.38–41\\nThe serum concentration of many micronutrients is alsoinversely related to the incidence of cancer.\\n42–46Based on these\\nepidemiological studies, it has been suggested that micro-nutrients and macronutrients present in our diet may act as\\ncancer inhibiting substances.\\nDietary carotenoids were one of the ﬁrst micronutrients\\nsuggested as risk factors for lung cancer.\\n38Epidemiological\\nstudies reported that individuals with a diet low in\\nβ-carotene-rich foods had a higher incidence of lung\\ncancer.39 40 47 48Retrospective case-control trials of serum\\nobtained from individuals who later developed lung cancerconﬁrmed that the serum concentrations of β-carotene were\\nlower in cases than in controls.\\n43 48Those in the highest'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 1}, page_content='obtained from individuals who later developed lung cancerconﬁrmed that the serum concentrations of β-carotene were\\nlower in cases than in controls.\\n43 48Those in the highest\\ncategory had a relative risk of 0.5–0.7 compared with those inthe highest. Another carotenoid, lycopene, a simple hydrocar-\\nbon precursor of β-carotene, has been studied.\\n49Lycopene is an\\neffective antioxidant (25% better than β-carotene) and is the\\nsecond most common dietary carotenoid. The most commonsource of lycopene in the diet is cooked or processed tomatoes\\nwhich contain about 30 mg/kg. Like β-carotene, epidemiologi-\\ncal studies of the dietary intake or serum concentration oflycopene found an inverse relationship with cancer of thebladder, lung and prostate.\\n49 50\\nOther dietary micronutrients may also be associated with\\nlung cancer risk. Knekt et alreported that dietary ﬂavonoids\\n(found in high concentration in apples) were a strong predic-\\ntor of lung cancer risk. In a population of 9959 Finnish men'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 1}, page_content='lung cancer risk. Knekt et alreported that dietary ﬂavonoids\\n(found in high concentration in apples) were a strong predic-\\ntor of lung cancer risk. In a population of 9959 Finnish men\\nand women, those with the highest intake of dietaryﬂavonoids had an incidence of lung cancer that was 59% ofthose in the lowest quartile.\\n51Isothiocyanates, which are\\nwidely distributed in cruciferous vegetables, have also been\\nshown to have an inverse relationship with the incidence of\\nlung cancer.52 53In vivo animal model systems have shown that\\nisothiocyanates have activity in decreasing the incidence of\\ncancer of the lung, oesophagus, liver, colon, and bladder.\\nCHEMOPREVENTION\\nThe pragmatic acceptance that tobacco abuse cannot be easily\\nand rapidly eliminated has given emphasis to the ﬁeld of lungcancer chemoprevention. Chemoprevention is deﬁned as the\\nuse of agents to prevent, inhibit, or reverse the process ofcarcinogenesis.\\n54The underlying hypothesis of prevention is'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 1}, page_content='use of agents to prevent, inhibit, or reverse the process ofcarcinogenesis.\\n54The underlying hypothesis of prevention is\\nthat carcinogenesis is the stepwise accumulation of genetic\\nand epigenetic changes that result in a cell with a malignant\\nphenotype. The goal of cancer prevention scientists is to\\ndevelop interventions that can interrupt, arrest, or reverse thisprocess.\\n55\\nHistorically, two major categories of compounds have been\\ninvestigated for cancer prevention activity. One group consists\\nof naturally occurring dietary micronutrients and their\\nsynthetic analogues which have been discussed above.\\nAlthough epidemiological associations cannot prove a causeand effect relationship, they show strong associations andsuggest hypotheses to be tested. The goal is to determine\\nwhich, if any, of these dietary substances (or combination of\\nsubstances) are important factors in modifying the incidenceof cancer,\\n56and whether supplementation of the diet with'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 1}, page_content='which, if any, of these dietary substances (or combination of\\nsubstances) are important factors in modifying the incidenceof cancer,\\n56and whether supplementation of the diet with\\nthese micronutrients is an effective method of cancer preven-\\ntion.\\nThe other group of compounds currently being investigated\\nare synthetic agents.57These include a large number of\\ncompounds with varying mechanisms including, for example,the non-steroidal anti-inﬂammatory agents (NSAIDS) which\\nare potent in vivo inhibitors of colon carcinogenesis\\n58–60and\\nagents such as DFMO (diﬂuoromethyl ornithine), a\\npolyamine synthase inhibitor, which has a broad spectrum of\\npreventive activity in vitro and in vivo.61–63\\nRetinoids\\nVitamin A and its family of compounds (the retinoids) werethe ﬁrst dietary constituents to have extensive in vitro and in\\nvivo evidence of chemopreventive activity.\\n64The retinoids have\\nbeen found to be active in many animal model systems using'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 1}, page_content='vivo evidence of chemopreventive activity.\\n64The retinoids have\\nbeen found to be active in many animal model systems using\\ndifferent organ sites as well as different inducing\\ncarcinogens.65When Sporn et alﬁrst discussed the concept of\\nchemoprevention, his work focused on the retinoids.54\\nRetinol, its palmitic acid ester, the trace retinoids all-trans-\\nretinoic acid and 13-cis-retinoic acid, together with the\\nsynthetic retinoids etretinate and 4-hydroxy phenyl retina-\\nmide have all been studied in vitro as well as in human inter-\\nvention trials. Trials with these agents were started in the early1980s and a number of them have matured and reportedresults.\\nOne of the earliest reported positive trials was that by Hong\\net alwho studied the effects of 13-cis-retinoic acid on the inci-\\ndence of recurrence and second primaries in patients witheach stage primary squamous cell carcinomas of the head andneck.\\n66This tobacco-associated malignancy has many analo-'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 1}, page_content='dence of recurrence and second primaries in patients witheach stage primary squamous cell carcinomas of the head andneck.\\n66This tobacco-associated malignancy has many analo-\\ngies to lung cancer. Although there was no decrease in the\\nincidence of recurrence, second primaries which, in general,\\nconsisted of other tobacco related cancers (head and neck,\\noesophageal, and lung) were signiﬁcantly fewer (p<0.05).This study is now undergoing conﬁrmation in a largeintergroup trial being conducted within the USA.\\nThe European Organization for Cancer (EORTC) studied a\\npopulation of patients with resected stage I non-small celllung cancer. Like patients with early primary cancers of thehead and neck, this group has a 60–70% cure rate of their pri-mary cancer with surgery alone. Retinyl palmitate (300 000IU/day) plus N-acetylcysteine (600 g/day) were given for two\\nyears. Their end points were recurrence and second primaries.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 1}, page_content='years. Their end points were recurrence and second primaries.\\nThis trial reported some early encouraging results although aﬁnal report in 2000 reported no beneﬁt in survival, relapse freesurvival, or incidence of second primaries.\\n67\\nA US intergroup trial of similar design tested 13-cis-retinoic\\nacid (30 mg/day) for 3 years in a similar population of subjects\\nwith stage I lung cancer. This phase III trial completed accrual\\nin 1997 and reported an increase in death rate in patients\\nreceiving 13-cis-retinoic acid. After a median follow up of 3.5Prevention of lung cancer 995\\nwww.thoraxjnl.com'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 2}, page_content='years there was no effect of the supplements on the time to\\nsecond primaries, recurrence, or mortality. There was asmoking-treatment interaction, with current smokers on theactive arm having increased recurrence and mortality.\\n68\\n13-cis-retinoic acid has also been tested using bronchial\\nmetaplasia as the end point.69This double blind, randomised\\ntrial showed no decrease in the incidence of metaplasia in theactive treatment arm. The positive results of the clinical trial inhead and neck cancers using cancer as an end point and thesenegative results help to emphasise that intermediate end\\npoints need to be clearly linked to cancer incidence before theycan be acceptable as a surrogate end point.\\nThe retinoids as a family continue to be investigated for\\nchemoprevention. It is likely that additional synthetic\\nretinoids which block or activate speciﬁc retinoid receptors(RXR) will be developed and tested in the clinic.\\n70Lung cancer\\nwill remain a prime target for these agents.\\nBeta-carotene'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 2}, page_content='retinoids which block or activate speciﬁc retinoid receptors(RXR) will be developed and tested in the clinic.\\n70Lung cancer\\nwill remain a prime target for these agents.\\nBeta-carotene\\nEpidemiological trials, together with an inﬂuential science\\neditorial in 1981, suggested that β-carotene was the most\\npromising lung cancer prevention agent.6In spite of only lim-\\nited in vitro and in vivo animal studies suggesting that\\nβ-carotene had preventive activity, human intervention trials\\nwere started in the early 1980s. Two of these trials focused on\\nlung cancer—the Alpha Tocopherol Beta Carotene Trial(ATBC) in Finland\\n71and the Carotene and Retinol Efﬁcacy\\nTrial (CARET) in the USA.72\\nCARET tested the combination of 30 mg β-carotene and\\n25 000 IU retinyl palmitate daily in 18 314 men and women\\naged 50–69 years at high risk for developing lung cancer.73The'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 2}, page_content='CARET tested the combination of 30 mg β-carotene and\\n25 000 IU retinyl palmitate daily in 18 314 men and women\\naged 50–69 years at high risk for developing lung cancer.73The\\nhigh risk groups consisted of 14 254 cigarette smokers with a20-pack year smoking history, either current smokers orex-smokers who had quit within 6 years, and 4060 men withextensive occupational asbestos exposure who were current or\\nex-smokers (up to 15 years since quitting). The interventionwas stopped 21 months early because of evidence of no beneﬁtand possible harm (mean follow up 4 years). There were 28%more lung cancers (p=0.02) and 17% more deaths (p=0.02)in the active intervention group. Because CARET administereda combination of β-carotene and retinyl palmitate it was not\\npossible to distinguish whether the adverse effects were due toβ-carotene, retinyl palmitate, or the combination.\\nThese results were remarkably similar to the ATBC trial\\nwhich was completed in Finland in a similar high risk popula-'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 2}, page_content='These results were remarkably similar to the ATBC trial\\nwhich was completed in Finland in a similar high risk popula-\\ntion and reported in 1994, before CARET.\\n74This NCI sponsored\\n2×2 placebo controlled trial administered 20 mg β-carotene\\nwith or without 50 mg α-tocopherol for 5–8 years (mean 6.1\\nyears) to 29 133 Finnish men aged 50–69 who smoked ﬁve or\\nmore cigarettes daily. There was no overall effect of\\nα-tocopherol on the incidence of lung cancer (relative risk\\n(RR) 0.99, 95% conﬁdence interval (CI) 0.87 to 1.13, p=0.86).On the other hand, β-carotene supplementation was associ-\\nated with an increase in lung cancer risk (RR 1.16, 95% CI 1.02to 1.33, p=0.02). The adverse effect of β-carotene appeared to\\nbe stronger in those who were heavy smokers of at least 20cigarettes per day (RR 1.25, 95% CI 1.07 to 1.46) than in thosewho smoked 19 cigarettes or less per day (RR 0.97, 95% CI 0.76to 1.23). These two trials clearly established that β-carotene'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 2}, page_content='supplements are harmful to cigarette smokers causing an\\nincrease in the incidence of lung cancer and mortality.\\nAnother smaller intervention trial has reported encourag-\\ning results in lung and other cancer. It has long been knownthat there is an inverse relationship between the incidence ofcancer and the selenium content of the soil (and hence locallygrown foods) and cancer.\\n75Based on this ﬁnding, Clark et al76\\nconducted a skin cancer prevention trial in individuals previ-\\nously diagnosed as having skin cancer. Participants were ran-domised to receive 200 µg/day selenium rich brewer yeast or\\nplacebo. An analysis in 1997 reported that selenium supple-mentation did not change the primary end point of new skincancers but did reduce the incidence of other primaries (lung,'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 2}, page_content='placebo. An analysis in 1997 reported that selenium supple-mentation did not change the primary end point of new skincancers but did reduce the incidence of other primaries (lung,\\np=0.05; prostate, p=0.001; colorectal, p=0.03). This study willrequire conﬁrmation since the population consisted ofpatients with previous skin cancer and the encouragingresults were seen only in the secondary analysis. A primaryintervention trial of selenium and α-tocopherol with a sample\\nsize of 32 000 with the primary end point of prostate cancerand secondary end points of lung cancer and colon cancer(SELECT) began recruitment in 2001.\\nThe ﬁndings of CARET and ATBC were a surprise since they\\nconﬂicted with the epidemiological data. However, bothCARET and ATBC administered high doses of β-carotene'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 2}, page_content='The ﬁndings of CARET and ATBC were a surprise since they\\nconﬂicted with the epidemiological data. However, bothCARET and ATBC administered high doses of β-carotene\\n(20–30 times the average daily intake). These results empha-sise the importance of carefully controlled intervention trialsin determining the role of dietary supplements or anyintervention agent. Because of the discouraging results of thelarge intervention trials as well as a rapidly expanding under-standing of lung cancer, there has been a shift in focus to smallclinical trials evaluating the effect of potential interventionagents on biomarkers of carcinogenesis.\\nBIOMARKERS OF CARCINOGENESIS\\nA better understanding of the molecular events that occur\\nduring carcinogenesis has opened new areas of research incancer prevention. Currently, pre-neoplasia is diagnosed based\\non histological examinations. However, for lung cancer, bron-'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 2}, page_content='during carcinogenesis has opened new areas of research incancer prevention. Currently, pre-neoplasia is diagnosed based\\non histological examinations. However, for lung cancer, bron-\\nchial metaplasia or dysplasia is not always a good predictor offuture cancer risk. Ex-smokers can have improvement inmetaplasia/dysplasia but their cancer risk remains\\nincreased.\\n77–79It is hoped that testing bronchial mucosa or\\nbronchial epithelial cells for the presence of genetic or epige-\\nnetic changes will better predict the risk of cancer. Patients\\nwith documented changes may be more appropriate for treat-\\nment with chemoprevention agents. In addition, chemopre-vention trials can be based on these molecular markers.Patients can be recruited to a trial by the presence of one or\\nmore of these markers. Those agents which cause an improve-'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 2}, page_content='more of these markers. Those agents which cause an improve-\\nment in marker proﬁle can then be further investigated forcancer prevention activity. These scenarios remain hypothesesto be tested since none of the molecular markers described hasbeen shown to be a reliable predictor of cancer incidence. Theirnatural history in high risk populations is unknown, and it isalso unknown if an agent which causes an improvement in\\nmarker status will ultimately decrease the incidence of cancer.\\nNumerous candidate markers are being investigated.\\nAlterations in the p53 tumour suppressor gene are commonlyacquired genetic lesions observed in lung cancer.\\n80–82Muta-\\ntions affect approximately 90% of small cell lung cancers and\\n50–60% of non-small cell lung cancers.83–91Lonardo et al92stud-\\nied the expression of p53 in bronchial epithelium andsquamous cell carcinomas and found that 61% of the\\nsquamous cell carcinomas, 54% of high grade dysplasias, and'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 2}, page_content='ied the expression of p53 in bronchial epithelium andsquamous cell carcinomas and found that 61% of the\\nsquamous cell carcinomas, 54% of high grade dysplasias, and\\nonly 6% with atypia overexpressed p53. p53 expression wasnot seen in squamous metaplasia or low grade dysplasia.Rusch et al\\n93had similar ﬁndings with 56% of non-small cell\\nand 16% of bronchial lesions exhibiting aberrant p53\\nimmunohistochemical staining.\\nMao et al94studied the sputum of high risk individuals and\\nfollowed them for cancer incidence. They found that 10 of 15patients who developed adenocarcinoma had mutations in the\\nras or p53 gene. They then examined sputum collected prior to\\ndiagnosis and found that eight of the 10 patients had theidentical mutation detected in at least one sputum sample.Mao et al\\n95later reported the detection of abnormalities in\\nbronchoscopic epithelial biopsy specimens in 40 current\\nsmokers and 14 former smokers. They determined DNA'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 2}, page_content='95later reported the detection of abnormalities in\\nbronchoscopic epithelial biopsy specimens in 40 current\\nsmokers and 14 former smokers. They determined DNA\\nsequence losses involving microsatellite DNA at three loci\\n(3p14, 9p21, and 17p13). DNA losses at 3p14, 9p21, and 17p13were detected in 27 (75%), 21 (57%), and six (18%),respectively, of the informative subjects (those who could be996 Goodman\\nwww.thoraxjnl.com'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='evaluated at that speciﬁc loci). Only one abnormality, loss of\\n3p14, was seen in ﬁve of nine of the informative non-smokers.These sites of DNA loss are known to be localised to chromo-\\nsomal sites important in cancer. The tumour suppressor gene\\np53 is located at 17p13.\\n96The other two loci contain the\\ntumour suppressor genes FHIT (3p14) and p16 (9p21).97–99This\\nstudy showed that relevant genetic abnormalities can be seen\\nin histologically normal bronchial epithelial cells of smokers\\nand are compatible with the hypothesis of a stepwise accumu-\\nlation of genetic abnormalities leading to cancer.\\nInactivation of the p16 tumour suppressor gene resulting\\nfrom either allelic loss or mutation of p16 or hypermethylationof CpG islands in its promoter region\\n100is also a promising\\nmarker in lung cancer.101–103Belinsky’s group used\\nmethylation-speciﬁc polymerase chain reaction (MSP)104 105to\\ndetermine the frequency of p16 methylation in premalignant'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='100is also a promising\\nmarker in lung cancer.101–103Belinsky’s group used\\nmethylation-speciﬁc polymerase chain reaction (MSP)104 105to\\ndetermine the frequency of p16 methylation in premalignant\\nlesions, carcinoma in situ lesions, squamous cell carcinomas,\\nand sputum samples. The frequency increased during disease\\nprogression from basal cell hyperplasia (17%) to squamousmetaplasia (24%) to carcinoma in situ (50%) lesions. Hefurther showed that aberrant p16 methylation could bedetected in sputum samples from three of seven patients with\\nlung cancer and ﬁve of 26 cancer-free individuals at high risk\\n(smokers). Ahrendt\\n101found methylated p16 alleles in\\nprospectively collected bronchoalveolar lavage (BAL) ﬂuid\\nfrom 63% of patients (12/19) with a primary resectable\\nnon-small cell lung cancer that had p16 methylation in the\\ncancer. Palmisano et al106found that aberrant methylation of\\nthe p16 and/or O6-methyl-guanine-DNA methyltransferase'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='non-small cell lung cancer that had p16 methylation in the\\ncancer. Palmisano et al106found that aberrant methylation of\\nthe p16 and/or O6-methyl-guanine-DNA methyltransferase\\n(MGMT) promoter regions can be detected in DNA from spu-\\ntum in all 10 patients with squamous cell lung carcinoma at\\nthe time of diagnosis and also in sputum samples of all 11patients up to 3 years before clinical diagnosis. Only ﬁve ofthese 21 patients had sputum cytologies positive for cancer.Furthermore, methylated p16 and MGMT sputum markers\\nwere detected in 12–19% and 16–36%, respectively, of cancer-\\nfree individuals at high risk (exposure to tobacco and/orradon) for developing lung tumours.\\nThe cyclins are a family of nuclear factors that are expressed\\nand control the progression of the cell through the cell cycle.Inappropriate expression or activity has been found in cancerand it has been suggested that the expression of these proteins\\nmay be a marker of early carcinogenesis. Lonardo et al\\n92stud-'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='may be a marker of early carcinogenesis. Lonardo et al\\n92stud-\\nied cyclin D1 and E in a series of bronchial biopsies ranging\\nfrom metaplasia to low grade dysplasia, high grade dysplasia,\\nand squamous cell carcinoma. They found that cyclin D1 was\\ndetected in 7% with squamous metaplasia, 15% with atypia,18% with low grade dysplasia, 47% with high grade dysplasia,and 42% with squamous cell carcinoma. Findings were similarwith cyclin E which was not detected in normal epithelium,\\nsquamous metaplasia, or low grade dysplasia but occurred in\\n9% with atypia, 33% with high grade dysplasia, and 54% withsquamous cell carcinomas. Papadimitrakopoulou et al\\n107\\nstudied 27 patients with biopsy specimens of the upper aero-\\ndigestive tract and found 50% expression of cyclin D.\\nCyclo-oxygenase (COX) is a constitutively expressed en-\\nzyme which is one of the rate limited steps in the conversion'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='digestive tract and found 50% expression of cyclin D.\\nCyclo-oxygenase (COX) is a constitutively expressed en-\\nzyme which is one of the rate limited steps in the conversion\\nof arachadonic acid to prostaglandins. An alternative form ofCOX, COX-2, is inducible and is expressed in response togrowth factors and to other stimuli. It appears that COX-2 isexpressed in many lung cancer cell line model systems and\\ntumours obtained from patients. Overexpression of COX-2\\noccurs in all cell types but appears more prominent in welldifferentiated cancers. It is also found in premalignant stagesand invasive cancers.\\n108–112Many COX-2 inhibitors have inhibi-\\ntory effects on cell lines.113 114It has been proposed that the\\nexpression of COX-2 may be an early marker of a genetically\\naltered epithelial cell destined to become cancer. Wolff et al111'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='tory effects on cell lines.113 114It has been proposed that the\\nexpression of COX-2 may be an early marker of a genetically\\naltered epithelial cell destined to become cancer. Wolff et al111\\nfound expression of COX-2 in 19 of 21 adenocarcinomas. Welldifferentiated adenocarcinomas appeared to have more COX-2staining than poorly differentiated tumours. Expression ofCOX-2 was also seen in 11 squamous cell carcinomas.Epidermal growth factor receptor (EGFR) is a member of the\\nerbB gene family of transmembrane tyrosine kinase. Activation\\nplays an important role in cell division and differentiation.Abnormalities of EGFR have been found in patients with lungcancer and those at high risk.\\n115–118While EGFR is expressed in\\nnormal epithelium, increased expression has been in found\\nmetaplastic lesions119 120and in 70% of squamous cell carcinomas\\nand around 50% of adenocarcinomas.\\nThese markers are just a few of the many which have been\\ndescribed that may serve as intermediate end points in identi-'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='and around 50% of adenocarcinomas.\\nThese markers are just a few of the many which have been\\ndescribed that may serve as intermediate end points in identi-\\nfying high risk individuals. Currently, many are acting as endpoints for an intervention trial. Although each marker isﬁrmly established as important in the carcinogenesis of lung\\ncancer, modulation of these markers by preventive agents does\\nnot guarantee that the agent will have activity in reducing theincidence of lung cancer. Trials are currently being conductedto evaluate multiple markers.\\nA better understanding of carcinogenesis has also fostered\\nthe development of agents speciﬁcally targeting the epigeneticand genetic changes which develop in neoplastic cancer cells.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='A better understanding of carcinogenesis has also fostered\\nthe development of agents speciﬁcally targeting the epigeneticand genetic changes which develop in neoplastic cancer cells.\\nSpeciﬁc agents are now available that block the COX-2 enzyme(Celecoxib). EGFR is activated in lung cancer and is expressedin pre-neoplasia. ZD1839 is a speciﬁc inhibitor of the EGFactivated tyrosine kinase. These compounds are examples ofagents currently being tested in the treatment of patients withestablished lung cancer and have good potential as preventiveagents.\\nChemoprevention is a new ﬁeld. Analogous to the develop-'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='Chemoprevention is a new ﬁeld. Analogous to the develop-\\nment of cancer chemotherapy in the 1940s and 1950s, thisﬁeld is in its infancy. As we gain a better understanding ofcarcinogenesis our development and use of agents will becomebased in modifying underlying mechanisms. Although thepast 10–15 years have been disappointing, we have establisheda strong foundation for future clinical trials. There is everyreason to believe that greater success will be achieved in thenext 10–15 years.\\nREFERENCES\\n1Murray C , Lopez A. Mortality by cause for eight regions of the world .\\nLancet 1997; 349:1269–76.\\n2Jemal A , Thomas A, Murray T, et al. Cancer statistics .C AC a n c e rJC l i n\\n2002; 52:23–47.\\n3Levi F , LaVecchia, Lucchini F. Cancer mortality in Europe 1990–1992.\\nEur J Cancer Prev 1995; 4:389–417.\\n4Cole P , Rodu B. Declining cancer mortality in the United States. Cancer\\n1996; 78:2045–8.\\n5Shopland DR , Hartman AM, Gibson J, et al. Cigarette smoking among'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='Eur J Cancer Prev 1995; 4:389–417.\\n4Cole P , Rodu B. Declining cancer mortality in the United States. Cancer\\n1996; 78:2045–8.\\n5Shopland DR , Hartman AM, Gibson J, et al. Cigarette smoking among\\nU.S. adults by state and region: estimates from the current population\\nsurvey. J Natl Cancer Inst 1996; 88:1748–58.\\n6Peto R , Lopez A, Boreman J. Mortality from smoking worldwide. Br Med\\nBull1996; 52:12–21.\\n7Parkin D , Whelan S, Ferlay J, et al.Cancer incidents in five continents .\\nLyon, France: IARC Scientific Publication, No 143, Vol 7, 1997.\\n8Stellman SD , Takezaki T, Wang L-E, et al. Smoking and lung cancer risk\\nin American and Japanese men: an international case-control study.\\nCancer Epidemiol Biomarkers Prevent 2001; 10:1193–9.\\n9Chollat-Traquet C . Tobacco or health: a WHO programme. Eur J\\nCancer 1992; 28:311–5.\\n10Gong YL , Koplan J, Feng W. Cigarette smoking in China. Prevalence,\\ncharacteristics, and attitudes in Minhang District. JAMA\\n1995; 274:1232–4.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='Cancer 1992; 28:311–5.\\n10Gong YL , Koplan J, Feng W. Cigarette smoking in China. Prevalence,\\ncharacteristics, and attitudes in Minhang District. JAMA\\n1995; 274:1232–4.\\n11National Research Council .Environmental tobacco smoke: Measuring\\nexposures and assessing health effects . Washington DC: National\\nAcademy, 1986.\\n12Wald NJ , Nanchahal K, Thompson S. Does breathing other people’s\\ntobacco smoke cause lung cancer ?BMJ Clin Res Ed 1986; 293:1217–\\n22.\\n13Spitzer WO , Lawrence V, Dales R. Links between passive smoking and\\ndisease: a best-evidence synthesis. A report of the Working Group on\\nPassive Smoking. Clin Invest Med 1990; 13:17–42; discussion 43–6.\\n14Cardenas VM , Thun M, Austin H. Environmental tobacco smoke and\\nlung cancer mortality in the American Cancer Society’s CancerPrevention Study. II.\\nCancer Causes Control , 1997; 8:57–64; erratum\\nCancer Causes Control 1997; 8:675.\\n15Halpern MT , Gillespie B, Warner K. Patterns of absolute risk of lung'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 3}, page_content='Cancer Causes Control , 1997; 8:57–64; erratum\\nCancer Causes Control 1997; 8:675.\\n15Halpern MT , Gillespie B, Warner K. Patterns of absolute risk of lung\\ncancer mortality in former smokers. J Natl Cancer Inst 1993; 85:457–64.\\n16Lubin JH , Blot W. Lung cancer and smoking cessation: patterns of risk. J\\nNatl Cancer Inst 1993; 85:422–3.Prevention of lung cancer 997\\nwww.thoraxjnl.com'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='17Strauss G , DeCamp M, Dibiccaro E. Lung cancer diagnosis is being\\nmade with increasing frequency in former cigarette smokers! Clin Oncol\\n1995; 14:362.\\n18Nazar-Stewart V , Motulsky AG, Eaton DL, et al. The glutathione\\nS-transferase u polymorphism as a marker for susceptibility to lung\\ncarcinoma. Cancer Res 1993; 53:2313–8.\\n19Yoshida K , Hamajima N, Kozaki K, et al. Association between the\\ndopamine de receptor A2/A2 genotype and smoking behaviour in theJapanese.\\nCancer Epidemiol Biomarkers Prevent 2001; 10:403–5.\\n20Risser NL . Prevention of lung cancer: the key is to stop smoking. Semin\\nOncol Nursing 1996; 12:260–9.\\n21Koh HK . An analysis of the successful 1992 Massachusetts tobacco tax\\ninitiative. Tobacco Control 1996; 5:220–5.\\n22Spitz MR , Bondy M. Genetic susceptibility to cancer. Cancer 1993; 72(3\\nSuppl):991–5.\\n23Perera F . Molecular epidemiology: insights into cancer susceptibility, risk\\nassessment, and prevention. J Natl Cancer Inst 1996; 88:496–509.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='Suppl):991–5.\\n23Perera F . Molecular epidemiology: insights into cancer susceptibility, risk\\nassessment, and prevention. J Natl Cancer Inst 1996; 88:496–509.\\n24Li D, Firozi P, Wang L-E, et al. Sensitivity to DNA damage induced by\\nbenzo(a)pyrene diol epoxide and risk of lung cancer: A case-control\\nanalysis. Cancer Res 2001; 61:1445–50.\\n25Wu X , Shi H, Jiang H, et al. Associations between cytochrome P4502E1\\ngenotype, mutagen sensitivity, cigarette smoking and susceptibility tolung cancer.\\nCarcinogenesis 1997; 18:967–73.\\n26Kato S , Shields P, Caporaso N, et al. Analysis of cytochrome P450 2E1\\ngenetic polymorphisms in relation to human lung cancer. Cancer\\nEpidemiol Biomarkers Prevent 1994; 3:515–8.\\n27Nakachi K , Imai K, Hayashi S, et al. Polymorphisms of the CYP1A1 and\\nglutathione S-transferase genes associated with susceptibility to lungcancer in relation to cigarette dose in a Japanese population.\\nCancer Res\\n1993; 53:2994–9.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='glutathione S-transferase genes associated with susceptibility to lungcancer in relation to cigarette dose in a Japanese population.\\nCancer Res\\n1993; 53:2994–9.\\n28Heckbert S , Weiss NS, Hornung SK, et al. Glutathione S-transferease\\nand epoxide hydrolase activity in human leukocytes in relation to risk oflung cancer and other smoking-related cancers.\\nJ Natl Cancer Inst\\n1992; 84:414–22.\\n29Zhou W , Liu G, Thurston SW, et al. Genetic polymorphisms in\\nN-acetyltransferase-2 and microsomal epoxide hydrolase, cumulativecigarette smolking, and lung cancer.\\nCancer Epidemiol Biomarkers\\nPrevent 2002; 11:15–21.\\n30Hou S-M , Falt S, Yang K, et al. Differential interactions between GSTM1\\nand NAT1 genotypes on aromatic DNA adduct level and HPRT mutantfrequency in lung cancer patients and population controls.\\nCancer\\nEpidemiol Biomarkers Prevent 2001; 10:133–40.\\n31Frazier ML , O’Donnell FT, Kong S, et al. Age-associated risk of cancer'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='Cancer\\nEpidemiol Biomarkers Prevent 2001; 10:133–40.\\n31Frazier ML , O’Donnell FT, Kong S, et al. Age-associated risk of cancer\\namong individuals with N-acetyltransferase 2 (NAT2) mutations andmutations in DNA mismatch repair genes.\\nCancer Res\\n2001; 61:1269–71.\\n32Zhou W , Thurston SW, Liu G, et al. The interaction between microsomal\\nepoxide hydrolase polymorphisms and cumulative cigarette smoking indifferent histological subtypes of lung cancer.\\nCancer Epidemiol\\nBiomarkers Prevent 2001; 10:461–6.\\n33Ratnzsinghe D , Yao S-X, Tangrea JA, et al. Polymorphisms of the DNA\\nrepair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers\\nPrevent 2001; 10:119–23.\\n34David-Beabes GL , Lunn RM, London SJ. No association between the\\nXPD (Lys751G1n) polymorphism or the XRCC3 (Thr241Met)\\npolymorphism and lung cancer risk. Cancer Epidemiol Biomarkers\\nPrevent 2001; 10:911–2.\\n35Park JY , Lee SY, Jeon H-S, et al. Polymorphism of the DNA repair gene'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers\\nPrevent 2001; 10:911–2.\\n35Park JY , Lee SY, Jeon H-S, et al. Polymorphism of the DNA repair gene\\nXRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers\\nPrevent 2002; 11:23–7.\\n36Woodson K , Stewart C, Barrett M, et al. Effect of vitamin intervention on\\nthe relationship between GSTM1, smoking, and lung cancer risk among\\nmale smokers. Cancer Epidemiol Biomarkers Prevent 1999; 8:965–70.\\n37Shen H , Spitz MR, Wang L-E, et al. Polymorphisms of\\nmethylene-tetrahydrofolate reductase and risk of lung cancer: acase-control study.\\nCancer Epidemiol Biomarkers Prevent\\n2001; 10:397–401.\\n38Ziegler R , Colavito E, Hartge P. Importance of alpha-carotene,\\nbeta-carotene, and other phytochemicals in the etiology of lung cancer. J\\nNatl Cancer Inst 1996; 88:612–5.\\n39Colditz GA , Stampfer MJ, Willett WC. Diet and lung cancer. A review\\nof the epidemiologic evidence in humans. Arch Intern Med\\n1987; 147:157–60.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='Natl Cancer Inst 1996; 88:612–5.\\n39Colditz GA , Stampfer MJ, Willett WC. Diet and lung cancer. A review\\nof the epidemiologic evidence in humans. Arch Intern Med\\n1987; 147:157–60.\\n40Byers T . Diet as a factor in the etiology and prevention of lung cancer.\\nIn: Samet J, ed. Epidemiology of lung cancer . New York: Marcel Dekker,\\n1994: 335–52.\\n41Block G . Fruit, vegetables, and cancer prevention: a review of the\\nepidemiological evidence. Nutr Cancer 1992; 18:1–29.\\n42Stahelin H , Gey K, Eichholzer M. Plasma anti-oxidant vitamins and\\nsubsequent cancer mortality in the 12-year follow-up of the prospective\\nBasel study. Am J Epidemiol 1991; 133:766–75.\\n43Nomura AM , Stemmermann G, Heilbrun L. Serum vitamin levels and the\\nrisk of cancer of specific sites in men of Japanese ancestry in Hawaii.\\nCancer Res 1985; 45:2369–72.\\n44Wald NJ , Thompson S, Densem J, et al. Serum beta-carotene and\\nsubsequent risk of cancer: results from the BUPA study. Br J Cancer\\n1988; 57:428–33.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='Cancer Res 1985; 45:2369–72.\\n44Wald NJ , Thompson S, Densem J, et al. Serum beta-carotene and\\nsubsequent risk of cancer: results from the BUPA study. Br J Cancer\\n1988; 57:428–33.\\n45Virtamo J , Valkeila E, Alfthan G. Serum selenium and risk of cancer. A\\nprospective follow-up of nine years. Cancer 1987; 60:145–8.\\n46Connett JE , Kuller L, Kjelsberg M. Relationship between carotenoids and\\ncancer. The Multiple Risk Factor Intervention Trial (MRFIT) study. Cancer\\n1989; 64:126–34.47Greenwald P . NCI cancer prevention and control research. Prevent Med\\n1993; 22:642–60.\\n48Willett WC , Polk B, Underwood B, et al. Relation of serum vitamins A\\nand E and carotenoids to the risk of cancer. N Engl J Med\\n1984; 310:430–4.\\n49Stahl W , Sies H. Lycopene: a biologically important carotenoid for\\nhumans ?Arch Biochem Biophys 1996; 336:1–9.\\n50Clinton SK , Emenhiser C, Schwartz S. cis-trans lycopene isomers,\\ncarotenoids, and retinol in the human prostate. Cancer Epidemiol\\nBiomarkers Prevent 1996; 5:823–33.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='50Clinton SK , Emenhiser C, Schwartz S. cis-trans lycopene isomers,\\ncarotenoids, and retinol in the human prostate. Cancer Epidemiol\\nBiomarkers Prevent 1996; 5:823–33.\\n51Knekt P , Jarvinen R, Seppanen R. Dietary flavonoids and the risk of lung\\ncancer and other malignant neoplasms. Am J Epidemiol\\n1997; 146:223–30.\\n52Hecht SS . Chemoprevention of lung cancer by isothiocyanates. Advan\\nExp Med Biol 1996; 401:1–11.\\n53Stoner GD , Morse M. Isothiocyanates and plant polyphenols as\\ninhibitors of lung and esophageal cancer. Cancer Lett 1997; 114:113–9.\\n54Sporn MB , Dunlop N, Newton D. Prevention of chemical carcinogenesis\\nby vitamin A and its synthetic analogs (retinoids). Fed Proc\\n1976; 35:1332–8.\\n55Bertram JS . Rationale and strategies for chemoprevention of cancer in\\nhumans. Cancer Res 1987; 47:3012–31.\\n56Goodman GE . Cancer prevention: chemoprevention vs dietary\\nmodifications. Prevent Med 1993; 22:689–92.\\n57Kelloff GJ , Hawk E, Crowell J, et al. Strategies for identification and'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='56Goodman GE . Cancer prevention: chemoprevention vs dietary\\nmodifications. Prevent Med 1993; 22:689–92.\\n57Kelloff GJ , Hawk E, Crowell J, et al. Strategies for identification and\\nclinical evaluation of promising chemoprevention agents. Oncology\\n1996; 10:1471–84.\\n58Giardiello FM , Hamilton S, Krush A. Treatment of colonic and rectal\\nadenomas with sulindac in familial adenomatous polyposis. N Engl J\\nMed 1993; 328:1313–6.\\n59Kelloff GJ , Crowell J, Boone C. Clinical development plan: piroxicam. J\\nCell BiochemSuppl 1994; 20:219–30.\\n60Kelloff GJ , Crowell J, Boone C. Clinical development plan: sulindac. J\\nCell Biochem Suppl 1994; 20:240–51.\\n61McCann P , Pegg A, Sjoeerdsma A. Inhibition of polyamine metabolism:\\nbiological significance and basis for new therapies . New York:\\nAcademic Press, 1987.\\n62Meyskens FL Jr , Emerson S, Pelot D. Dose de-escalation\\nchemoprevention trial of alpha-difluoromethylornithine in patients with\\ncolon polyps. J Natl Cancer Inst 1994; 86:1122–30.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='62Meyskens FL Jr , Emerson S, Pelot D. Dose de-escalation\\nchemoprevention trial of alpha-difluoromethylornithine in patients with\\ncolon polyps. J Natl Cancer Inst 1994; 86:1122–30.\\n63Kelloff GJ , Crowell J, Boone C. Clinical development plan:\\n2-difluoromethylornithine (DFMO). J Cell Biochem Suppl\\n1994; 20:147–65.\\n64Bollag W , Hartmann H. Prevention and therapy of cancer with retinoids\\nin animals and man. Cancer Surv 1983; 2:293–314.\\n65Lippman SM , Benner SE, Hong WK. Cancer chemoprevention. J Clin\\nOncol 1994; 12:851–73.\\n66Hong WK , Lippman SM, Itri L. Prevention of second primary tumors with\\nisotretinoin in squamous-cell carcinoma of the head and neck. N Engl J\\nMed 1990; 323:795–801.\\n67van Zandwijk N , Dalesio O, Pastorino U, et al. EUROSCAN, a\\nrandomized trial of vitamin A and N-acetylcysteine in patients with headand neck cancer or lung cancer.\\nJ Natl Cancer Inst 2000; 92:977–86.\\n68Lippman SM , Lee JJ, Karp DD, et al. Randomized phase III intergroup'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='J Natl Cancer Inst 2000; 92:977–86.\\n68Lippman SM , Lee JJ, Karp DD, et al. Randomized phase III intergroup\\ntrial of isotretinoin to prevent second primary tumors in stage Inon-small-cell lung cancer.\\nJ Natl Cancer Inst 2001; 93:605–18.\\n69Lee JS , Lippman SM, Benner SE. Randomized placebo-controlled trial of\\nisotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin\\nOncol 1994; 12:937–45.\\n70Dragney K , Rigas J, Dmitrovsky E. The retinoids and cancer prevention\\nmechanisms. Oncologist 2000; 5:361–8.\\n71Alpha Tocopherol Beta Carotene Trial Group . The effect of vitamin E\\nand beta-carotene on the incidence of lung cancer and other cancers inmale smokers.\\nN Engl J Med 1994; 330:1029–35.\\n72Omenn GS , Goodman GE, Thornquist M, et al. The beta-Carotene and\\nRetinol Efficacy Trial (CARET) for chemoprevention of lung cancer inhigh-risk populations: smokers and asbestos-exposed workers.\\nCancer\\nRes1994; 54:2038–43S.\\n73Omenn GS , Goodman GE, Thornquist M, et al. Risk factors for lung'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='Cancer\\nRes1994; 54:2038–43S.\\n73Omenn GS , Goodman GE, Thornquist M, et al. Risk factors for lung\\ncancer and for intervention effects in CARET, the beta-Carotene andRetinol Efficacy Trial.\\nJ Natl Cancer Inst 1996; 88:1550–9.\\n74Albanes D , Heinonen OP, Taylor PR, et al. Alpha-tocopherol and\\nbeta-carotene supplements and lung cancer incidence in thealpha-tocopherol, beta-carotene cancer prevention study: effects ofbase-line characteristics and study compliance.\\nJ Natl Cancer Inst\\n1996; 88:1560–70.\\n75van den Brandt PA , Goldbohm RA, van ‘t Veer P, et al. A prospective\\ncohort study on selenium status and the risk of lung cancer. Cancer Res\\n1993; 53:4860–5.\\n76Clark LC , Combs G, Turnbull B. Effects of selenium supplementation for\\ncancer prevention in patients with carcinoma of the skin. A randomizedcontrolled trial. Nutritional Prevention of Cancer Study Group.\\nJAMA\\n1996; 276:1957–63; erratum appears in JAMA 1997; 277:1520.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 4}, page_content='cancer prevention in patients with carcinoma of the skin. A randomizedcontrolled trial. Nutritional Prevention of Cancer Study Group.\\nJAMA\\n1996; 276:1957–63; erratum appears in JAMA 1997; 277:1520.\\n77Melamed MR , Zaman M, Flehinger B. Radiologically occult in situ and\\nincipient invasive epidermoid lung cancer: detection by sputum cytologyin a survey of asymptomatic cigarette smokers.\\nAm J Surg Pathol\\n1977; 1:5–16.\\n78Topping DC , Griesemer R, Nettesheim P. Quantitative assessment of\\ngeneralized epithelial changes in tracheal mucosa following exposure to7,12-dimethylbenz(a)anthracene.\\nCancer Res 1979; 39:4823–8.\\n79Ono J , Auer G, Caspersson T, et al. Reversibility of\\n20-methylcholanthrene-induced bronchial cell atypia in dogs. Cancer\\n1984; 54:1030–7.998 Goodman\\nwww.thoraxjnl.com'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 5}, page_content='80Greenblatt MS , Bennett WP, Hollstein M, et al. Mutations in the p53\\ntumor suppressor gene: clues to cancer etiology and molecular\\npathogenesis. Cancer Res 1994; 54:4855–78.\\n81Harris CC . p53: at the crossroads of molecular carcinogenesis and risk\\nassessment. Science 1993; 262:1980–1.\\n82Hollstein M , Sidransky D, Vogelstein B, et al. p53 mutations in human\\ncancers. Science 1991; 253:49–53.\\n83Bennett WP . Molecular epidemiology of human cancer risk:\\ngene-environment interactions and p53 mutation spectrum in human lung\\ncancer. J Pathol 1999; 187:8–18.\\n84Tammemagi MC , McLaughlin J, Bull S. Meta-analyses of p53 tumor\\nsuppressor gene alterations and clinicopathological features in resectedlung cancers.\\nCancer Epidemiol Biomarkers Prevent 1999; 8:625–34.\\n85Salgia R , Skarin A. Molecular abnormalities in lung cancer. J Clin Oncol\\n1998; 16:1207–17.\\n86Minna JD . The molecular biology of lung cancer pathogenesis. Chest\\n1993; 103(4 Suppl):449–56S.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 5}, page_content='85Salgia R , Skarin A. Molecular abnormalities in lung cancer. J Clin Oncol\\n1998; 16:1207–17.\\n86Minna JD . The molecular biology of lung cancer pathogenesis. Chest\\n1993; 103(4 Suppl):449–56S.\\n87Chiba I , Takahashi T, Nau M, et al. Mutations in the p53 gene are\\nfrequent in primary, resected non-small cell lung cancer. Lung Cancer\\nStudy Group. Oncogene 1990; 5:1603–10.\\n88D’Amico D , Carbone D, Mitsudomi T, et al. High frequency of\\nsomatically acquired p53 mutations in small-cell lung cancer cell linesand tumors.\\nOncogene 1992; 7:339–46.\\n89Takahashi T , Nau M, Chiba I, et al. p53: a frequent target for genetic\\nabnormalities in lung cancer. Science 1989; 246:491–4.\\n90Kishimoto Y , Murakami Y, Shiraishi M, et al. Aberrations of the p53\\ntumor suppressor gene in human non-small cell carcinomas of the lung.\\nCancer Res 1992; 52:4799–804.\\n91Gazdar AF . The molecular and cellular basis of human lung cancer.\\nAnticancer Res 1994; 14(1B):261–7.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 5}, page_content='Cancer Res 1992; 52:4799–804.\\n91Gazdar AF . The molecular and cellular basis of human lung cancer.\\nAnticancer Res 1994; 14(1B):261–7.\\n92Lonardo F , Rusch V, Langenfield J, et al. Overexpression of cyclins D1\\nand E is frequent in bronchial preneoplasia and precedes squamous cellcarcinoma development.\\nCancer Res 1999; 59:2470–6.\\n93Rusch V , Klimstra D, Linkov I, et al. Aberrant expression of p53 or the\\nepidermal growth factor receptor is frequent in early bronchial neoplasiaand coexpression precedes squamous cell carcinoma development.\\nCancer Res 1995; 55:1365–72.\\n94Mao L , Hruban R, Boyle J, et al. Detection of oncogen mutations in\\nsputum precedes diagnosis of lung cancer. Cancer Res\\n1994; 54:1634–7.\\n95Mao L , Lee J, Kurie J. Clonal genetic alterations in the lungs of current\\nand former smokers. J Natl Cancer Inst 1997; 89:857–62.\\n96Isobe M , Emanuel B, Givol D. Localization of gene for human p53\\ntumour antigen to band 17p13. Nature 1986; 320:84–5.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 5}, page_content='and former smokers. J Natl Cancer Inst 1997; 89:857–62.\\n96Isobe M , Emanuel B, Givol D. Localization of gene for human p53\\ntumour antigen to band 17p13. Nature 1986; 320:84–5.\\n97Ohta M , Inoue M, Cotticelli M. The FHIT gene, spanning the\\nchromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8)\\nbreakpoint, is abnormal in digestive tract cancers. Cell\\n1996; 84:587–97.\\n98Kamb A , Gruis N, Weaver-Feldhaus J. A cell cycle regulator potentially\\ninvolved in genesis of many tumor types. Science 1994; 264:436–40.\\n99Nobori T , Muira K, Wu D. Deletions of the cyclin-dependent kinase-4\\ninhibitor gene in multiple human cancers. Nature 1994; 368:753–6.\\n100 Shapiro GI , Park J, Edwards C, et al. Multiple mechanisms of\\np16INK4A inactivation in non-small cell lung cancer cell lines. Cancer\\nRes1995; 55:6200–9.101 Ahrendt SA . Molecular detection of tumor cells in bronchoalveolar\\nlavage fluid from patients with early stage lung cancer. J Natl Cancer Inst\\n1999; 91:332–9.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 5}, page_content='Res1995; 55:6200–9.101 Ahrendt SA . Molecular detection of tumor cells in bronchoalveolar\\nlavage fluid from patients with early stage lung cancer. J Natl Cancer Inst\\n1999; 91:332–9.\\n102 Belinsky SA . Aberrant methylation of p16(INK4a) is an early event in\\nlung cancer and a potential biomarker for early diagnosis. Proc Natl\\nAcad Sci USA 1998; 95:11891–6.\\n103 Merlo A , Herman J, Mao L, et al.5′CpG island methylation is\\nassociated with transcriptional silencing of the tumour suppressor\\np16/CDKN2/MTS1 in human cancers. Nature Med 1995; 1:686–92.\\n104 Swafford DS , Middleton S, Palmisano W, et al. Frequent aberrant\\nmethylation of p16INK4a in primary rat lung tumors. Mol Cell Biol\\n1997; 17:1366–74.\\n105 Herman JG , Graff J, Myohanen S, et al. Methylation-specific PCR: a\\nnovel PCR assay for methylation status of CpG islands. Proc Natl Acad\\nSci USA 1996; 93:9821–6.\\n106 Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 5}, page_content='novel PCR assay for methylation status of CpG islands. Proc Natl Acad\\nSci USA 1996; 93:9821–6.\\n106 Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer\\nby detecting aberrant promoter methylation in sputum. Cancer Res\\n2000; 60:5954–8.\\n107 Papadimitrakopoulou VA , Izzo J, Mao L, et al. Cyclin D1 and p16\\nalterations in advanced premalignant lesions of the upper aerodigestivetract: role in response to chemoprevention and cancer development.\\nClin\\nCancer Res 2001; 7:3127–34.\\n108 Soslow RA , Dannenberg A, Rush D, et al. COX-2 is expressed in human\\npulmonary, colonic, and mammary tumors. Cancer 2000; 89:2637–45.\\n109 Hosomi Y , Yokose T, Hirose Y, et al. Increased cyclooxygenase 2\\n(COX-2) expression occurs frequently in precursor lesions of humanadenocarcinoma of the lung.\\nLung Cancer 2000; 30:73–81.\\n110 Watkins DN , Lenzo J, Segal A, et al. Expression and localization of\\ncyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J\\n1999; 14:412–8.'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 5}, page_content='Lung Cancer 2000; 30:73–81.\\n110 Watkins DN , Lenzo J, Segal A, et al. Expression and localization of\\ncyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J\\n1999; 14:412–8.\\n111 Wolff H , Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2\\nin human lung carcinoma. Cancer Res 1998; 58:4997–5001.\\n112 Hida T , Yatabe Y, Achiwa H, et al. Increased expression of\\ncyclooxygenase 2 occurs frequently in human lung cancers, specificallyin adenocarcinomas.\\nCancer Res 1998; 58:3761–4.\\n113 Hung WC , Chang H, Pan M, et al. Induction of p27(KIP1) as a\\nmechanism underlying NS398-induced growth inhibition in human lungcancer cells.\\nMol Pharmacol 2000; 58:1398–403.\\n114 Eli Y , Przedecki F, Levin G, et al. Comparative effects of indomethacin on\\ncell proliferation and cell cycle progression in tumor cells grown in vitroand in vivo.\\nBiochem Pharmacol 2001; 61:565–71.\\n115 Brabender J , Danenberg K, Metzger R, et al. Epidermal growth factor'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 5}, page_content='cell proliferation and cell cycle progression in tumor cells grown in vitroand in vivo.\\nBiochem Pharmacol 2001; 61:565–71.\\n115 Brabender J , Danenberg K, Metzger R, et al. Epidermal growth factor\\nreceptor and HER2-neu mRNA expression in non-small cell lung cancer iscorrelated with survival.\\nClin Cancer Res 2001; 7:1850–5.\\n116 Hendler FJ , Ozanne B. Human squamous cell lung cancers express\\nincreased epidermal growth factor receptors. J Clin Invest\\n1984; 74:647–51.\\n117 Cerny T , Barnes D, Hasleton P, et al. Expression of epidermal growth\\nfactor receptor (EGF-R) in human lung tumours. Br J Cancer\\n1986; 54:265–9.\\n118 Veale D , Ashcroft T, Marsh C, et al. Epidermal growth factor receptors\\nin non-small cell lung cancer. Br J Cancer 1987; 55:513–6.\\n119 Ozanne B , Richards C, Hendler F J, et al. Over-expression of the EGF\\nreceptor is a hallmark of squamous cell carcinomas. J Pathol 1986; 149:\\n9–14.\\n120 Berger MS . Epidermal growth factor receptors in lung tumours. J Pathol'),\n",
              " Document(metadata={'source': 'Data/v057p00994.pdf', 'page': 5}, page_content='receptor is a hallmark of squamous cell carcinomas. J Pathol 1986; 149:\\n9–14.\\n120 Berger MS . Epidermal growth factor receptors in lung tumours. J Pathol\\n1987; 152:297–307.Prevention of lung cancer 999\\nwww.thoraxjnl.com'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 0}, page_content='Lung Cancer Prevention and Early \\nDetection \\nLung cancer is the second most common cancer in both men and women (not counting \\nskin cancer), and is by far the leading cause of cancer death among both men and women. \\nEach year, more people die of lung cancer than of colon, breast, and prostate canc ers \\ncombined.  \\nMost lung cancers could be prevented, because they are related to smoking (or \\nsecondhand smoke), or less often to exposure to radon or other environmental factors. \\nBut some lung cancers occur in people without any known risk factors for the disea se. It \\nis not yet clear if these cancers can be prevented. \\nMost lung cancers have already spread widely and are at an advanced stage w hen they \\nare first found. These cancers are very hard to cure. But in recent years, doct ors have \\nfound a test that can be used to screen for lung cancer in people at high risk of the \\ndisease. This test can help find some of these cancers early, which can lower the  risk of'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 0}, page_content='found a test that can be used to screen for lung cancer in people at high risk of the \\ndisease. This test can help find some of these cancers early, which can lower the  risk of \\ndying from this disease.   \\nWhat is lung cancer?  \\nLung cancer is a cancer that starts in the lungs. To understand lung cancer, it he lps to \\nknow about the normal structure and function of the lungs.  \\nThe lungs \\nYour lungs are 2 sponge-like organs found in your chest. Your right lung is divided into 3 \\nsections, called lobes . Your left lung has 2 lobes. The left lung is smaller because the \\nheart takes up more room on that side of the body.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 1}, page_content='When you breathe in, air enters through your mouth or nose and goes into your lungs \\nthrough the trachea  (windpipe). The trachea divides into tubes called the bronchi  \\n(singular, bronchus ), which enter the lungs and divide into smaller bronchi. These divide \\nto form smaller branches called bronchioles . At the end of the bronchioles are tiny air \\nsacs known as alveoli .  \\nMany tiny blood vessels run through the alveoli. They absorb oxygen from the inhaled ai r \\ninto your bloodstream and pass carbon dioxide from the body into the alveoli. This is \\nexpelled from the body when you exhale. Taking in oxygen and getting rid of carbon \\ndioxide are your lungs’ main functions.  \\nA thin lining layer called the pleura  surrounds the lungs. The pleura protects your lungs \\nand helps them slide back and forth against the chest wall as they expand and contract \\nduring breathing. \\nBelow the lungs, a thin, dome-shaped muscle called the diaphragm  separates the chest'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 1}, page_content='and helps them slide back and forth against the chest wall as they expand and contract \\nduring breathing. \\nBelow the lungs, a thin, dome-shaped muscle called the diaphragm  separates the chest \\nfrom the abdomen. When you breathe, the diaphragm moves up and down, forcing air in \\nand out of the lungs.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 2}, page_content='Start and spread of lung cancer \\nLung cancers can start in the cells lining the bronchi and parts of the lung such as t he \\nbronchioles or alveoli.  \\nLung cancers are thought to start as areas of pre-cancerous changes in the lu ng. The first \\nchanges in the genes (DNA) inside the lung cells may cause the cells t o grow faster. \\nThese cells may look a bit abnormal if seen under a microscope, but at this point they do \\nnot form a mass or tumor. They cannot be seen on an x-ray and they do not cause \\nsymptoms.  \\nOver time, the abnormal cells may acquire other gene changes, which cause  them to \\nprogress to true cancer. As a cancer develops, the cancer cells may make che micals that \\ncause new blood vessels to form nearby. These blood vessels nourish the cancer cells , \\nwhich can continue to grow and form a tumor large enough to be seen on imaging tests \\nsuch as x-rays.  \\nAt some point, cells from the cancer may break away from the original tumor and s pread'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 2}, page_content='which can continue to grow and form a tumor large enough to be seen on imaging tests \\nsuch as x-rays.  \\nAt some point, cells from the cancer may break away from the original tumor and s pread \\n(metastasize) to other parts of the body. Lung cancer is often a life-threa tening disease \\nbecause it tends to spread in this way even before it can be detected on an imaging  test \\nsuch as a chest x-ray. \\nTypes of lung cancer \\nThere are 2 main types of lung cancer: \\n• Small cell lung cancer (SCLC) \\n• Non-small cell lung cancer (NSCLC)  \\nSmall cell lung cancer  \\nAbout 10% to 15% of all lung cancers are small cell lung cancer (SCLC), named for the \\nsize of the cancer cells when seen under a microscope. Other names for SCLC are oat \\ncell cancer , oat cell carcinoma , and small cell undifferentiated carcinoma . It is very rare \\nfor someone who has never smoked to have small cell lung cancer. \\nSCLC often starts in the bronchi near the center of the chest, and it tends to spread wi dely'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 2}, page_content='for someone who has never smoked to have small cell lung cancer. \\nSCLC often starts in the bronchi near the center of the chest, and it tends to spread wi dely \\nthrough the body early in the course of the disease. This cancer is discussed in our \\ndocument Lung Cancer (Small Cell).  \\nNon-small cell lung cancer  \\nAbout 85% to 90% of lung cancers are non-small cell lung cancer (NSCLC). There ar e 3 \\nmain subtypes of NSCLC. The cells in these subtypes differ in size, shape, and chem ical'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 3}, page_content='make-up. But they are grouped together because the approach to treatment and prognosis \\n(outlook) are often very similar. \\nSquamous cell (epidermoid) carcinoma:  About 25% to 30% of all lung cancers are \\nsquamous cell carcinomas. These cancers start in early versions of squamous c ells, which \\nare flat cells that line the inside of the airways in the lungs. They are ofte n linked to a \\nhistory of smoking and tend to be found in the middle of the lungs, near a bronchus. \\nAdenocarcinoma:  About 40% of lung cancers are adenocarcinomas. These cancers start \\nin early versions of the cells that would normally secrete substances such as  mucus. This \\ntype of lung cancer occurs mainly in current or former smokers, but it is also the  most \\ncommon type of lung cancer in non-smokers. It is more common in women than in men, \\nand it is more likely to occur in younger people than other types of lung cancer. \\nAdenocarcinoma is usually found in the outer parts of the lung. It tends to grow slower'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 3}, page_content='and it is more likely to occur in younger people than other types of lung cancer. \\nAdenocarcinoma is usually found in the outer parts of the lung. It tends to grow slower \\nthan other types of lung cancer, and is more likely to be found before it has spread \\noutside of the lung.  \\nPeople with a type of adenocarcinoma called adenocarcinoma in situ  (previously called \\nbronchioloalveolar carcinoma ) tend to have a better outlook (prognosis) than those with \\nother types of lung cancer. \\nLarge cell (undifferentiated) carcinoma:  This type of cancer accounts for about 10% to \\n15% of lung cancers. It can appear in any part of the lung. It tends to grow and spre ad \\nquickly, which can make it harder to treat. A subtype of large cell carcinoma, know n as \\nlarge cell neuroendocrine carcinoma , is a fast-growing cancer that is very similar to \\nsmall cell lung cancer. \\nOther subtypes:  There are also a few other subtypes of non-small cell lung cancer, such'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 3}, page_content='small cell lung cancer. \\nOther subtypes:  There are also a few other subtypes of non-small cell lung cancer, such \\nas adenosquamous carcinoma and sarcomatoid carcinoma. These are much less common.  \\nFor more information about non-small cell lung cancer, see our document Lung Cancer \\n(Non-Small Cell) . \\nOther types of lung cancer \\nAlong with the 2 main types of lung cancer, other tumors can occur in the lungs.  \\nLung carcinoid tumors:  Carcinoid tumors of the lung account for fewer than 5% of lung \\ntumors. Most are slow-growing tumors that are called typical carcinoid tumors . They are \\ngenerally cured by surgery. Some typical carcinoid tumors can spread, but they  usually \\nhave a better prognosis than small cell or non-small cell lung cancer. Less c ommon are \\natypical carcinoid tumors . The outlook for these tumors is somewhere in between typical \\ncarcinoids and small cell lung cancer. For more information about typical and atypic al'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 3}, page_content='atypical carcinoid tumors . The outlook for these tumors is somewhere in between typical \\ncarcinoids and small cell lung cancer. For more information about typical and atypic al \\ncarcinoid tumors, see our document Lung Carcinoid Tumor .'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 4}, page_content='Other lung tumors:  Other types of lung cancer such as adenoid cystic carcinomas, \\nlymphomas, and sarcomas, as well as benign lung tumors such as hamartomas are ra re. \\nThese have different risk factors  from the more common lung cancers. They are not \\ndiscussed in this document. \\nCancers that spread to the lungs:  Cancers that start in other organs (such as the breast, \\npancreas, kidney, or skin) can sometimes spread (metastasize) to the lungs, but the se are \\nnot lung cancers. For example, cancer that starts in the breast and spreads to t he lungs is \\nstill breast cancer, not lung cancer. Treatment for cancer that has spread to t he lungs is \\nbased on which type of cancer it is.  \\nWhat are the risk factors for lung cancer?  \\nA risk factor is anything that affects a person’s chance of getting a di sease such as cancer. \\nDifferent cancers have different risk factors. Some risk factors, like sm oking, can be \\nchanged. Others, like a person’s age or family history, can’t be changed.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 4}, page_content='Different cancers have different risk factors. Some risk factors, like sm oking, can be \\nchanged. Others, like a person’s age or family history, can’t be changed. \\nBut risk factors don’t tell us everything. Having a risk factor, or even several  risk factors, \\ndoes not mean that you will get the disease. And some people who get the disease ma y \\nnot have had any known risk factors. Even if a person with lung cancer has a risk fact or, \\nit is often very hard to know how much that risk factor may have contributed to the \\ncancer. \\nSeveral risk factors can make you more likely to develop lung cancer. \\nTobacco smoke \\nSmoking is by far the leading risk factor for lung cancer. In the early 20th ce ntury, lung \\ncancer was much less common than some other types of cancer. But this changed once \\nmanufactured cigarettes became readily available and more people bega n smoking. \\nAt least 80% of lung cancer deaths are thought to result from smoking. The risk for l ung'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 4}, page_content='manufactured cigarettes became readily available and more people bega n smoking. \\nAt least 80% of lung cancer deaths are thought to result from smoking. The risk for l ung \\ncancer among smokers is many times higher than among non-smokers. The longer y ou \\nsmoke and the more packs a day you smoke, the greater your risk. \\nCigar smoking and pipe smoking are almost as likely to cause lung cancer as ciga rette \\nsmoking. Smoking low-tar or “light” cigarettes increases lung cancer r isk as much as \\nregular cigarettes. There is concern that menthol cigarettes may incr ease the risk even \\nmore since the menthol allows smokers to inhale more deeply. \\nSecondhand smoke:  If you don’t smoke, breathing in the smoke of others (called \\nsecondhand smoke or environmental tobacco smoke) can increase your risk of \\ndeveloping lung cancer by about 30%. Secondhand smoke is thought to cause more than \\n7,000 deaths from lung cancer each year.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 5}, page_content='Some evidence suggests that certain people are more susceptible to the cancer -causing \\neffect of tobacco smoke than others. \\nIf you or someone you care about needs help in quitting, see our document Guide to \\nQuitting Smoking  or call the American Cancer Society at 1-800-227-2345. \\nRadon \\nRadon is a naturally occurring radioactive gas that results from the breakdo wn of \\nuranium in soil and rocks. It cannot be seen, tasted, or smelled. According to the US \\nEnvironmental Protection Agency (EPA), radon is the second leading cause of lung \\ncancer in this country, and is the leading cause among non-smokers. \\nOutdoors, there is so little radon that it is not likely to be dangerous. But indoors, radon \\ncan be more concentrated. When it is breathed in, it enters the lungs, exposing them to \\nsmall amounts of radiation. This may increase a person’s risk of lung cancer.  \\nThe lung cancer risk from radon is much lower than that from tobacco smoke. However,'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 5}, page_content='small amounts of radiation. This may increase a person’s risk of lung cancer.  \\nThe lung cancer risk from radon is much lower than that from tobacco smoke. However, \\nthe risk from radon is much higher in people who smoke than in those who don’t.  \\nRadon levels in the soil vary across the country, but they can be high almost anywhere . \\nHomes in some parts of the United States built on soil with natural uranium deposits can \\nhave high indoor radon levels (especially in basements). Studies from these areas hav e \\nfound that the risk of lung cancer is higher in those who have lived for many years in a \\nradon-contaminated house.  \\nIf you are concerned about radon exposure, you can use a radon detection kit to test the \\nlevels in your home. State and local offices of the EPA can also give you the nam es of \\nreliable companies that can test your home (or other buildings) for radon and help y ou fix \\nthe problem, if needed. For more information, see our document  called  Radon.   \\nAsbestos'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 5}, page_content='reliable companies that can test your home (or other buildings) for radon and help y ou fix \\nthe problem, if needed. For more information, see our document  called  Radon.   \\nAsbestos \\nWorkplace exposure to asbestos fibers is an important risk factor for lung cancer . Studies \\nhave found that people who work with asbestos (in some mines, mills, textile plants, \\nplaces where insulation is used, shipyards, etc.) are several times more like ly to die of \\nlung cancer. In workers exposed to asbestos who also smoke, the lung cancer risk is \\nmuch greater than even adding the risks from these exposures separately. It’s not  clear to \\nwhat extent low-level or short-term exposure to asbestos might raise lung ca ncer risk. \\nBoth smokers and non-smokers exposed to asbestos also have a greater risk of \\ndeveloping mesothelioma, a type of cancer that starts in the pleura (the lining sur rounding \\nthe lungs). Because it is not usually considered a type of lung cancer, mesothe lioma is'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 5}, page_content='developing mesothelioma, a type of cancer that starts in the pleura (the lining sur rounding \\nthe lungs). Because it is not usually considered a type of lung cancer, mesothe lioma is \\ndiscussed in our document called Malignant Mesothelioma .'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 6}, page_content='In recent years, government regulations have greatly reduced the use of asbe stos in \\ncommercial and industrial products. It is still present in many homes and other older  \\nbuildings, but it is not usually considered harmful as long as it is not released into the a ir \\nby deterioration, demolition, or renovation. For more information, see our document \\ncalled Asbestos . \\nOther cancer-causing agents in the workplace \\nOther carcinogens (cancer-causing agents) found in some workplaces that can i ncrease \\nlung cancer risk include:  \\n• Radioactive ores such as uranium  \\n• Inhaled chemicals or minerals such as arsenic, beryllium, cadmium, silic a, vinyl \\nchloride, nickel compounds, chromium compounds, coal products, mustard gas, and \\nchloromethyl ethers  \\n• Diesel exhaust  \\nThe government and industry have taken steps in recent years to help protect worke rs \\nfrom many of these exposures. But the dangers are still present, so if you w ork around'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 6}, page_content='• Diesel exhaust  \\nThe government and industry have taken steps in recent years to help protect worke rs \\nfrom many of these exposures. But the dangers are still present, so if you w ork around \\nthese agents, you should be careful to limit your exposure whenever possible. \\nAir pollution \\nIn cities, air pollution (especially near heavily trafficked roads) appear s to raise the risk \\nof lung cancer slightly. This risk is far less than the risk caused by smoking, but some  \\nresearchers estimate that worldwide about 5% of all deaths from lung cancer  may be due \\nto outdoor air pollution. \\nRadiation therapy to the lungs \\nPeople who have had radiation therapy to the chest for other cancers are at higher risk for \\nlung cancer, particularly if they smoke. Typical patients are those treated f or Hodgkin \\ndisease or women who get radiation after a mastectomy for breast cancer. W omen who \\nreceive radiation therapy to the breast after a lumpectomy do not appear to have  a higher'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 6}, page_content='disease or women who get radiation after a mastectomy for breast cancer. W omen who \\nreceive radiation therapy to the breast after a lumpectomy do not appear to have  a higher \\nthan expected risk of lung cancer.  \\nArsenic in drinking water \\nStudies of people in parts of Southeast Asia and South America with high levels of \\narsenic in their drinking water have found a higher risk of lung cancer. In mos t of these \\nstudies, the levels of arsenic in the water were many times higher than those t ypically \\nseen in the United States, even in areas where arsenic levels are above norma l. For most'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 7}, page_content='Americans who are on public water systems, drinking water is not a major sourc e of \\narsenic. \\nPersonal or family history of lung cancer \\nIf you have had lung cancer, you have a higher risk of developing another lung cancer.  \\nBrothers, sisters, and children of those who have had lung cancer may have a slightl y \\nhigher risk of lung cancer themselves, especially if the relative was di agnosed at a \\nyounger age. It is not clear how much of this risk might be due to inherited genes a nd \\nhow much might be from shared household exposures (such as tobacco smoke or radon). \\nResearchers have found that genetics does seem to play a role in some families  with a \\nstrong history of lung cancer. For example, people who inherit certain DNA changes  in a \\nparticular chromosome (chromosome 6) are more likely to develop lung cancer, even if  \\nthey don’t smoke or only smoke a little. At this time these DNA changes cannot be \\nroutinely tested for. Research is ongoing in this area.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 7}, page_content='they don’t smoke or only smoke a little. At this time these DNA changes cannot be \\nroutinely tested for. Research is ongoing in this area. \\nCertain dietary supplements \\nStudies looking at the possible role of vitamin supplements in reducing lung cancer ris k \\nhave not been promising so far. In fact, 2 large studies found that smokers who took beta \\ncarotene supplements actually had an increased risk of lung cancer. The resul ts of these \\nstudies suggest that smokers should avoid taking beta carotene supplements. \\nFactors with uncertain or unproven effects on lung cancer \\nrisk \\nMarijuana smoking \\nThere are some reasons to think that marijuana smoking might increase lung canc er risk. \\nMarijuana smoke contains tar and many of the same cancer-causing substances tha t are in \\ntobacco smoke. (Tar is the sticky, solid material that remains after burning , and is thought \\nto contain most of the harmful substances in smoke.) Marijuana cigarettes (joints ) are'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 7}, page_content='tobacco smoke. (Tar is the sticky, solid material that remains after burning , and is thought \\nto contain most of the harmful substances in smoke.) Marijuana cigarettes (joints ) are \\ntypically smoked all the way to the end, where tar content is the highest. Marijua na is \\nalso inhaled very deeply and the smoke is held in the lungs for a long time, which give s \\nany cancer causing substances more opportunity to deposit in the lungs. And because \\nmarijuana is often an illegal substance, it may not be possible to control what other  \\nsubstances it might contain.  \\nBut those who use marijuana tend to smoke less marijuana in a day or week than the \\namount of tobacco consumed by cigarette smokers. For example, a light smoker may  \\nsmoke half of a pack (10 cigarettes) a day, but 10 marijuana cigarettes in a day  would be \\nvery heavy use of marijuana. In one study, most people who smoked marijuana did so 2'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 8}, page_content='to 3 times per month. The lesser amount smoked would make it harder to see an impact \\non lung cancer risk.  \\nIt has been hard to study whether there is a link between marijuana and lung cance r \\nbecause marijuana was illegal in many countries for so long, and it is not easy to gather \\ninformation about the use of illegal drugs. Also, in the studies that looked at past \\nmarijuana use in people who had lung cancer, most of the marijuana smokers also \\nsmoked cigarettes. This can make it hard to know how much of the risk is from tobacco \\nand how much might be from marijuana. More research is needed to know the cancer \\nrisks from smoking marijuana. \\nTalc and talcum powder  \\nTalc is a mineral that in its natural form may contain asbestos. Some studies have  \\nsuggested that talc miners and millers might have a higher risk of lung cance r and other \\nrespiratory diseases because of their exposure to industrial grade talc. But other studies \\nhave not found an increase in lung cancer rate.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 8}, page_content='respiratory diseases because of their exposure to industrial grade talc. But other studies \\nhave not found an increase in lung cancer rate.  \\nTalcum powder is made from talc. By law since 1973, all home-use talcum products \\n(baby, body, and facial powders) in the United States have been asbestos-free. The use  of \\ncosmetic talcum powder has not been found to increase the risk of lung cancer. \\nDo we know what causes lung cancer?  \\nWe don’t know what causes each case of lung cancer. But we do know many of the risk \\nfactors for these cancers and how some of them cause cells to become cancerous . \\nSmoking \\nTobacco smoking is by far the leading cause of lung cancer. At least 80% of lung  cancer \\ndeaths are caused by smoking, and many others are caused by exposure to secondhand \\nsmoke.  \\nSmoking is clearly the strongest risk factor for lung cancer, but it often inter acts with \\nother factors. Smokers exposed to other known risk factors such as radon and asbestos'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 8}, page_content='smoke.  \\nSmoking is clearly the strongest risk factor for lung cancer, but it often inter acts with \\nother factors. Smokers exposed to other known risk factors such as radon and asbestos \\nare at even higher risk. Not everyone who smokes gets lung cancer, so other factors l ike \\ngenetics likely play a role as well (see below).   \\nLung cancer in non-smokers \\nNot all people who get lung cancer are smokers. Many people with lung cancer a re \\nformer smokers, but many others never smoked at all.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 9}, page_content='Lung cancer in non-smokers can be caused by exposure to radon, secondhand smoke, air \\npollution, or other factors. Workplace exposures to asbestos, diesel exhaust, or certain \\nother chemicals can also cause lung cancers in some people who do not smoke.  \\nA small portion of lung cancers occur in people with no known risk factors for the \\ndisease. Some of these might just be random events that don’t have an outside cause, but \\nothers might be due to factors that we don’t yet know about.  \\nLung cancers in non-smokers are often different in some ways from those that occur i n \\nsmokers. They tend to occur at younger ages. Lung cancers in non-smokers often have \\ncertain gene changes that are different from those in tumors from smokers .  \\nGene changes that may lead to lung cancer \\nScientists now know how some of the risk factors for lung cancer can cause certa in \\nchanges in the DNA of lung cells. These changes can lead to abnormal cell gro wth and,'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 9}, page_content='Scientists now know how some of the risk factors for lung cancer can cause certa in \\nchanges in the DNA of lung cells. These changes can lead to abnormal cell gro wth and, \\nsometimes, cancer. DNA is the chemical in each of our cells that makes up our genes  – \\nthe instructions for how our cells function. We usually look like our parents because they \\nare the source of our DNA. But DNA affects more than how we look. It also can \\ninfluence our risk for developing certain diseases, including some kinds of cancer.  \\nSome genes contain instructions for controlling when cells grow, divide to make new  \\ncells, and die. Genes that help cells grow and divide are called oncogenes . Genes that \\nslow down cell division or cause cells to die at the right time are called tumor suppressor \\ngenes . Cancers can be caused by DNA changes that turn on oncogenes or turn off tumor \\nsuppressor genes.  \\nInherited gene changes'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 9}, page_content='genes . Cancers can be caused by DNA changes that turn on oncogenes or turn off tumor \\nsuppressor genes.  \\nInherited gene changes \\nSome people inherit DNA mutations (changes) from their parents that greatl y increase \\ntheir risk for developing certain cancers. But inherited mutations alone are not  thought to \\ncause very many lung cancers.  \\nStill, genes do seem to play a role in some families with a history of lung cance r. For \\nexample, some people seem to inherit a reduced ability to break down or get rid of cert ain \\ntypes of cancer-causing chemicals in the body, such as those found in tobacco smoke. \\nThis could put them at higher risk for lung cancer. \\nOther people may inherit faulty DNA repair mechanisms that make it more li kely they \\nwill end up with DNA changes. Every time a cell divides into 2 new cells, it must ma ke a \\nnew copy of its DNA. This process is not perfect, and copying errors sometime s occur.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 9}, page_content='will end up with DNA changes. Every time a cell divides into 2 new cells, it must ma ke a \\nnew copy of its DNA. This process is not perfect, and copying errors sometime s occur. \\nCells normally have repair enzymes that proofread the DNA to help prevent this. P eople \\nwith repair enzymes that don’t work as well might be especially vulnerable to c ancer-\\ncausing chemicals and radiation.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 10}, page_content='Researchers are developing tests that may help identify such people, but these t ests are \\nnot yet used routinely. For now, doctors recommend that all people avoid tobacco smoke \\nand other exposures that might increase their cancer risk. \\nAcquired gene changes \\nGene changes related to lung cancer are usually acquired during life rather t han inherited. \\nAcquired mutations in lung cells often result from exposure to factors in the environment , \\nsuch as cancer-causing chemicals in tobacco smoke. But some gene changes m ay just be \\nrandom events that sometimes happen inside a cell, without having an outside cause. \\nAcquired changes in certain genes are thought to be important in the development of lung \\ncancer. Changes in some genes may also make some lung cancers more likely  to grow \\nand spread than others. Not all lung cancers share the same gene changes, so ther e are \\nundoubtedly changes in other genes that have not yet been found. \\nCan lung cancer be prevented?'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 10}, page_content='and spread than others. Not all lung cancers share the same gene changes, so ther e are \\nundoubtedly changes in other genes that have not yet been found. \\nCan lung cancer be prevented? \\nNot all lung cancers can be prevented, but there are some ways you can reduce your r isk \\nof getting lung cancer. \\nThe best way to reduce your risk of lung cancer is not to smoke and to avoid breathing in \\nother people’s smoke.  \\nIf you stop smoking before a cancer develops, your damaged lung tissue gradually  starts \\nto repair itself. No matter what your age or how long you’ve smoked, quitting may low er \\nyour risk of lung cancer and help you live longer. People who stop smoking before age \\n50 cut their risk of dying in the next 15 years in half compared with those who continue \\nto smoke. If you would like help quitting smoking, see our document Guide to Quitting \\nSmoking  or call the American Cancer Society at 1-800-227-2345.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 10}, page_content='to smoke. If you would like help quitting smoking, see our document Guide to Quitting \\nSmoking  or call the American Cancer Society at 1-800-227-2345. \\nLimiting your exposure to secondhand smoke might also help lower your risk of lung \\ncancer, as well as some other cancers. For more information, see our document \\nSecondhand Smoke .  \\nRadon is an important cause of lung cancer. You can reduce your exposure to radon by \\nhaving your home tested and treated, if needed. For more information, see our document \\nRadon . \\nAvoiding exposure to known cancer-causing chemicals, in the workplace and elsewher e, \\nmay also be helpful (see “What are the risk factors for lung cancer?”). When people work \\nwhere these exposures are common, they should be kept to a minimum. Be sure to follow \\nproper safety procedures, such as wearing a respirator, if this applies at you r workplace. \\nA healthy diet with lots of fruits and vegetables may also help reduce your ris k of lung'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 10}, page_content='proper safety procedures, such as wearing a respirator, if this applies at you r workplace. \\nA healthy diet with lots of fruits and vegetables may also help reduce your ris k of lung \\ncancer. Some evidence suggests that a diet high in fruits and vegetables may help pr otect'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 11}, page_content='against lung cancer in both smokers and non-smokers. But any positive effect of fruits  \\nand vegetables on lung cancer risk would be much less than the increased risk from \\nsmoking.  \\nAttempts to reduce the risk of lung cancer in current or former smokers by giving them \\nhigh doses of vitamins or vitamin-like drugs have not been successful so far. In fact, \\nsome studies have found that beta-carotene, a nutrient related to vitamin A, appears  to \\nincrease the rate of lung cancer in these people. \\nSome people who get lung cancer do not have any clear risk factors. Although we know \\nhow to prevent most lung cancers, at this time we don’t know how to prevent all of them. \\nCan lung cancer be found early? \\nUsually symptoms of lung cancer do not appear until the disease is already in an \\nadvanced, non-curable stage. Even when symptoms of lung cancer do appear, many \\npeople may mistake them for other problems, such as an infection or long-term effect s'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 11}, page_content='advanced, non-curable stage. Even when symptoms of lung cancer do appear, many \\npeople may mistake them for other problems, such as an infection or long-term effect s \\nfrom smoking. This may delay the diagnosis. \\nSome lung cancers are diagnosed early because they are found by accident a s a result of \\ntests for other medical conditions. For example, lung cancer may be found by imagi ng \\ntests (such as a chest x-ray or chest CT scan), bronchoscopy (viewing the  inside of lung \\nairways through a flexible lighted tube), or sputum exam (microscopic exami nation of \\ncells in coughed up phlegm) done for other reasons in patients with heart disease, \\npneumonia, or other lung conditions. A small portion of these patients do very well and \\nmay be cured of lung cancer. \\nScreening is the use of tests or exams to detect a disease in people without sym ptoms of \\nthat disease. Doctors have looked for many years for a test to find lung cance r early and'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 11}, page_content='Screening is the use of tests or exams to detect a disease in people without sym ptoms of \\nthat disease. Doctors have looked for many years for a test to find lung cance r early and \\nhelp people live longer, but only in recent years has a study shown that a lung cancer \\nscreening test can help lower the risk of dying from this disease. \\nThe National Lung Screening Trial \\nThe National Lung Screening Trial (NLST) was a large clinical tria l that looked at using \\na type of CT scan known as low-dose CT (sometimes called low-dose spiral or heli cal \\nCT) to screen for lung cancer. CT scans of the chest provide more detailed pictur es than \\nchest x-rays and are better at finding small abnormalities in the lungs. (Bot h of these tests \\nare discussed in more detail in the section “Exams and tests to look for lung cancer.”) \\nLow-dose CT (LDCT) of the chest uses lower amounts of radiation than a standard che st \\nCT and does not require the use of intravenous (IV) contrast dye.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 11}, page_content='Low-dose CT (LDCT) of the chest uses lower amounts of radiation than a standard che st \\nCT and does not require the use of intravenous (IV) contrast dye.  \\nThe NLST compared LDCT of the chest to chest x-rays in people at high risk of lung \\ncancer to see if these scans could help lower the risk of dying from lung cancer. T he \\nstudy included more than 50,000 people aged 55 to 74 who were current or former'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 12}, page_content='smokers and were in fairly good health. To be in the study, they had to have at least a 30 \\npack-year history of smoking. A pack-year is the number of cigarette packs smoke d each \\nday multiplied by the number of years a person has smoked. Someone who smoked a \\npack of cigarettes per day for 30 years has a 30 pack-year smoking history, as doe s \\nsomeone who smoked 2 packs a day for 10 years and then a pack a day for another 10 \\nyears. Former smokers could enter the study if they had quit within the past 15 yea rs. The \\nstudy did not include people if they had a prior history of lung cancer or lung cancer \\nsymptoms, if they had part of a lung removed, if they needed to be on oxygen at home to \\nhelp them breathe, or if they had other serious medical problems. \\nPeople in the study got either 3 LDCT scans or 3 chest x-rays, each a year a part, to look \\nfor abnormal areas in the lungs that might be cancer. After several years , the study found'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 12}, page_content='People in the study got either 3 LDCT scans or 3 chest x-rays, each a year a part, to look \\nfor abnormal areas in the lungs that might be cancer. After several years , the study found \\nthat people who got LDCT had a 16% lower chance of dying from lung cancer than those \\nwho got chest x-rays. They were also 7% less likely to die overall (from a ny cause) than \\nthose who got chest x-rays.  \\nScreening with LDCT was also shown to have some downsides that need to be \\nconsidered. One drawback of this test is that it also finds a lot of abnormalities tha t have \\nto be checked out with more tests, but turn out not to be cancer. (About 1 out of 4 CT \\nscans in the NLST showed such a finding.) This may lead to additional tests such as other  \\nCT scans or more invasive tests such as needle biopsies or even surgery to remove a \\nportion of lung in some people. These tests can sometimes lead to complications (like  a'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 12}, page_content='CT scans or more invasive tests such as needle biopsies or even surgery to remove a \\nportion of lung in some people. These tests can sometimes lead to complications (like  a \\ncollapsed lung) or rarely, death, even in people who do not have cancer (or who have \\nvery early stage cancer).  \\nLDCTs also expose people to a small amount of radiation with each test. It is les s than \\nthe dose from a standard CT, but it is more than the dose from a chest x-ray. Some peopl e \\nwho are screened may end up needing further CT scans, which means more radiation \\nexposure. When done in tens of thousands of people, this radiation may cause a few \\npeople to develop breast, lung, or thyroid cancers later on.  \\nThe NLST was a large study, but it left some questions that still need to be answe red. For \\nexample, it’s not clear if screening with LDCT scans would have the same ef fect on \\npeople different from those allowed in the study, such as those who smoke less (or not at'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 12}, page_content='example, it’s not clear if screening with LDCT scans would have the same ef fect on \\npeople different from those allowed in the study, such as those who smoke less (or not at \\nall), or people younger than age 55 or older than 74. Also, in the NLST, patients got a \\ntotal of 3 scans over 2 years. It’s not yet clear what the effect would be if pe ople were \\nscreened for longer than 2 years.  \\nThese factors, and others, need to be taken into account by people and their doctors who \\nare considering whether or not screening with LDCT scans is right for t hem.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 13}, page_content='American Cancer Society guidelines for lung \\ncancer screening \\nThe American Cancer Society has thoroughly reviewed the subject of lung canc er \\nscreening and issued guidelines that are aimed at doctors and other health c are providers: \\nPatients should be asked about their smoking history. Patients who meet ALL of the \\nfollowing criteria may be candidates for lung cancer screening: \\n• 55 to 74 years old  \\n• In fairly good health (discussed further down)  \\n• Have at least a 30 pack-year smoking history (this was discussed above)  \\n• Are either still smoking or have quit smoking within the last 15 years \\nThese criteria were based on what was used in the NLST. \\nDoctors should talk to these patients about the benefits, limitations, and potential har ms \\nof lung cancer screening. Screening should only be done at facilities that have the  right \\ntype of CT scan and that have a great deal of experience in LDCT scans for lung ca ncer'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 13}, page_content='of lung cancer screening. Screening should only be done at facilities that have the  right \\ntype of CT scan and that have a great deal of experience in LDCT scans for lung ca ncer \\nscreening. The facility should also have a team of specialists that can provi de the \\nappropriate care and follow-up of patients with abnormal results on the scans. \\nFor patients \\nIf you fit all of the criteria for lung cancer screening listed above, you and y our doctor (or \\nother health care provider) should talk about starting screening. He or she will ta lk to you \\nabout what you can expect from screening, including possible benefits and harms, as  well \\nas the limitations of screening. \\nThe main benefit is a lower chance of dying of lung cancer, which accounts for ma ny \\ndeaths in current and former smokers. Still, it is important to be aware that, like wi th any \\ntype of screening, not everyone who gets screened will benefit. Screening wit h LDCT'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 13}, page_content='deaths in current and former smokers. Still, it is important to be aware that, like wi th any \\ntype of screening, not everyone who gets screened will benefit. Screening wit h LDCT \\nwill not find all lung cancers, and not all of the cancers that are found will be found ear ly. \\nEven if a cancer is found by screening, you may still die from lung cancer. Also, LDCT \\noften finds things that turn out not to be cancer, but have to be checked out with more \\ntests to know what they are. This can mean more CT scans, or even invasive tests suc h as \\na lung biopsy, in which a piece of lung tissue is removed with a needle or in surgery. \\nThese tests have risks of their own (see above).  \\nScreening should only be done at facilities that have the right type of CT scanner a nd that \\nhave a great deal of experience in LDCT scans for lung cancer screening. The f acility \\nshould also have a team of specialists that can provide the appropriate care and follow -up'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 14}, page_content='of patients with abnormal results on the scans. You might not have the right kind of \\nfacility nearby, so you may need to travel some distance to be screened. \\nIf you and your doctor decide that you should be screened, you should get a LDCT every \\nyear until you reach the age of 74, as long as you remain in good health. \\nIf you are a current smoker, you should receive counseling about stopping. You should be \\ntold about your risk of lung cancer and referred to a smoking cessation program. \\nScreening is not a good alternative to stopping smoking. For help quitting smoking, see \\nour document Guide to Quitting Smoking  or call the American Cancer Society at 1-800-\\n227-2345. \\nWhat does “in fairly good health” mean? \\nScreening is meant to find cancer in people who do not have symptoms of the disease. \\nPeople who already have symptoms that might be caused by lung cancer may need te sts \\nsuch as CT scans to find the underlying cause, which in some cases may be cancer . Still,'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 14}, page_content='People who already have symptoms that might be caused by lung cancer may need te sts \\nsuch as CT scans to find the underlying cause, which in some cases may be cancer . Still, \\nthis kind of testing is for diagnosis and is not the same as screening. Some of the poss ible \\nsymptoms of lung cancer that kept people out of the NLST were coughing up blood and \\nweight loss without trying. \\nTo get the most potential benefit from screening, patients need to be in good health. F or \\nexample, they need to be able to have surgery and other treatments to try to cure lung  \\ncancer if it is found. Patients who require home oxygen therapy most likely could not  \\nwithstand having part of a lung removed, and so are not candidates for screening. Patients  \\nwith other serious medical problems that would shorten their lives or keep them from \\nhaving surgery may also not be able to benefit enough from screening for it to be worth \\nthe risks, and so should also not be screened.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 14}, page_content='having surgery may also not be able to benefit enough from screening for it to be worth \\nthe risks, and so should also not be screened. \\nMetal implants in the chest (like pacemakers) or back (like rods in the spine)  can interfere \\nwith x-rays and lead to poor quality CT images of the lungs. People with these types  of \\nimplants were also kept out of the NLST, and so should not be screened with CT scans \\nfor lung cancer according to the ACS guidelines.  \\nPeople who have been treated for lung cancer often have follow-up tests, including C T \\nscans to see if the cancer has come back or spread. This is called surveillanc e and is not \\nthe same as screening. (People with a prior history of lung cancer were not elig ible for \\nthe NLST.) \\nCosts of screening and insurance coverage \\nThe cost for a low-dose CT scan as a screening test for lung cancer is gener ally about \\n$300 for each test, but prices vary widely at different centers.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 15}, page_content='At this time, some private insurers are covering the cost of lung cancer sc reening, but \\nmany others are not. Medicare recently decided to cover the cost of lung cancer  \\nscreening, and more insurers may cover the tests in the future.  \\nBecause insurance coverage (and laws related to it) is changing, it is importa nt to check \\nwith your health insurance provider, as well as the center performing the te st, so that you \\nhave an idea about what you might have to pay. Even if your insurance doesn’t cover \\nlung cancer screening, it is likely to cover further tests needed because som ething \\nabnormal is found during screening. Still, it is best to check to see what you can expe ct in \\nterms of costs such as co-pays and deductibles. \\nIf something abnormal is found during screening \\nAbout 1 out of 4 screening tests will show something abnormal in the lungs or nearby \\nareas that might be cancer. Most of these abnormal findings will turn out not to be canc er,'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 15}, page_content='About 1 out of 4 screening tests will show something abnormal in the lungs or nearby \\nareas that might be cancer. Most of these abnormal findings will turn out not to be canc er, \\nbut additional CT scans or other tests will be needed to be sure. Some of these tests a re \\ndescribed in the section “Exams and tests to look for lung cancer.” \\nCT scans of the lungs can also sometimes show problems in other organs that just happen \\nto be in the field of view of the scans. Your doctor will discuss any such findings with \\nyou if they are found.  \\nSigns and symptoms of lung cancer \\nMost lung cancers do not cause any symptoms until they have spread too far to be cured, \\nbut symptoms do occur in some people with early lung cancer. If you go to your doctor \\nwhen you first notice symptoms, your cancer might be diagnosed at an earlier st age, \\nwhen treatment is more likely to be effective. The most common symptoms of lung \\ncancer are: \\n• A cough that does not go away or gets worse'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 15}, page_content='when treatment is more likely to be effective. The most common symptoms of lung \\ncancer are: \\n• A cough that does not go away or gets worse \\n• Chest pain that is often worse with deep breathing, coughing, or laughing \\n• Hoarseness \\n• Weight loss and loss of appetite  \\n• Coughing up blood or rust-colored sputum (spit or phlegm) \\n• Shortness of breath \\n• Feeling tired or weak \\n• Infections such as bronchitis and pneumonia that don’t go away or keep coming back'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 16}, page_content='• New onset of wheezing \\nIf lung cancer spreads to distant organs, it may cause: \\n• Bone pain (like pain in the back or hips) \\n• Nervous system changes (such as headache, weakness or numbness of an arm or leg, \\ndizziness, balance problems, or seizures), from cancer spread to the brain or spinal \\ncord \\n• Yellowing of the skin and eyes (jaundice), from cancer spread to the liver \\n• Lumps near the surface of the body, due to cancer spreading to the skin or to lymph \\nnodes (collections of immune system cells), such as those in the neck or above the \\ncollarbone  \\nMost of the symptoms listed above are more likely to be caused by conditions other than \\nlung cancer. Still, if you have any of these problems, it’s important to see your do ctor \\nright away so the cause can be found and treated, if needed.  \\nSome lung cancers can cause a group of very specific symptoms. These are  often \\ndescribed as syndromes.  \\nHorner syndrome'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 16}, page_content='right away so the cause can be found and treated, if needed.  \\nSome lung cancers can cause a group of very specific symptoms. These are  often \\ndescribed as syndromes.  \\nHorner syndrome \\nCancers of the top part of the lungs (sometimes called Pancoast tumors ) may damage a \\nnerve that passes from the upper chest into your neck. This can cause severe shoulder  \\npain. Sometimes these tumors can affect certain nerves to the eye and part of the  face, \\ncausing a group of symptoms called Horner syndrome :  \\n• Drooping or weakness of one eyelid \\n• Having a smaller pupil (dark part in the center of the eye) in the same eye \\n• Reduced or absent sweating on the same side of the face  \\nConditions other than lung cancer can also cause Horner syndrome. \\nSuperior vena cava syndrome \\nThe superior vena cava (SVC) is a large vein that carries blood from the head and arms  \\nback to the heart. It passes next to the upper part of the right lung and the lymph nodes'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 16}, page_content='The superior vena cava (SVC) is a large vein that carries blood from the head and arms  \\nback to the heart. It passes next to the upper part of the right lung and the lymph nodes \\ninside the chest. Tumors in this area may push on the SVC, which can cause the blood to \\nback up in the veins. This can cause swelling in the face, neck, arms, and upper chest \\n(sometimes with a bluish-red skin color). It can also cause headaches, dizziness , and a \\nchange in consciousness if it affects the brain. While SVC syndrome can develop'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 17}, page_content='gradually over time, in some cases it can become life-threatening, and needs to be  treated \\nright away. \\nParaneoplastic syndromes \\nSome lung cancers can make hormone-like substances that enter the bloodstream and \\ncause problems with distant tissues and organs, even though the cancer has not sprea d to \\nthose tissues or organs. These problems are called paraneoplastic syndromes . Sometimes \\nthese syndromes may be the first symptoms of lung cancer. Because the sympt oms affect \\norgans besides the lungs, patients and their doctors may suspect at first that a dis ease \\nother than lung cancer is causing them. \\nSome of the more common paraneoplastic syndromes associated with small cell l ung \\ncancer (SCLC) are: \\n• SIADH (syndrome of inappropriate anti-diuretic hormone):  In this condition, the \\ncancer cells make a hormone (ADH) that causes the kidneys to retain water. This  \\ncauses salt levels in the blood to become very low. Symptoms of SIADH can include'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 17}, page_content='cancer cells make a hormone (ADH) that causes the kidneys to retain water. This  \\ncauses salt levels in the blood to become very low. Symptoms of SIADH can include \\nfatigue, loss of appetite, muscle weakness or cramps, nausea, vomiting, restle ssness, \\nand confusion. Without treatment, severe cases may lead to seizures and coma.  \\n• Cushing syndrome:  In some cases, lung cancer cells may make ACTH, a hormone \\nthat causes the adrenal glands to secrete cortisol. This can lead to symptoms  such as \\nweight gain, easy bruising, weakness, drowsiness, and fluid retention. Cushing \\nsyndrome can also cause high blood pressure and high blood sugar levels (or even \\ndiabetes). \\n• Neurologic problems:  Small cell lung cancer can sometimes cause the body’s \\nimmune system to attack parts of the nervous system, which can lead to problems. \\nOne example is a muscle disorder called the Lambert-Eaton syndrome . In this \\nsyndrome, muscles around the hips become weak. One of the first signs may be'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 17}, page_content='One example is a muscle disorder called the Lambert-Eaton syndrome . In this \\nsyndrome, muscles around the hips become weak. One of the first signs may be \\ntrouble getting up from a sitting position. Later, muscles around the shoulder may \\nbecome weak. A rarer problem is paraneoplastic cerebellar degeneration , which can \\ncause loss of balance and unsteadiness in arm and leg movement, as well as trouble \\nspeaking or swallowing. SCLC can also cause other nervous system problems, suc h \\nas muscle weakness, sensation changes, vision problems, or even changes in \\nbehavior.  \\nSome of the more common paraneoplastic syndromes that can be caused by non-small \\ncell lung cancer (NSCLC) include: \\n• High blood calcium levels ( hypercalcemia ), which can cause frequent urination, \\nthirst, constipation, nausea, vomiting, belly pain, weakness, fatigue, dizziness, \\nconfusion, and other nervous system problems'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 18}, page_content='• Excess growth of certain bones, especially those in the finger tips, which is oft en \\npainful  \\n• Blood clots \\n• Excess breast growth in men ( gynecomastia ) \\nAgain, many of the symptoms listed above are more likely to be caused by conditions  \\nother than lung cancer. Still, if you have any of these problems, it’s important  to see your \\ndoctor right away so the cause can be found and treated, if needed. \\nExams and tests to look for lung cancer  \\nIf your doctor thinks you might have lung cancer based on the results of a screening  test \\nor because of symptoms you are having, he or she will do exams and tests to find out for \\nsure. \\nMedical history and physical exam \\nYour doctor will want to  take a medical history to check for any risk factors and to learn \\nmore about any symptoms you are having. Your doctor will also examine you for signs  of \\nlung cancer or other health problems. \\nIf the results of the history and physical exam suggest you might have lung cancer , more'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 18}, page_content='lung cancer or other health problems. \\nIf the results of the history and physical exam suggest you might have lung cancer , more \\ninvolved tests will be done (see below). \\nTests that might be used to look for lung cancer \\nSputum cytology \\nFor this test, a sample of sputum (mucus you cough up from the lungs) is looked at under \\na microscope to see if it contains cancer cells. The best way to do this is to get ea rly \\nmorning samples from you 3 days in a row. This test is more likely to help find cancer s \\nthat start in the major airways of the lung, such as most small cell lung canc ers and \\nsquamous cell lung cancers. It may not be as helpful for finding other types of non-sm all \\ncell lung cancer. \\nChest x-ray \\nIf you have symptoms that might be due to lung cancer, this is often the first test your \\ndoctor will do to look for any masses or spots on the lungs. Plain x-rays of your chest ca n \\nbe done at imaging centers, hospitals, and even in some doctors’ offices. If the x-r ay is'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 19}, page_content='normal, you probably don’t have lung cancer (although some lung cancers may not show \\nup on an x-ray). If something suspicious is seen, your doctor may order more tests.  \\nComputed tomography (CT) scan \\nA CT (or CAT) scan is more likely to show lung tumors than routine chest x-rays. A C T \\nscan can also provide precise information about the size, shape, and position of any lung \\ntumors and can help find enlarged lymph nodes that might contain cancer that has spread \\nfrom the lung.  \\nThe CT scan uses x-rays to produce detailed cross-sectional images of your  body. Instead \\nof taking one picture, like a regular x-ray, a CT scanner takes many pictures  as it rotates \\naround you while you lie on a table. A computer then combines these pictures into \\nimages of slices of the part of your body being studied. Unlike a regular x-r ay, a CT scan \\ncreates detailed images of the soft tissues in the body. \\nBefore the CT scan, you may be asked to drink a contrast solution or you may get an'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 19}, page_content='creates detailed images of the soft tissues in the body. \\nBefore the CT scan, you may be asked to drink a contrast solution or you may get an \\ninjection of a contrast solution through an IV (intravenous) line. This helps better outline  \\nstructures in your body. The contrast may cause some flushing (a feeling of wa rmth, \\nespecially in the face). Some people are allergic and get hives. Rarely, more s erious \\nreactions like trouble breathing or low blood pressure can occur. Be sure to tell the  doctor \\nif you have any allergies or if you ever had a reaction to any contrast ma terial used for x-\\nrays. \\nA CT scanner has been described as a large donut, with a narrow table that slides  in and \\nout of the middle opening. You will need to lie still on the table while the scan is being \\ndone. CT scans take longer than regular x-rays, and you might feel a bit confined by  the \\nring while the pictures are being taken. \\nFurther tests if you have an abnormal screening tes t result'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 19}, page_content='done. CT scans take longer than regular x-rays, and you might feel a bit confined by  the \\nring while the pictures are being taken. \\nFurther tests if you have an abnormal screening tes t result \\nIt is common for a low-dose CT scan of the lungs to show small, abnormal areas (c alled \\nnodules or  masses ) in the lungs, especially in current or former smokers. Most lung \\nnodules seen on CT scans are not cancer. They are more often the result of old infecti ons, \\nscar tissue, or other causes. But tests are often needed to be sure a nodule is not cance r.  \\nMost often the next step is to get a repeat CT scan to see if the nodule is growi ng over \\ntime. The time between scans might range anywhere from about a month to a yea r, \\ndepending on how likely your doctor thinks it is that the nodule could be cancer. This is \\nbased on the size, shape, and location of the nodule, as well as whether it appears to be'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 19}, page_content='depending on how likely your doctor thinks it is that the nodule could be cancer. This is \\nbased on the size, shape, and location of the nodule, as well as whether it appears to be \\nsolid or filled with fluid. If the nodule is larger, your doctor might also want to get  \\nanother type of imaging test called a positron emission tomography (PET) scan , which \\ncan often help tell if it is cancer.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 20}, page_content='If the second scan shows that the nodule has grown, or if the nodule has other concerning \\nfeatures, your doctor will want to get a sample of it to check it for cancer cell s (called a \\nbiopsy ). This can be done in different ways: \\n• The doctor might pass a long, thin tube (called a bronchoscope ) down your throat and \\ninto the airways of your lung to reach the nodule. A small, hollow needle on the end \\nof the bronchoscope can be used to get a sample of the nodule. \\n• If the nodule is in the outer part of the lung, the doctor might pass a thin, hollow \\nneedle through the skin of the chest wall and into the nodule to get a biopsy sample. \\n• If there is a higher chance that the nodule is cancer (or if the nodule can’t be bi opsied \\nwith a needle), surgery might be done to remove the nodule and some surrounding \\nlung tissue. Sometimes larger parts of the lung might be removed at the same time a s \\nwell.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 20}, page_content='with a needle), surgery might be done to remove the nodule and some surrounding \\nlung tissue. Sometimes larger parts of the lung might be removed at the same time a s \\nwell.  \\nThese types of tests, biopsies, and surgeries are described in more detail in our docum ents \\nLung Cancer (Non-Small Cell)  and Lung Cancer (Small Cell)  as are the options for \\ntreatment if lung cancer is found. \\nFurther tests if you have possible signs or symptom s of lung \\ncancer \\nIf your doctor is concerned you might have lung cancer because of signs or symptom s \\nyou are having, a chest x-ray or chest CT scan to look for tumors in the lung is likely  to \\nbe the next step. Other tests that might be done include having you cough up sputum \\n(phlegm) to have it looked at for cancer cells, or having a bronchoscopy, where the \\ndoctor puts a long, thin tube down your throat and into your lungs to look for anything \\nabnormal. \\nIf any of these tests are suspicious for cancer, further tests such as a biops y or even'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 20}, page_content='doctor puts a long, thin tube down your throat and into your lungs to look for anything \\nabnormal. \\nIf any of these tests are suspicious for cancer, further tests such as a biops y or even \\nsurgery will likely be needed to get samples from any tumors. \\nThese tests and procedures are described in more detail in our documents Lung Cancer \\n(Non-Small Cell)  and Lung Cancer (Small Cell) , along with the options for treatment if \\nlung cancer is found.'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 21}, page_content='Additional resources for lung cancer \\nprevention and early detection  \\nMore information from your American Cancer Society \\nThe following related information may also be helpful to you. These materials  may be \\nordered from our toll-free number, 1-800-227-2345. \\nLung cancer \\nLung Cancer (Non-Small Cell) (also in Spanish) \\nLung Cancer (Small Cell) (also in Spanish) \\nTobacco \\nGuide to Quitting Smoking (also in Spanish) \\nQuestions About Smoking, Tobacco, and Health (also in Spanish) \\nSecondhand Smoke (also in Spanish) \\nOther possible causes \\nArsenic \\nAsbestos (also in Spanish) \\nDiesel Exhaust \\nRadon (also in Spanish) \\nTalcum Powder and Cancer \\nYour American Cancer Society also has books that you might find helpful. Call us at  1-\\n800-227-2345 or visit our bookstore online to find out about costs or to place an order.  \\nNational organizations and websites* \\nIn addition to the American Cancer Society, other sources of patient information a nd \\nsupport include: \\nAmerican Lung Association'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 21}, page_content='National organizations and websites* \\nIn addition to the American Cancer Society, other sources of patient information a nd \\nsupport include: \\nAmerican Lung Association \\nToll-free number: 1-800-586-4872 (1-800-LUNGUSA) \\nWebsite: www.lungusa.org'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 22}, page_content='Lungcancer.org  \\nToll-free number: 1-800-813-4673 (1-800-813-HOPE) \\nWebsite: www.lungcancer.org  \\nLung Cancer Alliance \\nToll-free number: 1-800-298-2436  \\nWeb site: www.lungcanceralliance.org  \\nNational Cancer Institute \\nToll-free number: 1-800-422-6237 (1-800-4-CANCER) \\nWebsite: www.cancer.gov  \\n*Inclusion on this list does not imply endorsement by the American Cancer Society. \\nNo matter who you are, we can help. Contact us anyt ime, day or night, for information \\nand support. Call us at 1-800-227-2345  or visit www.cancer.org. \\nReferences: Lung cancer prevention and \\nearly detection \\nAmerican Cancer Society. Cancer Facts & Figures 2014 . Atlanta, Ga: American Cancer \\nSociety; 2014.  \\nAmerican Cancer Society. Lung Cancer (Non-Small Cel l) Detailed Guide. 2014. \\nAmerican Cancer Society. Lung Cancer (Small Cell) D etailed Guide. 2014. \\nNational Comprehensive Cancer Network. NCCN Clinica l Practice Guidelines in \\nOncology: Lung Cancer Screening. V.1.2015. Accessed  at'),\n",
              " Document(metadata={'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf', 'page': 22}, page_content='National Comprehensive Cancer Network. NCCN Clinica l Practice Guidelines in \\nOncology: Lung Cancer Screening. V.1.2015. Accessed  at \\nwww.nccn.org/professionals/physician_gls/pdf/lung_s creening.pdf on August 22, 2014. \\nPinsky PF, Church TR, Izmirlian G, Kramer BS. The N ational Lung Screening Trial: \\nresults stratified by demographics, smoking history , and lung cancer histology. Cancer . \\n2013 Nov 15;119(22):3976-83. Epub 2013 Aug 26. \\n \\nLast Medical Review: 8/22/2014 \\nLast Revised: 2/6/2015 \\n \\n2014 Copyright American Cancer Society')]"
            ]
          },
          "execution_count": 95,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "texts"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "Ly0AO5YBa7Bd",
        "outputId": "08f694bf-ed7a-4569-cc04-a2fa4a2b8e78"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: chromadb in /usr/local/lib/python3.10/dist-packages (0.5.5)\n",
            "Requirement already satisfied: build>=1.0.3 in /usr/local/lib/python3.10/dist-packages (from chromadb) (1.2.1)\n",
            "Requirement already satisfied: pydantic>=1.9 in /usr/local/lib/python3.10/dist-packages (from chromadb) (2.8.2)\n",
            "Requirement already satisfied: chroma-hnswlib==0.7.6 in /usr/local/lib/python3.10/dist-packages (from chromadb) (0.7.6)\n",
            "Requirement already satisfied: fastapi>=0.95.2 in /usr/local/lib/python3.10/dist-packages (from chromadb) (0.114.0)\n",
            "Requirement already satisfied: uvicorn>=0.18.3 in /usr/local/lib/python3.10/dist-packages (from uvicorn[standard]>=0.18.3->chromadb) (0.30.6)\n",
            "Requirement already satisfied: numpy<2.0.0,>=1.22.5 in /usr/local/lib/python3.10/dist-packages (from chromadb) (1.26.4)\n",
            "Requirement already satisfied: posthog>=2.4.0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (3.6.3)\n",
            "Requirement already satisfied: typing-extensions>=4.5.0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (4.12.2)\n",
            "Requirement already satisfied: onnxruntime>=1.14.1 in /usr/local/lib/python3.10/dist-packages (from chromadb) (1.19.2)\n",
            "Requirement already satisfied: opentelemetry-api>=1.2.0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (1.27.0)\n",
            "Requirement already satisfied: opentelemetry-exporter-otlp-proto-grpc>=1.2.0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (1.27.0)\n",
            "Requirement already satisfied: opentelemetry-instrumentation-fastapi>=0.41b0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (0.48b0)\n",
            "Requirement already satisfied: opentelemetry-sdk>=1.2.0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (1.27.0)\n",
            "Requirement already satisfied: tokenizers>=0.13.2 in /usr/local/lib/python3.10/dist-packages (from chromadb) (0.19.1)\n",
            "Requirement already satisfied: pypika>=0.48.9 in /usr/local/lib/python3.10/dist-packages (from chromadb) (0.48.9)\n",
            "Requirement already satisfied: tqdm>=4.65.0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (4.66.5)\n",
            "Requirement already satisfied: overrides>=7.3.1 in /usr/local/lib/python3.10/dist-packages (from chromadb) (7.7.0)\n",
            "Requirement already satisfied: importlib-resources in /usr/local/lib/python3.10/dist-packages (from chromadb) (6.4.4)\n",
            "Requirement already satisfied: grpcio>=1.58.0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (1.64.1)\n",
            "Requirement already satisfied: bcrypt>=4.0.1 in /usr/local/lib/python3.10/dist-packages (from chromadb) (4.2.0)\n",
            "Requirement already satisfied: typer>=0.9.0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (0.12.5)\n",
            "Requirement already satisfied: kubernetes>=28.1.0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (30.1.0)\n",
            "Requirement already satisfied: tenacity>=8.2.3 in /usr/local/lib/python3.10/dist-packages (from chromadb) (8.5.0)\n",
            "Requirement already satisfied: PyYAML>=6.0.0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (6.0.2)\n",
            "Requirement already satisfied: mmh3>=4.0.1 in /usr/local/lib/python3.10/dist-packages (from chromadb) (4.1.0)\n",
            "Requirement already satisfied: orjson>=3.9.12 in /usr/local/lib/python3.10/dist-packages (from chromadb) (3.10.7)\n",
            "Requirement already satisfied: httpx>=0.27.0 in /usr/local/lib/python3.10/dist-packages (from chromadb) (0.27.2)\n",
            "Requirement already satisfied: packaging>=19.1 in /usr/local/lib/python3.10/dist-packages (from build>=1.0.3->chromadb) (24.1)\n",
            "Requirement already satisfied: pyproject_hooks in /usr/local/lib/python3.10/dist-packages (from build>=1.0.3->chromadb) (1.1.0)\n",
            "Requirement already satisfied: tomli>=1.1.0 in /usr/local/lib/python3.10/dist-packages (from build>=1.0.3->chromadb) (2.0.1)\n",
            "Requirement already satisfied: starlette<0.39.0,>=0.37.2 in /usr/local/lib/python3.10/dist-packages (from fastapi>=0.95.2->chromadb) (0.38.4)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx>=0.27.0->chromadb) (3.7.1)\n",
            "Requirement already satisfied: certifi in /usr/local/lib/python3.10/dist-packages (from httpx>=0.27.0->chromadb) (2024.8.30)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx>=0.27.0->chromadb) (1.0.5)\n",
            "Requirement already satisfied: idna in /usr/local/lib/python3.10/dist-packages (from httpx>=0.27.0->chromadb) (3.8)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from httpx>=0.27.0->chromadb) (1.3.1)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx>=0.27.0->chromadb) (0.14.0)\n",
            "Requirement already satisfied: six>=1.9.0 in /usr/local/lib/python3.10/dist-packages (from kubernetes>=28.1.0->chromadb) (1.16.0)\n",
            "Requirement already satisfied: python-dateutil>=2.5.3 in /usr/local/lib/python3.10/dist-packages (from kubernetes>=28.1.0->chromadb) (2.8.2)\n",
            "Requirement already satisfied: google-auth>=1.0.1 in /usr/local/lib/python3.10/dist-packages (from kubernetes>=28.1.0->chromadb) (2.27.0)\n",
            "Requirement already satisfied: websocket-client!=0.40.0,!=0.41.*,!=0.42.*,>=0.32.0 in /usr/local/lib/python3.10/dist-packages (from kubernetes>=28.1.0->chromadb) (1.8.0)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (from kubernetes>=28.1.0->chromadb) (2.32.3)\n",
            "Requirement already satisfied: requests-oauthlib in /usr/local/lib/python3.10/dist-packages (from kubernetes>=28.1.0->chromadb) (1.3.1)\n",
            "Requirement already satisfied: oauthlib>=3.2.2 in /usr/local/lib/python3.10/dist-packages (from kubernetes>=28.1.0->chromadb) (3.2.2)\n",
            "Requirement already satisfied: urllib3>=1.24.2 in /usr/local/lib/python3.10/dist-packages (from kubernetes>=28.1.0->chromadb) (2.0.7)\n",
            "Requirement already satisfied: coloredlogs in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.14.1->chromadb) (15.0.1)\n",
            "Requirement already satisfied: flatbuffers in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.14.1->chromadb) (24.3.25)\n",
            "Requirement already satisfied: protobuf in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.14.1->chromadb) (3.20.3)\n",
            "Requirement already satisfied: sympy in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.14.1->chromadb) (1.13.2)\n",
            "Requirement already satisfied: deprecated>=1.2.6 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-api>=1.2.0->chromadb) (1.2.14)\n",
            "Requirement already satisfied: importlib-metadata<=8.4.0,>=6.0 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-api>=1.2.0->chromadb) (8.4.0)\n",
            "Requirement already satisfied: googleapis-common-protos~=1.52 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-exporter-otlp-proto-grpc>=1.2.0->chromadb) (1.65.0)\n",
            "Requirement already satisfied: opentelemetry-exporter-otlp-proto-common==1.27.0 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-exporter-otlp-proto-grpc>=1.2.0->chromadb) (1.27.0)\n",
            "Requirement already satisfied: opentelemetry-proto==1.27.0 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-exporter-otlp-proto-grpc>=1.2.0->chromadb) (1.27.0)\n",
            "Requirement already satisfied: opentelemetry-instrumentation-asgi==0.48b0 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb) (0.48b0)\n",
            "Requirement already satisfied: opentelemetry-instrumentation==0.48b0 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb) (0.48b0)\n",
            "Requirement already satisfied: opentelemetry-semantic-conventions==0.48b0 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb) (0.48b0)\n",
            "Requirement already satisfied: opentelemetry-util-http==0.48b0 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-instrumentation-fastapi>=0.41b0->chromadb) (0.48b0)\n",
            "Requirement already satisfied: setuptools>=16.0 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-instrumentation==0.48b0->opentelemetry-instrumentation-fastapi>=0.41b0->chromadb) (71.0.4)\n",
            "Requirement already satisfied: wrapt<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-instrumentation==0.48b0->opentelemetry-instrumentation-fastapi>=0.41b0->chromadb) (1.16.0)\n",
            "Requirement already satisfied: asgiref~=3.0 in /usr/local/lib/python3.10/dist-packages (from opentelemetry-instrumentation-asgi==0.48b0->opentelemetry-instrumentation-fastapi>=0.41b0->chromadb) (3.8.1)\n",
            "Requirement already satisfied: monotonic>=1.5 in /usr/local/lib/python3.10/dist-packages (from posthog>=2.4.0->chromadb) (1.6)\n",
            "Requirement already satisfied: backoff>=1.10.0 in /usr/local/lib/python3.10/dist-packages (from posthog>=2.4.0->chromadb) (2.2.1)\n",
            "Requirement already satisfied: annotated-types>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from pydantic>=1.9->chromadb) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.20.1 in /usr/local/lib/python3.10/dist-packages (from pydantic>=1.9->chromadb) (2.20.1)\n",
            "Requirement already satisfied: huggingface-hub<1.0,>=0.16.4 in /usr/local/lib/python3.10/dist-packages (from tokenizers>=0.13.2->chromadb) (0.24.6)\n",
            "Requirement already satisfied: click>=8.0.0 in /usr/local/lib/python3.10/dist-packages (from typer>=0.9.0->chromadb) (8.1.7)\n",
            "Requirement already satisfied: shellingham>=1.3.0 in /usr/local/lib/python3.10/dist-packages (from typer>=0.9.0->chromadb) (1.5.4)\n",
            "Requirement already satisfied: rich>=10.11.0 in /usr/local/lib/python3.10/dist-packages (from typer>=0.9.0->chromadb) (13.8.0)\n",
            "Requirement already satisfied: httptools>=0.5.0 in /usr/local/lib/python3.10/dist-packages (from uvicorn[standard]>=0.18.3->chromadb) (0.6.1)\n",
            "Requirement already satisfied: python-dotenv>=0.13 in /usr/local/lib/python3.10/dist-packages (from uvicorn[standard]>=0.18.3->chromadb) (1.0.1)\n",
            "Requirement already satisfied: uvloop!=0.15.0,!=0.15.1,>=0.14.0 in /usr/local/lib/python3.10/dist-packages (from uvicorn[standard]>=0.18.3->chromadb) (0.20.0)\n",
            "Requirement already satisfied: watchfiles>=0.13 in /usr/local/lib/python3.10/dist-packages (from uvicorn[standard]>=0.18.3->chromadb) (0.24.0)\n",
            "Requirement already satisfied: websockets>=10.4 in /usr/local/lib/python3.10/dist-packages (from uvicorn[standard]>=0.18.3->chromadb) (13.0.1)\n",
            "Requirement already satisfied: cachetools<6.0,>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from google-auth>=1.0.1->kubernetes>=28.1.0->chromadb) (5.5.0)\n",
            "Requirement already satisfied: pyasn1-modules>=0.2.1 in /usr/local/lib/python3.10/dist-packages (from google-auth>=1.0.1->kubernetes>=28.1.0->chromadb) (0.4.0)\n",
            "Requirement already satisfied: rsa<5,>=3.1.4 in /usr/local/lib/python3.10/dist-packages (from google-auth>=1.0.1->kubernetes>=28.1.0->chromadb) (4.9)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.16.4->tokenizers>=0.13.2->chromadb) (3.15.4)\n",
            "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.16.4->tokenizers>=0.13.2->chromadb) (2024.6.1)\n",
            "Requirement already satisfied: zipp>=0.5 in /usr/local/lib/python3.10/dist-packages (from importlib-metadata<=8.4.0,>=6.0->opentelemetry-api>=1.2.0->chromadb) (3.20.1)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests->kubernetes>=28.1.0->chromadb) (3.3.2)\n",
            "Requirement already satisfied: markdown-it-py>=2.2.0 in /usr/local/lib/python3.10/dist-packages (from rich>=10.11.0->typer>=0.9.0->chromadb) (3.0.0)\n",
            "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from rich>=10.11.0->typer>=0.9.0->chromadb) (2.16.1)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx>=0.27.0->chromadb) (1.2.2)\n",
            "Requirement already satisfied: humanfriendly>=9.1 in /usr/local/lib/python3.10/dist-packages (from coloredlogs->onnxruntime>=1.14.1->chromadb) (10.0)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.10/dist-packages (from sympy->onnxruntime>=1.14.1->chromadb) (1.3.0)\n",
            "Requirement already satisfied: mdurl~=0.1 in /usr/local/lib/python3.10/dist-packages (from markdown-it-py>=2.2.0->rich>=10.11.0->typer>=0.9.0->chromadb) (0.1.2)\n",
            "Requirement already satisfied: pyasn1<0.7.0,>=0.4.6 in /usr/local/lib/python3.10/dist-packages (from pyasn1-modules>=0.2.1->google-auth>=1.0.1->kubernetes>=28.1.0->chromadb) (0.6.0)\n"
          ]
        }
      ],
      "source": [
        "!pip install chromadb"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "AvO2id-6a6-8"
      },
      "outputs": [],
      "source": [
        "from langchain_community.vectorstores import Chroma"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "YWuqbnXXa660"
      },
      "outputs": [],
      "source": [
        "vectorstore=Chroma.from_documents(documents=texts,embedding=huggingface_embeddings)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "xPYnNi4Ga64c"
      },
      "outputs": [],
      "source": [
        "retriever=vectorstore.as_retriever(search_kwargs={\"k\":1})"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "Y-boLUr0a61s"
      },
      "outputs": [],
      "source": [
        "docs=retriever.get_relevant_documents(\"How to prevent lung cancer\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "EyqF9DZpa6y0",
        "outputId": "9d64cc23-ee43-4148-a337-8b912b61e8f3"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "1"
            ]
          },
          "execution_count": 101,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "len(docs)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "GTFYit7KjFcD"
      },
      "outputs": [],
      "source": [
        "import os\n",
        "os.environ[\"HUGGINGFACE_API_TOKEN\"]=\"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\""
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "z6DEXzXhjNlk"
      },
      "outputs": [],
      "source": [
        "template= \"\"\"\n",
        "<|system|>\n",
        "Answer the question based on your knowledge. Use the following context to help:\n",
        "\n",
        "{context}\n",
        "\n",
        "</s>\n",
        "<|user|>\n",
        "{question}\n",
        "</s>\n",
        "<|assistant|>\n",
        "\n",
        " \"\"\""
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "eMQwlqvXjzoV"
      },
      "outputs": [],
      "source": [
        "from langchain.prompts import PromptTemplate\n",
        "prompt = PromptTemplate(\n",
        "    input_variables=[\"context\", \"question\"],\n",
        "    template=template, # Use the 'template' variable defined earlier\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "E0oNbsfskHKq"
      },
      "outputs": [],
      "source": [
        "chain= prompt | llm"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "ZrfenD41mGS3",
        "outputId": "9364b021-3fd8-4aab-d978-357e1d8ab67d"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: langchain-huggingface in /usr/local/lib/python3.10/dist-packages (0.0.3)\n",
            "Requirement already satisfied: huggingface-hub>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from langchain-huggingface) (0.24.6)\n",
            "Requirement already satisfied: langchain-core<0.3,>=0.1.52 in /usr/local/lib/python3.10/dist-packages (from langchain-huggingface) (0.2.38)\n",
            "Requirement already satisfied: sentence-transformers>=2.6.0 in /usr/local/lib/python3.10/dist-packages (from langchain-huggingface) (3.0.1)\n",
            "Requirement already satisfied: tokenizers>=0.19.1 in /usr/local/lib/python3.10/dist-packages (from langchain-huggingface) (0.19.1)\n",
            "Requirement already satisfied: transformers>=4.39.0 in /usr/local/lib/python3.10/dist-packages (from langchain-huggingface) (4.44.2)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (3.15.4)\n",
            "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (2024.6.1)\n",
            "Requirement already satisfied: packaging>=20.9 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (24.1)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (6.0.2)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (2.32.3)\n",
            "Requirement already satisfied: tqdm>=4.42.1 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (4.66.5)\n",
            "Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.23.0->langchain-huggingface) (4.12.2)\n",
            "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3,>=0.1.52->langchain-huggingface) (1.33)\n",
            "Requirement already satisfied: langsmith<0.2.0,>=0.1.75 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3,>=0.1.52->langchain-huggingface) (0.1.116)\n",
            "Requirement already satisfied: pydantic<3,>=1 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3,>=0.1.52->langchain-huggingface) (2.8.2)\n",
            "Requirement already satisfied: tenacity!=8.4.0,<9.0.0,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.3,>=0.1.52->langchain-huggingface) (8.5.0)\n",
            "Requirement already satisfied: torch>=1.11.0 in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=2.6.0->langchain-huggingface) (2.4.0+cu121)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=2.6.0->langchain-huggingface) (1.26.4)\n",
            "Requirement already satisfied: scikit-learn in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=2.6.0->langchain-huggingface) (1.3.2)\n",
            "Requirement already satisfied: scipy in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=2.6.0->langchain-huggingface) (1.13.1)\n",
            "Requirement already satisfied: Pillow in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=2.6.0->langchain-huggingface) (9.4.0)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.10/dist-packages (from transformers>=4.39.0->langchain-huggingface) (2024.5.15)\n",
            "Requirement already satisfied: safetensors>=0.4.1 in /usr/local/lib/python3.10/dist-packages (from transformers>=4.39.0->langchain-huggingface) (0.4.4)\n",
            "Requirement already satisfied: jsonpointer>=1.9 in /usr/local/lib/python3.10/dist-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.3,>=0.1.52->langchain-huggingface) (3.0.0)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.75->langchain-core<0.3,>=0.1.52->langchain-huggingface) (0.27.2)\n",
            "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.75->langchain-core<0.3,>=0.1.52->langchain-huggingface) (3.10.7)\n",
            "Requirement already satisfied: annotated-types>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1->langchain-core<0.3,>=0.1.52->langchain-huggingface) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.20.1 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1->langchain-core<0.3,>=0.1.52->langchain-huggingface) (2.20.1)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.23.0->langchain-huggingface) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.23.0->langchain-huggingface) (3.8)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.23.0->langchain-huggingface) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.23.0->langchain-huggingface) (2024.8.30)\n",
            "Requirement already satisfied: sympy in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence-transformers>=2.6.0->langchain-huggingface) (1.13.2)\n",
            "Requirement already satisfied: networkx in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence-transformers>=2.6.0->langchain-huggingface) (3.3)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence-transformers>=2.6.0->langchain-huggingface) (3.1.4)\n",
            "Requirement already satisfied: joblib>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from scikit-learn->sentence-transformers>=2.6.0->langchain-huggingface) (1.4.2)\n",
            "Requirement already satisfied: threadpoolctl>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from scikit-learn->sentence-transformers>=2.6.0->langchain-huggingface) (3.5.0)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.75->langchain-core<0.3,>=0.1.52->langchain-huggingface) (3.7.1)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.75->langchain-core<0.3,>=0.1.52->langchain-huggingface) (1.0.5)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.75->langchain-core<0.3,>=0.1.52->langchain-huggingface) (1.3.1)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.75->langchain-core<0.3,>=0.1.52->langchain-huggingface) (0.14.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->torch>=1.11.0->sentence-transformers>=2.6.0->langchain-huggingface) (2.1.5)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.10/dist-packages (from sympy->torch>=1.11.0->sentence-transformers>=2.6.0->langchain-huggingface) (1.3.0)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.75->langchain-core<0.3,>=0.1.52->langchain-huggingface) (1.2.2)\n"
          ]
        }
      ],
      "source": [
        "!pip install langchain-huggingface"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "xZRxibsLkbp7"
      },
      "outputs": [],
      "source": [
        "from langchain_huggingface import HuggingFacePipeline\n",
        "from langchain.prompts import PromptTemplate\n",
        "from transformers import pipeline\n",
        "from langchain_core.output_parsers import StrOutputParser\n",
        "import torch\n",
        "from transformers import AutoModelForCausalLM, AutoTokenizer"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true
        },
        "id": "IeOJxYRVmL4o",
        "outputId": "8187facd-2602-4bbb-c9dd-4a7f4c43fdbd"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/transformers/tokenization_utils_base.py:1601: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be depracted in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
            "  warnings.warn(\n"
          ]
        }
      ],
      "source": [
        "model_name = \"EleutherAI/gpt-neo-1.3B\"\n",
        "model = AutoModelForCausalLM.from_pretrained(model_name)\n",
        "tokenizer = AutoTokenizer.from_pretrained(model_name)\n",
        "\n",
        "text_generation_pipeline = pipeline(\n",
        "    model=model,\n",
        "    tokenizer=tokenizer,\n",
        "    task=\"text-generation\",\n",
        "    temperature=0.1,\n",
        "    do_sample=True,\n",
        "    repetition_penalty=1.1,\n",
        "    return_full_text=True,\n",
        "    max_new_tokens=400,\n",
        ")\n",
        "llm = HuggingFacePipeline(pipeline=text_generation_pipeline)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "XFNx8KF0mb36"
      },
      "outputs": [],
      "source": [
        "from langchain_core.runnables import RunnablePassthrough\n",
        "rag_chain = {\"context\": retriever, \"question\": RunnablePassthrough()} | chain"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true,
          "base_uri": "https://localhost:8080/"
        },
        "id": "XBNhNKHHmxWU",
        "outputId": "4584692f-2bab-4273-93bf-ac3dad5c1f1d"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "Setting `pad_token_id` to `eos_token_id`:50256 for open-end generation.\n"
          ]
        },
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Response: <|system|>\n",
            "Answer the question based on your knowledge. Use the following context to help:\n",
            "\n",
            "[Document(metadata={'page': 10, 'source': 'Data/Lung cancer preventions and early detection_american cancer society_booklet (1).pdf'}, page_content='proper safety procedures, such as wearing a respirator, if this applies at you r workplace. \\nA healthy diet with lots of fruits and vegetables may also help reduce your ris k of lung \\ncancer. Some evidence suggests that a diet high in fruits and vegetables may help pr otect')]\n",
            "\n",
            "\n",
            "<|user|>\n",
            "hOW can you prevent lung cancer\n",
            "\n",
            "<|assistant|>\n"
          ]
        }
      ],
      "source": [
        "question = \"hOW can you prevent lung cancer\"\n",
        "\n",
        "response = rag_chain.invoke(question)\n",
        "\n",
        "# Making the response readable\n",
        "response = response.replace(\"</s>\", \"\").strip()\n",
        "print(\"Response:\", response)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "LSVr1sVom5QN"
      },
      "outputs": [],
      "source": []
    }
  ],
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyPsuzCDmu1NukT5HbMvU8la"
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}